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Abstract 
  
 Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase 
(HMGCR), the key enzyme in the mevalonate pathway that leads to the synthesis of 
cholesterol and ergosterol in animal and fungal cells, respectively. Their extensive 
use in treatment and prevention of cardiovascular diseases placed statins among 
the best-selling pharmaceuticals. Industrial scale production of natural statins (i.e. 
compactin and lovastatin) and their semi-synthetic derivatives (i.e. pravastatin and 
simvastatin) is based on fermentation of statin-producing filamentous fungi, such as 
Penicillium sp. and Aspergillus sp.. Production limitations associated with the unique 
physiology and morphology of the natural producers can be overcome by 
heterologous expression of the pathway in a fast-growing host, such as S. 
cerevisiae. Future construction of S. cerevisiae cell factory for the production of high 
concentrations of natural statins will require the establishment of a non-destructive 
self-resistance mechanism to overcome the undesirable growth inhibition effects of 
statins. In an effort to resolve this challenge, two putative self-resistance genes, 
mlcD and mlcE, originating from the P. citrinum compactin gene cluster, were tested 
for their ability to protect yeast from statins. Chromosomal gene integration 
approach was used to express the genes in S. cerevisiae. 
 This study showed that mlcD could mediate statin-resistance when 
expressed heterologously in S. cerevisiae, increasing yeast resistance from 0.25 mM 
to at least 1.24 mM. Successful complementation of Sc-HMG1 and Sc-HMG2 in 
yeast, in addition, proved that MlcD functions as HMGCR. A phylogenetic analysis 
of fungal HMGCRs revealed that HMGCRs from the known statin gene clusters 
(mlcD and lvrA/mokG) are likely derived from HMGCRs involved in primary 
metabolism. However, the occurrence of these genes in the different statin gene 
clusters probably did not arise from a recent duplication of the primary HMGCR in 
the producing organism. A model was proposed, in which the HMGCR-encoding 
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genes at some time during evolution were duplicated and then recruited to the statin 
gene clusters, a situation that has increased the chance for becoming co-regulated 
with the cluster and hence statin production. Collectively these results suggest that 
statin self-resistance is based on the HMGRS's association with the cluster, e.g. 
increased concentration of HMGCR at the right time, and is not due to the HMGCR 
being statin-insensitive. This model will require further validation by e.g. direct 
measurement of enzymes sensitivity to statins. 
 Heterologous expression of mlcE, the second putative self-resistance gene 
from the compactin gene clsuter, significantly increased S. cerevisiae’s resistance to 
natural statins (8.6-fold increase in growth efficiency compared to the wild-type 
strain). Sequence based analysis showed that MlcE likely contains 14 
transmembrane spanning domains and phylogenetically it clusters together with 
known toxin efflux pumps from both fungi and bacteria. RFP-tagging of MlcE 
showed that it was localized to the plasma and vacuolar membranes in yeast. 
Collectively these results indicate that mlcE encodes for a transmembrane 
transporter, and thus likely provides the resistance to statins by secreting the 
compounds outside of the cells. Further testing of MlcE’s role as a self-resistance 
mechanism surprisingly showed that it was not only capable of protecting yeast 
from the negative effects of natural statins, but also semi-synthetic statins (i.e 
simvastatin). 
 This work provides possible engineering strategies for improvement of future 
yeast based production of natural and semi-synthetic statins in yeast. Moreover, it 
gives new insights into the statin self-resistance mechanisms in the natural 
producers. 
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Sammenfatning 
 
Statiner er inhibitorer af 3-hydroxy-3-methylglutaryl coenzym A reduktase 
(HMGCR), det vigtigste enzym i mevalonat biosyntesevejen, der er ansvarlig for 
produktion af henholdsvis kolesterol og ergosterol i dyre- og svampeceller. Deres 
omfattende brug til forebyggelse og behandling af cholestrol forårsagede hjerte-kar 
sygdomme har betydet at statiner er blandt de bedst sælgende lægemidler. 
Produktion af naturlige statiner (compactin og lovastatin) og deres semisyntetiske 
derivater (pravastatin og simvastatin) i industriel skala er baseret på fermentering af 
naturligt statin-producerende skimmelsvampe som Penicillium og Aspergillus. De 
naturlige producenters unikke fysiologi og morfologi udgør i dag en begrænsning for 
den industrielle produktion, men disse begrænsninger forventes at kunne omgås 
ved at udtrykke biosyntesevejen heterologt i en hurtigt groende vært som 
Saccharomyces cerevisiae (gær). Konstruktion af en højt ydende S. cerevisiae 
cellefabrik, til produktion af naturlige statiner, vil dog kræve at der udvikles en 
effektiv og nedbrydnings-uafhængig resistensmekanisme der kan modvirke den 
uønskede væksthæmmende effekt statiner har på gærceller. I et forsøg på at 
identificere løsninger på denne problemstilling, blev to formodede resistens 
kodende gener, MlcD og MlcE fra compactin gen-clusteret i P. citrinum, testet for 
deres evne til at beskytte gærceller mod statiners negative effekter. Genernes 
duelighed blev testet ved at integrere dem kromosomalt i S. cerevisiae.  
Det gennemførte studie demonstrerede at heterolog ekspression af MlcD i S. 
cerevisiae forøgede gærs resistensniveau for compactin fra 0.25 mM til mindst 1.24 
mM. Derudover viste en komplementeringsanalyse af Sc-HMG1 og Sc-HMG2 
mutationerne i gær, at MlcD fungerer som en HMGCR, da den kunne reversere 
begge mutanter til vild-type fænotypen. En fylogenetisk analyse af svampe HMGCR 
enzymer afslørede at HMGCR’er der koder for gener fra de kendte statin 
producerende genclustre (mlcD og lvrA/mokG) sandsynligvis stammer fra HMGCR 
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involveret i primær metabolisme. Tilstedeværelsen af disse gener i de forskellige 
genclustre, der er ansvarlige for statin produktion, er formentlig ikke resultatet af en 
nylig genduplikation af den primære HMGCR i de producerende svampe. En model 
der muligvis kan forklare den nuværende situation er, at de HMGCR-kodende gener 
på et tidspunkt i evolutionen blev duplikeret og derefter rekrutteret til statin-
genclustrene; en situation der har forøget sandsynligheden for at deres 
ekspressionsmønster er blevet co-reguleret med clusteret, og dermed statin-
produktionen. Samlet set betyder dette, at opståen af HMGCR baseret 
statinresistens er associeret med rekruttering af de HMGCR kodende gener til statin 
genclustrene, hvilket har øget koncentrationen af HMGCR i statin-producerede 
celler; dette gør modeller hvor statinresistens skyldes udviklingen af statin 
insensitive HMGCR i forbindelse med statin-clusterne mindre sandsynlige. Denne 
model kræver yderligere validering via for eksempel direkte måling af enzymernes 
resistens overfor statin-inhibering. 
Heterolog udtryk af MlcE, det andet formodede resistensgen fra compactin 
genclusteret, forøgede S. cerevisiae's resistens mod naturlige statiner signifikant 
(8.6-fold forøget biomasseudbytte sammenlignet med vildtypen). Sekvensbaseret 
analyse viste, at MlcE formentlig indeholder 14 transmembrane domæner og rent 
fylogenetisk grupperer den med kendte toksin udstøms-pumper fra både 
skimmelsvampe og bakterier. RFP-mærkning af MlcE demonstrerede at det er 
lokaliseret nær plasma- og vakuolemembraner i gær. Samlet indikerer disse 
resultater at MlcE koder for et transmembrant transportprotein, og at det 
afstedkommer statin-resistens ved at pumpe statinerne ud af cellen. Yderligere 
analyser af MlcE’s rolle som resistensmekanisme viste overraskende nok at den ikke 
kun er i stand til at beskytte gær mod de negative effekter af naturlige statiner, men 
også semi-syntetiske statiner (simvastatin). 
Dette projekt har tilvejebragt to eksperimentelle strategier der vil muliggøre 
forbedring af fremtidige gær-baserede cellefabrikker til produktion af naturlige og 
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semi-syntetiske stationer i gær. Derudover, giver det nye indsigter i statin-
producerende skimmelsvampes naturlige resistensmekanismer overfor statiner. 
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 1 
Introduction 
  
 Coronary heart disease (CHD) is the leading cause of death according to the 
World Health Organization. Today, the treatment and prevention of CHD is primarily 
based on lowering the patients plasma cholesterol levels, as high concentration of 
cholesterol in the blood (hypercholesterolemia) can result in abnormal deposition of 
cholesterol and its ester in the walls of arteries, eventually leading to the buildup of 
plaques (atherosclerosis) that can completely block the arteries or rupture and 
cause a heart attack or a stroke. First choice of treatment and prevention of CHD is 
a combination of diet changes and a therapy with statins, a group of 
pharmaceuticals that reduces the plasma cholesterol levels by inhibiting the key 
enzyme in the cholesterol biosynthesis, namely HMG-CoA reductase. Due to the 
vast number of patients with elevated plasma cholesterol levels, statins are 
commercially extremely successful, and the competition with generic versions of 
statins is tough. The challenge of the pharmaceutical industry is not just in the 
discovery of novel statins, with improved pharmacokinetic and pharmacodynamic 
properties, but also in ensuring the availability of statins in the market at the best 
possible price. 
 The emergence of synthetic statins (e.g. atorvastatin) has not diminished the 
importance of biotechnological production of the natural (i.e. compactin – also 
called mevastatin or ML-236B – and lovastatin) and semi-synthetic statins (i.e. 
pravastatin and simvastatin) using fermentation-based processes. In fact, statins of 
microbial origin remain the first-line treatment of choice for patients with high 
plasma cholesterol and CHD. Industrial biotechnology, with its potential to improve 
the biological production of statins, is therefore indispensable. 
 In general, two main approaches are exploited for improving the 
biotechnological production of biopharmaceuticals. The first approach involves the 
production technology, where optimization of cultivation conditions and purification 
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processes can significantly improve the production yield of the desired compound. 
The second approach is based on the improvement of the production organism, and 
includes engineering of a native host, or the use and engineering of a heterologous 
host organism. Industrial scale production of natural and semi-synthetic statins is 
based on fermentation of statin-producing filamentous fungi. Optimization of 
bioprocessing conditions, as well as improvement of the natural producers aimed at 
increased production yields have been exploited extensively. In contrary, the use of 
heterologous hosts for the production of statins remains largely unexplored, 
however some of the production limitations associated with the unique physiology 
and morphology (e.g. filamentous growth) of the natural producers can be overcome 
by heterologous expression of the biosynthetic pathway in a fast-growing host, such 
as Saccharomyces cerevisiae.  
 My PhD project focused on the use of S. cerevisiae as a cell factory for the 
production of natural and semi-synthetic statins. The objective of my thesis work 
was to develop a S. cerevisiae based cell factory for the production of compactin, 
one of the two known natural statins that is produced as a secondary metabolite by 
the filamentous fungus Penicillium citrinum. I aimed at heterologous expression of 
the compactin biosynthetic pathway from P. citrinum in S. cerevisiae by using 
available genetic tools that allow for stable integration of multiple genes into the 
yeast genome. The second aim of this project concerned a statin resistance 
mechanism; if biologically active compounds, such as statins, are to be 
heterologously produced, an important consideration is the need for a resistance 
mechanism to protect the heterologous host from any toxic effects of the product 
may have. Since the target of compactin, HMG-CoA reductase is essential for 
eukaryotes, it is also found in S. cerevisiae, and therefore this consideration is 
inevitable. Self-resistance mechanisms present in the native producers can 
represent a toolbox for solving the resistance problem in a heterologous host, 
therefore I aimed at elucidating the resistance mechanism to statins and explore its 
potential to confer the statin resistance in S. cerevisiae.  
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 I have divided this thesis into two parts; in the first part I aim at providing the 
theoretical background of my PhD project, which consists of Chapters 1-3. Statins 
are an excellent example of the successful use of naturally occurring bioactive 
compounds in medicine. In Chapter 1, I present the impact of natural products to 
our society, and I highlight the fungal secondary metabolites as one the most 
important sources of biopharmaceuticals. Chapter 2 is devoted to statins, where I 
present their important applications, chemical and biosynthetic features, and 
different aspects of biotechnological production of statins. In Chapter 3 I provide an 
overview of the different self-resistance mechanisms that organisms possess in 
order to cope with the negative effects of the secondary metabolites, which they 
synthesize. The possibility to utilize the self-mechanisms in the engineering of a cell-
factory is also discussed, and examples are provided. The second part of the thesis 
covers the experimental part of my project, and consists of Chapters 4-6, each 
representing a specific research case. The first case – an attempt to construct a S. 
cerevisiae cell factory for compactin production – is briefly described in Chapter 4. 
The two subsequent research cases involved elucidation of the statin resistance 
mechanism, and investigation its potential in S. cerevisiae. This part of the project 
concerned two different putative resistance genes from P. citrinum (Figure 1); in 
Chapter 5 I present my work that involved a putative HMG-CoA reductase-encoding 
gene (mlcD), and in Chapter 6 I describe the work associated with a putative efflux 
pump (mlcE). Chapter 6 is a research article that was submitted for publication. 
Moreover, the findings from Chapter 6 served as a basis for a patent, which was 
filed in April 2014, and which is shown as an appendix to the thesis. Overview of the 
structure of this thesis is presented in Figure 1. 
 4 
 
Figure 1: Overview of the thesis and research work. Chapters 1-3 provide theoretical background, and Chapters 4-6 
describe the experimental work. Patent based on the work described in Chapter 6 is added as an appendix to this 
thesis. 
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CHAPTER 1 
1.Secondary metabolites 
 
1.1 Naturally occurring bioactive molecules – secondary 
metabolites 
 
Nature is an important source of novel bioactive compounds, many of which 
have had a tremendous impact to our society. They have reduced the pain and 
suffering, moved the borders of medicine by allowing organ transplantation, and are 
among the most important drugs for treatment of cancer and infectious diseases. 
Molecules originating from biological systems can be applied unmodified in 
medicine or any other field (e.g. agriculture), or can serve as a starting material for 
chemical or microbial derivatizations. Furthermore, they can be used as lead 
compounds for chemical synthesis of new analogs or as templates for rational drug 
design studies (Berdy, 2005; Newman and Cragg, 2012). Most of the naturally 
occurring bioactive compounds are products of secondary metabolism, which helps 
the organisms to meet the needs and challenges of their natural environment and 
lifestyle. Secondary metabolites are structurally heterogeneous, small and often 
complex molecules that are, in contrast to primary metabolites, not required for 
growth (at least under laboratory conditions), but which provide a competitive 
advantage to the producing organism (Williams et al., 1989). Both, higher eukaryotic 
forms of life, such as plants (mostly higher plants, but also lichens and algae) and 
animals (especially marine animals), as well as microorganisms are producing 
secondary metabolites, however synthesis of specific compounds is typically 
restricted to narrow taxonomic groups of organisms, e.g. strains within species 
(Challis and Hopwood, 2003). 
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Microorganisms are the most frequent and versatile producers of secondary 
metabolites (Demain, 1999). Most of the biologically active secondary metabolites 
have been isolated from actinomycetes (filamentous bacteria) and filamentous fungi 
(Bérdy, 2005). Several different biological functions have been attributed to 
microbial secondary metabolites, including (i) the inhibition or killing of competing 
organisms in the battle for the resources, (ii) metal uptake and transport, (iii) 
protection against abiotic stress (e.g. light), (iv) differentiation effectors etc. (Challis 
and Hopwood, 2003; Demain, 2000). A more general explanation of the natural 
function of secondary metabolites came from Bérdy (Bérdy, 2005), who defined 
secondary metabolites as a chemical interface between microbes and the rest of the 
world – the interface that is manifested in diverse interactions, e.g. antagonistic, 
synergistic, regulatory, modulatory, and with different living systems, e.g. other 
microbes, animals and plants. 
 
To date statins have only been identified as products of filamentous fungi, 
and this group will therefore be introduced in the following section.  
 
1.2 Fungal secondary metabolites 
 
The discovery of penicillin in 1928 (Fleming, 1929) accelerated the in 
research of fungal metabolites, including discovery, isolation and characterization of 
numerous novel secondary metabolites (Bennett, 2001). Fungal secondary 
metabolites have proven to be an excellent source of natural products with 
pharmaceutical applications, ranging from antibiotics (e.g. penicillins and 
cephalosporins), antitumor agents (e.g. macrosporin), immunosuppressive agents 
(e.g. cyclosporin A and mycophenolic acid), and cholesterol-lowering agents (i.e. 
lovastatin and compactin). The later compounds are the molecules of interest for 
this thesis, and Chapter 2 is devoted to a thorough introduction to this class of 
compounds. In contrast to the pharmaceutically attractive secondary metabolites, 
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fungi also produce potent toxins, such as aflatoxins and trichothecenes (Figure 2) 
(Hoffmeister and Keller, 2007). 
 
 
Figure 2: Examples of fungal secondary metabolites. Penicillin G from Penicillium chrysogenum is a clinically used 
antibiotic, and lovastatin from Aspergillus terreus is used as cholesterol-lowering compound. Cyclosporin A is 
immunosuppressant produced by Tolypaocladium inflatum. Ergotamines from Claviceps purpurea are anti-migraine 
agents. Fumitremorgin C from A. fumigatus, and related compounds can be used to improve chemotherapy in 
breast cancer treatment. Gibberellin GA3, a potent plant-growth regulator, is produced by Fusarium fujikuroi. Many 
secondary metabolites are toxic, including gliotoxin from A. fumigatus, aflatoxins from A. flavus, and trichothecenes 
and fusarin C from Fusarium species. Aristolochene from P. roquefortii is a precursor of a PR toxin (Brakhage, 2013; 
Keller et al., 2005; Sanchez et al., 2012). 
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1.2.1 Biosynthesis of fungal secondary metabolites 
 
 Despite their chemical diversity and complexity (Figure 2), fungal secondary 
metabolites are synthesized by a limited number of basic biosynthetic mechanisms, 
and from a limited number of precursors derived from primary metabolism (Figure 
3). The enzyme classes involved in the biosynthesis of secondary metabolites form 
the basis for chemical classification of the metabolites into the following groups: 
polyketides, non-ribosomal peptides, alkaloids, terpenes, and compounds of mixed 
biosynthetic origin (examples of each class are presented in Figure 2), polyketides 
being the most abundant (Keller et al., 2005). Statins are synthesized via the 
polyketide pathway, thus the mechanism of polyketide biosynthesis is briefly 
described below. 
 
 
Figure 3: Secondary metabolites are derived from the precursors that originate from the primary metabolism.  
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1.2.2 Polyketide biosynthesis 
 
Polyketides were first characterized as compounds with polyketomethylene 
groups (CH2-CO)n (Collie, 1907). However, it is the way in which polyketides are 
synthesized – by polyketide synthases (PKSs) – that joins these compounds in a 
group (Bentley and Bennett, 1999). Fungal polyketides are usually synthesized by 
type I PKSs, enzymes structurally and functionally related to eukaryotic fatty-acid 
synthases (FASs). Both enzyme classes catalyze a Claisen condensation of primary 
metabolites – short-chain carboxylic acids, usually acetyl coenzyme A (acetyl-CoA) 
and malonyl CoA – forming carbon chains of varying lengths. Both, type I PKSs and 
FASs have a multi-domain structure with β-keto-synthase (KS), acyltransferase (AT) 
and acyl carrier protein (ACP) domains being essential for the synthesis of the 
carbon backbone. Moreover, β-ketoreductase (KR), dehydratase (DH) and enoyl 
reductase (ER) domains, which are always present in FASs and are required for the 
reduction of the carbon backbone, are optional domains in the type I PKSs (Fujii et 
al., 2001). The degree of reduction of the carbon chain is the main difference 
between the polyketides and the fatty acids, the later being fully reduced. Other 
catalytic domains, affecting the structure of the polyketide have been found in 
fungal type I PKSs, some of which are listed in Table 1. 
 
Table 1 
Different active domains found in fungal type I PKSs and their functions (Frandsen, 2010; Fujii et al., 2001).  
Domain  Function 
ACP – Acyl carrier protein Carries the growing polyketide chain as a thioester 
SAT – Starter acyltransferase Loads the starter units in the non-reducing PKSs 
AT – Acyltransferase Loads the starter, extender and intermediate units 
KS – Ketoacyl-CoA synthase Catalyzes Claisen condensation reaction 
KR – Ketoreductase  Reduces ketone groups to hydroxyl groups 
DH – Dehydratase Reduces hydroxyl groups to enoyl groups 
ER – Enoyl reductase Reduces enoyl groups to alkyl groups 
TE – Thioesterase Catalyzes hydrolysis of the thioester linking the polyktetide to PKS 
MT – Methyltransferase Transfers methyl groups to the growing polyketide chain 
CYC – Cyclase Facilitates ring formation by Claisen type cyclization reaction 
PT – Product template Determines the folding pattern of the polyketide chain in non-reducing 
iterative PKSs 
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The active domains of PKSs are organized in modules, defined as a 
complete set of domains that are able to extend the growing polyketide chain by 
one ketide unit. In contrast to bacterial type I PKSs, which can consist of several 
modules – one for each condensation reaction – fungal type I PKSs always consist 
of a single module, which is able to carry out biosynthetic reactions repeatedly 
during formation of a single product, thus called iterative PKSs. The basic 
mechanism of polyketide biosynthesis by iterative PKS is illustrated in Figure 4, 
where the reducing steps are also shown. The high chemical diversity of fungal 
polyketides results from several factors; number of iterations of the condensation 
reaction (Figure 4, step 3), type of building blocks used for the synthesis (Figure 4, 
steps 1 and 2), number of reductions and cyclisation of the polyketide chain (Figure 
4, steps 4-6), methylation or other branching of the polyketide chain. In addition to 
the factors that are “programed” by the domain structure of the PKS and influence 
the polyketide structure during its synthesis, post-PKS modifications can further 
modify the molecules, introducing additional chemical diversity. Enzymes such as 
oxidases, dehydrogenases, esterases, methyl-transferases, reductases, etc. – often 
called tailoring enzymes – carry out these modifications. 
 
 13 
 
Figure 4: Mechanism of polyketide synthesis by fungal iterative type I PKS. A starter unit (acetyl-CoA in this 
example) and an extender unit (malonyl-CoA in this example) are loaded to the KS and ACP domain, respectively by 
the AT1 domain (steps 1 and 2). The ACP domain has a flexible 4’-phosphopantetheine group. The later is able to 
covalently attach the substrates, intermediates and final products in a thioester linkage and move them between 
different active sites in the enzyme (Nelson and Cox, 2005). The KS domain catalyzes Claisen condensation 
between the starter and extender unit (step 3), resulting in the release of CO2 and the formation of the carbon-
carbon bond between the two units. The growing polyketide chain can then be either (i) transferred back to the KS 
domain to enter a new round of adding the extender unit (step 8), (ii) released from the PKS by the TE domain (step 
7), or (iii) can be first reduced before it is further elongated or released. During the reducing steps the ACP presents 
the polyketide chain to the different reducing domains (KR, DH, ER). The reduction process can be stopped at any 
stage (4, 5 or 6), resulting in the different degrees of reduction of the polyketide (adapted from (Frandsen, 2010)). 
                                                
1 The AT domain is responsible for loading of the starter unit in reducing PKSs, however in the non-reducing PKSs 
this function is carried out by the SAT domain (Crawford et al., 2006; Foulke-Abel and Townsend, 2012). 
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1.2.3 Organization and regulation of fungal secondary metabolite genes 
 
Genes encoding the biosynthetic apparatuses for the formation of secondary 
metabolites are usually arranged in contiguous clusters in fungal genome (Brakhage, 
2013; Smith et al., 1990). Besides the genes encoding the key synthases (e.g. PKSs 
and non-ribosomal peptide synthase (NRPSs)), these gene clusters also encode 
tailoring enzymes, and regulatory proteins, most often cluster-specific transcription 
factors. Secondary metabolite gene clusters are not constitutively expressed; their 
complex regulation depends on the pathway-specific transcription factors (e.g. AflR, 
MlcR, etc.) as well as “global regulators” (transcription factors and regulatory 
networks). The global regulators are encoded by genes that do not belong to any 
cluster and control the response to environmental conditions such as carbon (e.g. 
CreA), nitogen (e.g. AreA), pH (e.g. PacC), and light (e.g. LaeA, VeA) (Brakhage, 
2013; Hoffmeister and Keller, 2007). In addition to the genes encoding proteins for 
biosynthesis, modifications and regulation, clusters can also include genes 
encoding transporters and self-resistance mechanisms, a subject that is further 
presented in Chapter 3. 
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CHAPTER 2 
2.Statins: cholesterol-lowering 
secondary metabolites 
 
2.1 The use of statins as pharmaceuticals 
 
 Elevated level of cholesterol in the blood (hypercholesterolemia) can result in 
abnormal deposition of cholesterol and its ester in the walls of the coronary arteries, 
causing buildup of plaques (atherosclerosis). Such a situation can lead to a 
complete blockage of the arteries, and thereby heart attack or stroke. 
Hypercholesterolemia is known to be the primary risk factor in coronary heart 
disease (CHD) (KANNEL et al., 1961; Stamler, 1978), which caused one third of all 
deaths worldwide in 2012 according to the World Health Organization, and is 
considered as the leading cause of death (WHO, 2014). As approximately two-thirds 
of the total body cholesterol are derived from its de novo synthesis, mainly in the 
liver (Grundy and Diego, 1978), inhibition of cholesterol biosynthesis represents the 
most important approach to lower the plasma cholesterol levels, and thereby reduce 
the risk of CHD. 
 Cholesterol is synthesized via the mevalonate pathway (Bloch, 1957; Frantz 
and Schroepfer, 1967), where the rate-limiting step is the conversion of 3-hydroxy-
3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate by the enzyme HMG-CoA 
reductase (HMGCR) (Rodwell et al., 1976) (Figure 5). The later therefore is a prime 
target for pharmacological intervention (Alberts et al., 1980). Statins are a class of 
pharmaceuticals that inhibit HMGCR, and thereby effectively lower the plasma 
cholesterol levels (Corsini et al., 1995). They have been successfully used to treat 
and prevent CHD, thus became one of the best-selling pharmaceuticals in past 
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decades. In 2012 the worldwide statin market value was estimated to 19.7 billion 
USD. The introduction of generic statins has temporarily meant a decline in the 
market value to 12.2 billion USD in 2018 (GBI Research, 2013), but it is predicted to 
make statin-based therapies more accessible, and the market is expected to reach 
35 billion USD by 2023 (dos Santos et al., 2014). In Denmark, more than 10 % of the 
population receives statin therapy annually (Fokusrapport – Viden om forbrug og 
bivirkninger ved behandling med statiner, 2012)2. 
 
 
Figure 5: Schematic representation of the mevalonate pathway. Statins inhibit HMG-CoA reductase, the key enzyme 
in the mevalonate pathway (adapted from (Thurnher et al., 2012)). 
                                                
2 English translation: Focus Report - Knowledge of consumption and side effects of treatment with statins. 
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 Besides their cholesterol-lowering effect, statins have been shown to have a 
variety of pleiotropic effects (Davignon and Leiter, 2005), and have therefore 
emerged as possible medicines to treat non-cardiovascular conditions, such as 
cancer (Gauthaman et al., 2009), dementia (Jick et al., 2014; Wolozin et al., 2000), 
osteoporosis (Pahan et al., 1997), multiple sclerosis (C.-Y. Wang et al., 2008a), 
rheumatoid arthritis (McCarey et al., 2005), and Parkinson`s disease (Becker, 2008). 
These pleiotropic effects are thought to be the result of a modified protein 
prenylation pattern. Isoprenoids derived from the mevalonate pathway are important 
lipid attachments of proteins involved in the intracellular signaling (Figure 5) (C.-Y. 
Wang et al., 2008b). More specifically, farnesyl pyrophosphate and geranylgeranyl 
pyrophosphate are attached to proteins during posttranslational modification, a 
process referred to as protein prenylation. These lipid adjuncts play a role in 
membrane attachment or protein-protein interactions, which can be essential for the 
protein functionality. Therefore it is hypothesized that inhibition of HMGCR, resulting 
in modulation of isoprenoid synthesis, and thereby protein prenylation, is the key 
mechanism by which statins interfere with the inflammatory and immune responses 
(Greenwood et al., 2006; Thurnher et al., 2012).  
 
2.2 Structure and mode of inhibition 
 
 Different types of statins are available, and these are divided into three 
categories based on their origin; (i) natural statins (also called microbial statins (dos 
Santos et al., 2014)) (i.e. lovastatin and compactin), (ii) semi-synthetic statins (e.g. 
simvastatin and pravastatin), and (iii) statins of synthetic origin (e.g. atorvastatin, 
rosuvastatin, fluvastatin). All statins share an HMG-like substructure, responsible for 
the HMGCR inhibition activity (Istvan and Deisenhofer, 2001). The HMG-like moiety 
can be present in an active form (i.e. open, hydroxy-acid) or inactive form (i.e. 
closed, lactone) (Figure 6C). Unlike synthetic statins, natural and semi-synthetic 
statins are obtained in lactone form, however, in vivo, these statins are enzymatically 
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hydrolyzed to the active form (Corsini et al., 1995). The natural and semi-synthetic 
statins all have a very similar structure (Figure 6); a core polyketide backbone, 
hexahydronaphtalene ring system with different side chains linked to C8 and C6. 
Lovastatin (also called mevinolin or monacolin K) differs from compactin only by the 
presence of methyl group attached to the C8. Simvastatin has an additional methyl 
group in the side chain, and pravastatin is a C6-hydroxy analogue of compactin. 
Besides the HMG-like moiety, synthetic statins do not share any other structural 
similarity to natural statins (Figure 6).  
 All statins are competitive inhibitors of HMGCR with respect to the binding of 
the substrate, HMG-CoA. With their HMG-like moiety, statins bind to the active site 
of HMGCR, thus sterically prevent the substrate from accessing and binding to the 
HMG-CoA binding site (Istvan and Deisenhofer, 2001). 
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Figure 6: Structures of statins – HMGCR inhibitors – and the enzyme substrate HMG-CoA. (A) Structure of HMG-
CoA. (B) Structures of natural statins (lovastatin and compactin), their semi-synthetic derivatives (simvastatin and 
pravastatin), and synthetic statins (atorvastatin, fluvastatin and rosuvastatin). (C) Statins exist in two forms: closed 
lactone form (left), and open hydroxyl acid form (right). The HMG-like moieties are colored blue; the unique groups 
of natural and semi-synthetic statins are colored red. Carbon atom numbering of the hexahydronaphtalene ring 
system of the natural and semi-synthetic statins is shown on the example of lovastatin.  
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2.3 Biosynthesis of natural statins 
 
 The natural statins are synthesized as secondary metabolites by many fungi. 
The first statin, i.e. compactin, was isolated from Penicillium citrinum (Endo et al., 
1976a) in 1976, and shortly after, lovastatin was isolated from Monascus ruber 
(Endo et al., 1979) and Aspergillus terreus (Endo, 1979). Early biosynthesis studies 
on these fungi using labeled precursors revealed that both, compactin and 
lovastatin originate from a similar biosynthetic pathway, i.e. polyketide pathway 
starting with acetate (Endo et al., 1985; Kimura et al., 1990; Komagata et al., 1989; 
Moore et al., 1985). Moreover the biosynthetic gene clusters of lovastatin in A. 
terreus (Hendrickson et al., 1999; Hutchinson et al., 2000; Kennedy et al., 1999) and 
M. pilosus (Chen et al., 2008), and of compactin in P. citrinum (Abe et al., 2002b) all 
contain nine genes, encoding for enzymes with similar amino acid sequences 
(Figure 7). Most of the knowledge about the biosynthesis of the natural statins and 
the molecular genetics of the producer strains is based on the biochemical and 
genetic studies of the lovastatin biosynthetic pathway in A. terreus, I will therefore 
use lovastatin as an example to describe the statin biosynthesis in the next section.  
 
 
Figure 7: Biosynthetic gene clusters of natural statins in filamentous fungi. 
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2.3.1 Lovastatin biosynthesis 
 
 The polyketide backbone of lovastatin is synthesized by two highly reducing 
iterative type I polyketide synthases, LovB and LovF (Hendrickson et al., 1999; 
Kennedy et al., 1999). LovB contains seven active domains (Ma and Tang, 2007) 
(Figure 8) and is responsible for synthesizing of the first intermediate in the pathway, 
a nonaketide called dihydromonacolin L acid (Figure 9). The enzyme is hence called 
lovastatin nonaketide synthase. LovB catalyzes the Claisen condensation of nine 
malonyl-CoA units in successive iterations. After each condensation, the polyketide 
backbone is decorated by the use of different combinations of the tailoring domains, 
i.e. methytransferase (MT), ketoreductase (KR), and dehydratase (DH). As LovB 
contains an inactive enoyl reductase (ER) domain, the reduction of the nonaketide 
backbone is assisted by the trans-acting enoyl reductase LovC (Ames et al., 2012; 
Auclair et al., 2001; Kennedy et al., 1999), which specifically reduces tetraketide, 
pentaketide and heptaketide intermediates during the nonaketide synthesis. 
 
 
 
Figure 8: Domain structure of lovastatin and compactin polyketide synthases. LovB and LovF – Lovastatin 
nonaketide and diketide synthase, respectively. MlcA and MlcB – Compactin nonaketide and diketide synthase, 
respectively. KS – β-ketosynthase; AT – acyltransferase; DH – dehydratase; MT – methyltransferase (MT0 – inactive); 
ER – enoyl reductase (ER0 - inactive); KR – ketoreductase; ACP – acyl carrier protein; CON – condensation domain 
(adapted from (Campbell and Vederas, 2010)). 
 
 Besides the Claisen condensation, LovB is thought to have a Diels-Alderase 
activity responsible for formation of the fused rings of the decalin system of 
dihydromonacolin L (Auclair, 2000; Kelly, 2008; Witter and Vederas, 1996). 
Dihydromonacolin L acid is further modified (hydroxylation and dehydration) by the 
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cytochrome P450 monooxygenase LovA to produce monacolin L acid, which is 
further hydrolyzed by LovA to afford monacolin J acid (Figure 9) (Barriuso et al., 
2011). Lovastatin diketide synthase LovF differs from LovB by the presence of an 
active ER domain (Figure 8) and is responsible for synthesizing the α-methylbutyryl 
side chain of lovastatin by condensation and reduction of two acetyl units (Kennedy 
et al., 1999). The LovF formed diketide chain is transferred to the C-8 hydroxy group 
of monacolin J acid by the acyl transferase LovD (Xie et al., 2009), resulting in the 
formation of lovastatin acid (Figure 9). One unique feature of highly reducing 
polyketide synthases, also found in the two lovastatin polyketide synthases, LovB 
and LovF, is the lack of a functional thioesterase (TE) domain, which in other types 
of polyketide synthases releases the product form the enzyme (M. Wang et al., 
2009; Zhou et al., 2010a). In vitro biochemical studies have revealed that the acyl 
transferase LovD removes the α-methylbutyryl side chain from LovF via direct 
protein-protein interaction and transfers it to monacolin J acid, thereby freeing the 
active site of LovF allowing for initiation of a new synthesis (Kennedy et al., 1999; 
Xie et al., 2009). Similarly, LovB is dependent on the activity of stand-alone 
thioesterase LovG, which releases the formed dihydromonacolin L acid from LovB 
(Xu et al., 2013). Furthermore, LovG is also responsible for the clearance of irregular 
intermediates from LovB (Xu et al., 2013).  
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Figure 9: Lovastatin biosynthetic pathway. LovB (lovastatin nonaketide synthase) produces the first intermediate 
Dihydromonacolin L acid, which is released form the enzyme by the stand-alone thioesterease LovG. The 
nonaketide backbone is tailored by enoyl reductase LovC and cytochrome P450 monooxygenase LovA. The 
diketide portion of lovastatin is synthesized by LovF (lovastatin diketide synthase), which is transferred to the 
nonaketide intermediate monacolin J acid by acyl transferase LovD (adapted from (Ma et al., 2009a; Xu et al., 
2013)). 
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2.3.2 Compactin biosynthesis 
 
 The structure of compactin is very similar to lovastatin, and so is the 
biosynthetic pathway and the enzymes involved in the biosynthesis (Abe et al., 
2002b). The compactin nonaketide synthase MlcA, like LovB, requires a trans-acting 
enoyl reductase, in this case MlcC, to synthesize the first nonaketide intermediate, 
due to the lack of the thioesterase domain. The methytransferase (MT) domains 
present in LovB and LovF were also found in MlcA and the compactin diketide 
synthase MlcB. The methyl group, which is introduced at the C6 position of 
lovastatin is not present in the compactin structure, therefore it is thought that the 
MT domain in MlcA is inactive (Abe et al., 2002b). 
  
 Transcription of the statin biosynthetic genes is regulated by the 
transcriptional activators (mlcR and lovE), which are also encoded in the statin gene 
clusters (Figure 7) (Baba et al., 2006; Chen et al., 2010; Hutchinson et al., 2000). 
Synthesis of many secondary metabolite gene clusters in filamentous fungi are 
controlled by global regulators, such as LaeA and VeA (Bayram et al., 2008; Bok and 
Keller, 2004; Keller et al., 2005), and it has been shown that the two regulators also 
control the compactin synthesis in P. citrinum by modulating the expression of 
mlcR, a transcriptional activator from the compactin cluster (Baba et al., 2012). 
 
2.4 Biotechnological production of natural and semi-
synthetic statins 
 
 Although most of the newer statins are of synthetic origin, the microbial 
statins and their semi-synthetic derivatives are still the first-line treatment of choice 
for patients with high plasma cholesterol and CHD (dos Santos et al., 2014; Tobert, 
2003), simvastatin being the third most prescribed drug in the United States (IMS, 
2012). 
 25 
 Fermentation-based processes using filamentous fungi are the core 
technology in the production of natural and semi-synthetic statin. Lovastatin is 
produced by a variety of filamentous fungi, among which different Monascus (Endo, 
1979; Miyake et al., 2006; Sayyad et al., 2007; Seraman et al., 2010) and Aspergillus 
(Alberts et al., 1980; Benedetti et al., 2002; Casas López et al., 2003; Gupta et al., 
2007; Kumar et al., 2000; Porcel Rodriguez et al., 2008; Samiee et al., 2003) species 
were found to be the most significant producers, however, the commercial 
production of lovastatin is mostly based on the fermentation of Aspergillus terreus, 
and the majority of the research towards improved production of statins has been 
based on this species. Compactin is produced by several species of Penicillium 
(Brown et al., 1976; Choi et al., 2004; Endo et al., 1976a, 1976b; ZafferAhamad et 
al., 2006), and although it is not used medically due to its many side effects, it 
represents an important source for the production of pravastatin, a more effective 
statin. Most of the biotechnological production processes of natural statins are 
based on the liquid submerged fermentation, however in the past decade the solid 
state fermentation (SSF) became a promising alternative production system as it 
showed to have several advantages for the production of statins, e.g. higher 
product yield, lower energy requirement etc. (Baños et al., 2009; Mahesh et al., 
2012; Praveen and Savitha, 2012; Raghavarao et al., 2003; S. Singh and Pandey, 
2013).   
 Compactin is converted to pravastatin in a second stage fermentation via 
biotransformation (hydroxylation) (Endo et al., 1979; Terahara and Tanaka, 1982) by 
different bacteria; Streptomyces (Gururaja et al., 2003; Matsuoka et al., 1989), 
Nocardia (Serizawa et al., 1983a, 1983b), Actinomadura (Peng et al., 1997; Yashphe 
et al., 1997). One of the major problems during the biotransformation of compactin 
to pravastatin is the sensitivity of bacteria to compactin, therefore, searching for the 
conversion organism must include screening for the compactin resistance (Chen et 
al., 2006). Two-step fermentation requires purification of compactin and its 
subsequent biotransformation in another fermentation process, reducing the yields 
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and increasing the cost of the compound (Hosobuchi et al., 1993; Park et al., 2003). 
Therefore, efforts towards developing one-step fermentation process have been 
made; a hydrolase gene from Streptomyces carbophilus that is usually employed in 
the second stage fermentation, has been inserted into the compactin producing P. 
citrinum, and the transformation resulted in a pravastatin producing strain (Luiten et 
al., 2000). Recently, introduction of the compactin biosynthetic pathway and 
Amycolatopsis orientalis cytochrome P450 into Penicillium chrysogenum resulted in 
a successful single-step fermentative production of pravastatin (McLean et al., 
2015). 
 Simvastatin is traditionally obtained via a semi-synthetic multistep process, 
where the 2-methylbutyrate side chain of lovastatin is chemically modified to 2,2-
dimethylbutyrate (Askin et al., 1991; Hoffman et al., 1986). As the semi-synthetic 
conversion is very laborious, simvastatin is approximately five times more expensive 
than lovastatin (Barrios-González and Miranda, 2010), and numerous efforts have 
been made towards establishing a biotechnological process for simvastatin 
production. A one-step whole-cell biocatalytic process has been established by Xie 
et al (Xie and Tang, 2007) by expressing acyltransferase LovD in Escehrichia coli, 
which was able to convert monacolin J to simvastatin. Moreover, the broad 
substrate specificity of LovD (Xie et al., 2006) was exploited, and a suitable 
membrane-permeable acyl donor (α-dimethylbutyryl-S-methyl-mercaptopropionate 
(DMB-SMMP)) was found to be efficiently utilized by LovD in this process (Xie and 
Tang, 2007). To further improve simvastatin production in this biocatalytic process 
LovD has been engineered using directed evolution (Jiménez-Osés et al., 2014). The 
activity of wild-type LovD in A. terreus is depended on acyl-carrier protein (ACP) 
domain of LovF, and has a poor activity towards the non-natural donor DMB-
SMMP, thus Jimenez-Oses et al engineered a LovD, which does not require the 
ACP, and accepts a free DMB-SMMP, making it significantly more efficient for the 
simvastatin synthesis (Jiménez-Osés et al., 2014). 
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 The high impact of statins to human health and their commercial value are 
driving research towards improved biotechnological production of statins. Besides 
the optimization of the existing production processes and statin-producing fungal 
strains, production of statins in a heterologous host represents an attractive 
approach, which remained largely unexploited. The possibility to synthesize statins 
in a heterologous host is discussed in Chapter 4. 
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CHAPTER 3 
3.Self-resistance to secondary 
metabolites 
 
3.1 Introduction 
 
 Secondary metabolites (e.g. antibiotics and mycotoxins) are often toxic to 
the cells that synthesize them; therefore a specific self-resistance mechanism must 
be present in these cells to avoid self-intoxication (Cundliffe, 1989; Demain, 1974). 
Most secondary-metabolite producing organisms carry genes for the self-
protection, and these genes are usually found in clusters together with the genes 
encoding for the biosynthetic machinery and regulation (Hopwood, 2007; Martín et 
al., 2005), as described in Chapter 1. Very little is known about self-resistance 
mechanisms in fungi, which is surprising considering the impact that fungal 
secondary metabolites have in human health. This is also the case for industrially 
relevant systems such as the statin-producing filamentous fungi. Elucidation of the 
self-resistance mechanism to statins is one of the goals of this project; therefore I 
will introduce the concept of self-resistance in the present chapter.  
 The self-toxicity of secondary metabolites is not an issue only in fungi but 
also in plants and bacteria, where much more knowledge regarding the self-
protection mechanisms is available. Insight into the self-resistance mechanisms in 
one type of organisms can hopefully guide discovery and understanding of similar or 
alternative solutions to the same basic problem in other types of organisms. In this 
chapter I will provide an overview of known self-resistance mechanisms to 
secondary metabolites including examples from both, plants and microorganisms 
(bacteria and fungi). Organisms respond to toxic compounds in many different 
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ways, however some mechanisms are compound-specific, and some are of a 
general nature, responding to a variety of different compounds, and some are 
compound-specific responses. The focus in this chapter will be on mechanisms, for 
which the encoding genes are found within the secondary metabolite gene clusters, 
as these are presumed to be metabolite-specific mechanisms.  
Mechanisms by which producers can overcome the deleterious effects of 
producing a bioactive compound have been studied extensively in the antibiotic-
producing bacteria, and mechanisms utilized by plants and fungi have typically been 
identified in connection with studies of plant diseases (Coleman and Mylonakis, 
2009; Del Sorbo et al., 2000; Sirikantaramas et al., 2008). The main mechanisms of 
self-resistance are common in all three types of organisms, and rely on the 
reduction of the metabolite’s concentration at the site where it could have a toxic 
effect. This can be achieved by secreting the secondary metabolite from the cell by 
an efficient transport system (Figure 10, part 1), modifying the metabolite into an 
inactive or less active form (Figure 10, part 2), or sequestering the metabolite into 
compartments where the target is not present (Figure 10, part 3). Moreover, the 
synthesis of the metabolite itself can be controlled by a negative feedback 
mechanism that responds to the increased concentrations of the metabolite in the 
cell, and thereby prevents further increases in the compound concentration (Figure 
10, part 4). Another concept used to confer self-resistance is based on prevention of 
the target-metabolite interaction by alteration of the target site. This can be 
achieved by posttranslational modification of the target, or synthesis of an 
insensitive version of the target (Figure 10, parts 5 and 6, respectively). The target 
protein can also be overexpressed resulting in reduction of the relative 
concentration ratio between the bioactive compound and the target protein (Figure 
10, part 7). In the following sections the different mechanisms are described and 
examples from all three types of organisms (bacteria, plants, fungi) are provided. 
 31 
 
 
Figure 10: Mechanisms of self-resistance to secondary metabolites. (1) Secretion, (2 and 3a) modification, and (3) 
sequestration of the metabolite. (4 and 4a) Feedback inhibition of metabolite biosynthesis. Target alteration by (5) 
posttranslational modification of the target, (6) synthesis of an insensitive version of the target, and (7) target 
overexpression. 
 
 
3.2 Metabolite secretion by transport proteins 
 
The transport proteins encoded by genes located in the secondary 
metabolite gene clusters can serve several purposes. Firstly, they ensure that the 
endogenously produced secondary metabolites reach the extracellular environment, 
where they can act as communication signals, alter the local environment in a way 
to fit the needs of the producing organisms, inhibit the growth of or kill other 
organisms (Martín et al., 2005). Secondly, an efficient efflux mechanism of the 
metabolites protects the producing cells from self-intoxication (Coleman and 
Mylonakis, 2009; Cundliffe, 1989; Del Sorbo et al., 2000). Transport proteins are also 
involved in movement of the intermediates between the different cellular 
compartments. The transporters found in the secondary metabolite gene clusters 
are structurally diverse, and can be divided into two major classes based on the 
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source of energy they are using; (i) ATP-binding cassette (ABC) transporters, and (ii) 
major facilitator superfamily (MFS) transporters (Figure 11). 
 
 
 
Figure 11: Main classes of transporters involved in the secondary metabolite secretion and self-resistance; ABC 
transporters hydrolyze ATP in order to secrete the metabolites and are usually composed of two nucleotide binding 
domains (NBD), and two hydrophobic regions, each containing 6 transmembrane domains (TMS). MFS transporters 
use the transmembrane electrochemical gradient of protons to transport the metabolites across the membrane and 
contain 12 or 14 TMS (adapted from (Coleman and Mylonakis, 2009; Piddock, 2006). 
 
ABC transporters use the energy from ATP hydrolysis to export the 
metabolite. Most ABC transporters are composed of nucleotide-binding domain 
(NBD), followed by a hydrophobic region containing 6 transmembrane domains 
(TMS). The two parts can be synthesized as one polypeptide, which dimerize to 
form a fully functional protein, however, in fungi a single polypeptide containing two 
NBD and two TMS regions is synthesized (Higgins, 1992; Hyde et al., 1990; Saier, 
2003). Numerous ABC transporters from bacterial secondary metabolite gene 
clusters have been characterized, mostly from different antibiotic-producing 
Streptomyces species (Fernández et al., 1996; Linton, 1994; Olano, 1995; Rosteck, 
1991; Schoner et al., 1992). In contrast, only a few examples of secondary-
metabolite ABC transporters have been found in fungal secondary metabolite gene 
clusters; SirA confers self-resistance to sirodesmin in Leptosphaeria maculans. 
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Sirodesmin is a cyclic dipeptide with a disulfide bridge that generates reactive 
oxygen species (ROS) in the cells and interacts with susceptible thiol residues on 
proteins, resulting in their inactivation. L. maculans sirA mutant was considerably 
more sensitive to sirodesmin than the wild-type strain (Gardiner et al., 2005). FUM19 
from Fusarium verticillioide was proposed to confer the self-resistance to fumonisin 
- inhibitor of ceramide synthase, enzyme involved in sphingolipid metabolism, 
because the gene encoding for this transporter is located in the fumonisin 
biosynthetic gene cluster and its deletion affected the synthesis of fumonisin, 
however, the direct role in self-resistance is yet to be confirmed (Proctor et al., 
2003).  Other ABC transporters found to be conferring self-resistance to secondary 
metabolites in fungi are ATR1, efflux pump for ROS-generating compound 
cercosporin from Cercospora nicotianae (Amnuaykanjanasin and Daub, 2009), and 
AtrD transporter from Aspergillus nidulans capable of secreting penicillin (Andrade et 
al., 2000). Special for the two latter examples is that the genes encoding the pumps 
are located outside the gene clusters encoding the biosynthetic apparatuses. ABC 
transporters are also important in conferring the self-resistance in plants (Jasiński et 
al., 2001; Stukkens et al., 2005; Van Den Brûle et al., 2002).  
Members of MFS of transporters are characterized by the presence of a 
single polypeptide that usually includes 12 or 14 TMS. They are capable of 
transporting only small molecules and utilize the transmembrane electrochemical 
gradient of protons to drive the transport of the metabolites (Pao et al., 1998; 
Paulsen et al., 1996). Like ABC transporters, most of the characterized MFS 
transporters originate from Streptomyces spp., where they typically are responsible 
for exporting antibiotics, such as cephamycins (Coque, 1993; Liras, 1999; Pérez-
Llarena et al., 1998) and tetracycline (Ohnuki et al., 1985; Reynes et al., 1988). In 
fungi, MFS transporters are the most numerous types of transporters (Coleman and 
Mylonakis, 2009). Despite their abundance, only a few MFS transporters have been 
functionally characterized, and shown to be directly involved in self-resistance to 
secondary metabolites. GliA, MFS transporter from Aspergillus fumigatus encoded 
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in the gliotoxin biosynthetic gene cluster, exports this ROS-generating compound 
from the fungus (Wang et al., 2014). Similarly, TOXA exports HC-toxin, which is an 
inhibitor of histone deacetylases, from Cochliobolus carbonum (Pitkin et al., 1996), 
TRI12 exports trichothecene toxin, an inhibitor of protein synthesis, from Fusarium 
sporotrichioides (Alexander et al., 1999), and CFP is capable of secreting 
cercosporin from Cercospora kikuchii (Callahan et al., 1999; Upchurch et al., 2002). 
Secondary metabolite gene clusters containing more than one transporter 
have also been described. The gene encoding for a HC-toxin efflux pump TOXA is 
present as two linked copies in most toxin-producing isolates (Pitkin et al., 1996). 
Moreover, the cephalosporin cluster in Acremonium chrysohenum contains two 
genes encoding for the putative MFS transporters, cefM and cefT, and a gene 
encoding for a transporter of an uncharacterized family, cefP. While CefT exports β-
lactam antibiotic cephalosporin from the cells and likely confers self-resistance 
(Ullán et al., 2002), CefM and CefP translocate the intermediates between cellular 
compartments, and are thereby directly involved in the cephalosporin biosynthesis. 
CefP transports isopenicillin N into peroxisomes (Ullán et al., 2010), where it is 
converted to penicillin N. The latter is then transported from the peroxisomes to the 
cytosol by CefM, where it is converted into the final compound cephalosporin C 
(Teijeira et al., 2009). This example shows that transport proteins also play an 
important role in the intracellular transport of secondary metabolites between the 
different compartments, a process that can also confer the self-resistance, as 
described in the next section. The role of transporter proteins in sequestrations is 
well known in plants, where certain ABC transporters transfer secondary 
metabolites into vacuoles (Goodman et al., 2004; Klein et al., 2000; Lu et al., 1997). 
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3.3 Sequestration of the metabolite by 
compartmentalization 
 
 Spatial organization is one of the least studied aspects of secondary 
metabolism. Nevertheless, studies of both myco- and phytotoxin biosynthetic 
pathways in the past decade have revealed that the key elements in secondary 
metabolism (i.e. biosynthetic enzymes, intermediates and end products) are often 
localized in distinct sub-cellular compartments (vacuoles, peroxisomes, vesicles, 
cytoplasm), in highly specialized cells, or in different tissues. One possible role of 
the compartmentalization of secondary metabolites is that sequestration can 
provide self-resistance (Roze et al., 2011; Sirikantaramas et al., 2008). This type of 
self-resistance is often found in plants. In many cases the toxic metabolites are 
transported into the vacuole, where they can accumulate without damaging the 
cells, a common mechanism of self-protection against flavonoids (e.g. anthocyanins 
(Ahmed, 1994; Rueff, 1995)) and alkaloids (Deus-Neumann and Zenk, 1984). In 
addition to the compartmentalization of the toxic compounds, the synthesis of the 
metabolites can be carried out in specialized compartments, as in the synthesis of 
cannabinoids in glandular trichomes (Sirikantaramas et al., 2005), compartments 
that are essentially outside of the plant body (Wagner, 1991). Different vesicles are 
also involved in the secondary metabolite biosynthesis and self-resistance in fungi. 
Penicillin biosynthesis in Penicillium chrysogenum is compartmentalized in Golgi-
derived vesicles, cytosol and peroxisomes (Kuryłowicz et al., 1987; Meijer et al., 
2010; Van De Kamp, 1999), however localization of the first catalytic enzyme in the 
synthesis (ACVS3) is still controversial (Lendenfeld et al., 1993; Müller et al., 1991; 
van der Lende et al., 2002). Similarly, the aflatoxin biosynthesis in Aspergillus 
parasiticus is carried out in several different vesicles, including specialized vesicles 
named aflatoxisomes, which are thought to confer the self-resistance to the 
mutagenic aflatoxin (Figure 12) (Chanda et al., 2009; Hong and Linz, 2009, 2008; 
                                                
3 δ-(L-α-amino- adipyl)-L-cysteinyl-D-valine (ACV) synthetase 
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Lee et al., 2004). Tolypocladium inflatum has been shown to deposits cyclosporin in 
the vacuole upon its complete synthesis (Hoppert et al., 2001). Besides the self-
protection role, the different vesicles in fungi are predicted to have a role in storage, 
protein turnover, transport or export of the secondary-metabolites by exocytosis as 
an alternative secretion mechanism to the transporter-mediated export. 
Compartmentalization can also ensure a high concentration of substrates, cofactors 
and intermediates at the same site where key enzymes are present, thus increase 
the flow through the pathway, and can prevent cross-chemistry between the 
pathways (Chanda et al., 2009; Roze et al., 2011). Specific conditions in a 
compartment, such as the low pH of the vacuole, can theoretically also modify the 
compound resulting in the inactivation of the compound (Figure 10, part 3a). 
 
 
 
Figure 12: Model for compartmentalization of the aflatoxin biosynthesis in Aspergillus spp. The first steps in aflatoxin 
biosynthesis are carried out in peroxisomes. It is not known how the early enzymes (PKS, FAS) translocate into the 
peroxisomes. Vesicles originating from peroxisomes and mitochondria fuse with CVT (cytoplasm-to-vacuole-
transport) vesicles that contain middle and late aflatoxin enzymes, and eventually with secretory vesicles to develop 
aflatoxisomes. The late stages in aflatoxin biosynthesis are carried out in aflatoxisomes, which are also responsible 
for the aflatoxin export (adapted from (Chanda et al., 2009; Kistler and Broz, 2015; Roze et al., 2011)). 
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3.4 Enzymatic metabolite modification 
 
 Several secondary-metabolite producers possess enzymatic systems 
capable of modifying endogenously produced metabolites, transforming them into 
less active or inactive forms (Figure 10, part 2). These modifications need to be 
reversible in order to keep the ability of the compounds to play their role in the 
organisms’ environment. Enzymatic metabolite modification is a common 
mechanism of self-resistance in antibiotic-producing bacteria, where – despite the 
chemical diversity of the produced antibiotics – two modes of metabolite 
modifications are prevailing; N-acetylation of amino groups and O-phosphorylation 
of hydroxyls (reviewed by (Cundliffe, 1989)). Reduction and glycosylation of 
antibiotics in some Streptomyces spp. have also been identified as mechanisms of 
self-resistance (Cundliffe, 1992; Jenkins and Cundliffe, 1991; Lee et al., 1996; Zhao, 
1998). In plants, glycosylation is an important detoxifying mechanism and several 
toxic metabolites have been shown to be stored as glucosides, e.g. benzoxazinoids 
(Osbourn, 1996; Schulz and Wieland, 1999; Sicker et al., 2000), reactive 
phenylpropanoids (Meyermans et al., 2000), cyanogenic glucosides (Conn, 1980) 
and glucosinolates (Rask et al., 2000). In fungi, only one example of metabolite 
modification as a self-protection mechanism have been published so far; GliT is an 
oxidase encoded in the gliotoxin biosynthetic gene cluster of Aspergillus fumigatus, 
responsible for oxidation of gliotoxin and thereby formation of the disulfide bridge in 
this compound. In addition to its role in the biosynthesis, GliT has also been shown 
to confer the self-resistance to gliotoxin in this fungus, probably by preventing 
unwanted redox cycling, as well as conjugation of gliotoxin with susceptible 
proteins. It has also been proposed that, since reduced gliotoxin was not found in 
the broth of the GliT-deletion mutant, the oxidized form with the disulfide bridge 
might be the requirement for the gliotoxin export (Scharf et al., 2010). Reduction of 
cercosporin was proposed to provide the self-resistance to this toxic compound in 
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Cercospora spp., but it is not known how does the reduction take place (Daub et al., 
1992). 
 
3.5 Feedback regulation 
 
Biosynthesis of secondary metabolites is often subjected to negative 
feedback regulation. Because primary and secondary metabolism share a pool of 
precursors, it has been proposed that antibiotic producers evolved negative 
feedback inhibition of the secondary metabolite’s synthesis to ensure the 
maintenance of the primary metabolism (Koehn, 2013). However, since secondary 
metabolites can be toxic to the producers, one might consider the feedback 
regulation as a way of self-protection. The exact mechanism of feedback regulation 
is often not known, but some of the examples suggest that the secondary 
metabolite can either directly inhibit the activity of a preexisting biosynthetic enzyme 
(Figure 10, part 4) (Hamano et al., 2007), or it can affect expression of the genes 
involved in its biosynthesis and regulation, a mechanism also referred to as 
feedback repression (Sanchez and Demain, 2002) (Figure 10, part 4a) (Ajithkumar 
and Prasad, 2010; Clay et al., 2009; Srinivasan et al., 2010). As described in 
previous sections, transporters often maintain subinhibitory physiological 
concentration of the secondary metabolites within the cells. Deletion of these 
transporters in the secondary metabolite producing cells can result in increased 
sensitivity of the cells to toxic metabolites added externally in the medium, but it can 
also lead to the decreased production of the compound. This has been shown for 
the cercosporin and trichothecene specific efflux pumps, where deletion of the 
encoding genes reduced the synthesis of the given secondary metabolite in fungus 
(Alexander et al., 1999; Amnuaykanjanasin and Daub, 2009; Callahan et al., 1999; 
Choquer et al., 2007). Results, which suggest that a negative product feedback 
regulation exist in these systems, and that the pumps prevent the intracellular 
accumulation of the product. Regulatory feedback mechanism is also present in the 
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lovastatin biosynthesis in A. terreus, however it is not clear how does lovastatin 
inhibits its own synthesis (Casas López et al., 2004).  
 
3.6 Target alteration 
  
 Targets of bioactive secondary metabolites are often enzymes involved in 
the primary metabolism or in the synthesis of macromolecules, and self-resistance 
mechanisms involving the target enzymes exist. Posttranslational modification of a 
sensitive target enzyme, which weakens or prevent the interaction of the enzyme 
with the secondary metabolite, can afford self-resistance to the given compound 
(Figure 10, part 5). Self-resistance can be also achieved by replacement of the 
target enzyme with its resistant version; in some cases a resistant enzyme have 
evolved with altered amino acid sequence that prevents the interaction of the 
enzyme with the toxic compound (Figure 10, part 6). Such resistant enzyme is co-
expressed with the genes encoding for the biosynthetic pathway. Alternatively, the 
target enzyme might be overexpressed (Figure 10, part 7), resulting in sufficient 
activity in the presence of the toxic secondary metabolite. The basic concept behind 
the latter mechanism is reduction of the relative concentration ration between the 
bioactive compound and the target protein; nevertheless, the mechanism involves 
the target enzyme, and is therefore included in this section.  
 Resistance enzymes that modify the metabolite target site are common in 
bacteria that produce inhibitors of protein synthesis; Streptomyces spp. 
synthesizing thiostrepton (Thompson et al., 1982), kanamycin (Nakano et al., 1984) 
or erythromycin (Skinner and Cundliffe, 1982; Teraoka and Tanaka, 1974) have 
ribosomal RNA (rRNA) methylases that confer the self-resistance by introducing a 
single methyl group into rRNA, an alteration that prevents the antibiotics to bind to 
this target molecule, the ribosome. As for many other self-resistance mechanisms, 
the encoding genes for rRNA methylation are located within the antibiotic 
biosynthesis gene clusters (Stanzak et al., 1986; Yanai and Murakami, 2004). 
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 Many examples of the synthesis of resistant version of the target protein 
have been described in bacteria that produce antibiotics with non-ribosomal 
targets. Novobiocin is an inhibitor of DNA gyrase, and the producer of this antibiotic 
Streptomyces sphaeroides carries two genes encoding for DNA gyrase in its 
genome. One of these two genes is located in the novobiocin biosynthetic gene 
cluster (Steffensky et al., 2000) and its expression is induced by novobiocin. The 
DNA gyrase encoded within the cluster is resistant to novobiocin, whereas the 
product of the second gene, which is constitutively expressed, is novobiocin-
sensitive (Thiara and Cundliffe, 1989, 1988). Another example was shown in the 
pentalenolactone (PL)-producing Streptomyces spp. PL inhibits glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), and the producer contains two GAPDH 
isozymes, one sensitive to PL, and one PL-insensitive. Gene encoding for the PL–
insensitive GAPDH is located in the PL biosynthetic gene cluster, and its 
transcription is increased upon the PL synthesis (Fröhlich et al., 1989; Tetzlaff et al., 
2006). Kirromycin produced by Streptomyces ramocissimus inhibits protein 
synthesis by binding to the polypeptide chain elongation factor (EF)-Tu (Olsthoorn-
Tieleman et al., 2007). Gene encoding for a kirromycin-resistant EF-Tu has been 
found in Streptomyces ramocissimus, however, kirromycin does not induce 
transcription of this putative self-resistance gene (Glöckner and Wolf, 1984). 
Interestingly, the producing organism contains two more genes encoding for EF-Tu, 
which are constitutively expressed and the product of both is kirromycin sensitive 
(Olsthoorn-Tieleman et al., 2007; Vijgenboom et al., 1994), therefore overexpression 
of the target enzyme might be the mechanism of self-resistance in this case. Only 
two examples of target alteration as a self-resistance mechanism in fungi have been 
published so far. Camptothecin producing fungus Fusarium solani protects itself 
from this DNA topoisomerase I inhibitor by synthesizing DNA topoisomerase I with a 
structure that prevents camptothecin from binding to it (Kusari et al., 2011), however 
the location of the self-resistance gene in the fungal genome is not known. A 
resistant version of inosine-5-monophosphate (IMP) dehydrogenase, a target of 
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mycophenolic acid (MPA) was found in the MPA producer Penicillium 
brevicompactum, and the gene encoding for this enzyme lies within the MPA 
biosynthetic cluster (Hansen et al., 2011; Sun et al., 2011).  
 
3.7 Self-resistance is a complex system  
 
 From the examples above it is clear that one self-resistance mechanism can 
serve multiple different functions. Compartmentalization of secondary metabolites 
function as sequestration, but it can also play a role in the modification/activity of 
the metabolites, as specific conditions in the compartment (e.g. low pH in the 
vacuole) can affect the structure, and thereby activity of the compound. This duality 
is similar for efflux pumps, which secrete the secondary metabolites out of the 
producing cells, but are also involved in metabolite sequestration by transporting 
them into different compartments. Moreover, secondary metabolite biosynthetic 
gene clusters, in both bacteria and fungi, often include more than one gene 
encoding for self-resistance mechanism, one of them being a transporter (either 
MFS or ABC) in most of the published examples (Pernodet et al., 1993; Proctor et 
al., 2003; Siegers and Entian, 1995; Wang et al., 2014). Thus, self-resistance is 
typically not a single-protein activity, but rather a complex system composed of 
several mechanisms, which allows for the production of increased concentrations of 
the bioactive compound.    
 
3.8 Engineering self-resistance for improved 
biotechnological processes 
 
 Understanding the molecular biological basis underlying the self-resistance 
mechanisms in secondary metabolite producers can provide novel tools for 
improvement of biotechnological processes. Especially knowledge regarding the 
molecular mechanisms of metabolite secretion has an important, but so far largely 
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ignored, biotechnological potential as it can be used for strain engineering to 
increase the secretion of these product metabolites reducing purification costs. In 
addition to the improved resistance and reduced purification cost, the increased 
secretion of the products will also remove the negative feedback inhibition that 
sometimes limits the biosynthesis of the end product. Up to 2-fold increase in the 
cephalosporin production, a β-lactam antibiotic from fungus Acremonium 
chrysogenum, was observed when the MFS transporter gene cefT was 
overexpressed (Ullán et al., 2002). Moreover, overexpression of ABC transporters 
improved production of several medically important compounds; the productivity of 
antibiotic avermectin in Streptomyces avermitilis was 1.5 times higher upon 
overexpression of the AvtAB transporter (Zhang et al., 2002b). Similarly, an 
engineered strain of Streptomyces peucetius expressing multiple copies of ABC 
transporter DrrAB enhanced the production (2.2-fold increase) of an antitumor 
compound doxorubicin and had a longer life span than the parental strain (Malla et 
al., 2010). Production of doxorubicin in Streptomyces peucetius was also improved 
(5.1-fold increase) when another self-resistance gene was overexpressed, drrC 
encoding for an UvrA-like protein that protects the cells through excisional repair of 
DNA (Lomovskaya et al., 1996; Malla et al., 2010). In Streptomyces coelicolor it has 
been shown that the expression of ABC transporter ActAB is a critical determinant 
of antibiotic actinorhodin yields. Deletion of the transcriptional repressor of actAB 
operon resulted in a 4- to 5-fold increase in actinorhodin production (Xu et al., 
2012).  
 In cases where secondary metabolites inhibit or repress their own 
biosynthesis metabolic engineering approaches can be used to achieve 
overproduction of the secondary metabolites. One general strategy is to increase 
the step after formation of the inhibitory metabolite, and as discussed before, 
increased secretion is a good option. Alternatively, genes encoding feedback-
insensitive enzymes can be introduced in the producing organisms (Sanchez and 
Demain, 2002). 
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 Understanding of the compartmentalization of a biosynthetic-pathway can 
also provide novel strategies for metabolic engineering of the secondary-metabolite 
producing organisms, and guide an expression of the pathways in a heterologous 
host. As exemplified by the finding that co-localization of the penicillin biosynthetic 
enzymes in peroxisomes improved penicillin production in Aspergillus nidulans (Herr 
and Fischer, 2014). The three main enzymes required for the synthesis of penicillin 
are located in different subcellular compartments. Whereas the nonribosomal 
peptide synthase AcvA and the isopenicillin N (IPN) synthase IpnA localize to 
cytoplasm, the last enzyme that converts IPN to penicillin G, namely AatA, resides in 
peroxisomes. Targeting of AcvA to peroxisomes led to a 3.2-fold increase in 
penicillin yield. Moreover, the number of peroxisomes was doubled, resulting in 2.3 
times higher production of penicillin.  
 Improvement of cell factories by increasing their resistance to the produced 
metabolites cannot always be achieved by overexpression the self-resistance genes 
or by modification of feedback regulation or compartmentalization, as they are often 
unknown. In these cases, other approaches have to be used to construct the strains 
that can tolerate high concentrations of the toxic compounds. Random mutagenesis 
or genome shuffling (Zhang et al., 2002a) are some of the possible approaches. The 
latter was successfully used to improve the self-resistance to antibiotic 
pristinamycin in Streptomyces pristinaespiralis. Strain with improved resistance also 
exhibited 1.9-fold increase in the production of this antibiotic compared to the wild 
type strain (Xu et al., 2008). Moreover, target engineering (i.e. generating mutations 
that confer drug resistance) (Ochi, 2007) improved production of several antibiotics 
in Streptomyces spp. (Hesketh, 1997; Shima et al., 1996; Tanaka et al., 2009; G. 
Wang et al., 2008)  
 If bioactive secondary metabolite is to be produced in a heterologous host, a 
resistance mechanism will be necessary to overcome the product toxicity where the 
target of the produced compound is present in the host organism. Genes encoding 
for the self-resistance mechanisms in the natural producers are good candidates for 
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co-expression in the host microorganism. However, it is not likely that all types of 
self-resistance mechanisms are equally easy to transfer to a heterologous host, e.g. 
methylation of rRNA might not be compatible with other organisms. Understanding 
the self-resistance mechanism in a natural producer can also guide the engineering 
of the heterologous host. Improvement of the secondary-metabolite resistance has 
been shown to be a good metabolic engineering strategy towards increased 
production of the compound in a heterologous host; de novo biosynthesis of vanillin 
in Schizosaccharomyces pombe was improved by introduction of UDP-
glycosyltransferase from the plant Arabidopsis thaliana, an enzyme that converts 
vanillin, which is toxic to yeast, to nontoxic vanillin β-D-glucoside (Hansen et al., 
2009). In conclusion, a growing body of evidence suggests that the use of both, 
self-resistance mechanisms as well as other strategies for improved resistance can 
improve yields of secondary metabolites, and thereby have a potential to 
significantly improve biotechnological processes for their production. 
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CHAPTER 4 
4.Attempt to construct a Saccharomyces cerevisiae 
cell factory for production of compactin  
 
  
 The goal of this subproject was to express the P. citrinum compactin 
biosynthetic pathway in a heterologous host, i.e. Saccharomyces cerevisiae. This 
ambition was not accomplished, nevertheless, in this chapter I will briefly explain the 
reasoning behind the choice of organism, and provide a summary of the work aimed 
at constructing the yeast-based compactin cell factory, as it places the further 
experimental chapters (Chapters 5 and 6) into a perspective. 
 
4.1 Introduction 
 
 As presented in Chapter 2, the biotechnological production of natural and 
semi-natural statins is based on submerged fermentation of filamentous fungi, such 
as Aspergillus spp. and Penicillium spp.. The filamentous growth of these organisms 
lead to formation of dense pellets that increase viscosity and reduce oxygen 
solubility, which make their cultivation in standard liquid fermentation systems 
difficult and expensive. Moreover, statins are synthesized when the fungal growth is 
limited, and the nutrients are exhausted (Hajjaj et al., 2001), which increases the 
difficulty of the fermentation process control. The filamentous fungi used for 
production are also capable of synthesizing numerous other secondary metabolites; 
a feature that can reduce yields and complicate the product purification steps. One 
example of an undesirable co-metabolite during lovastatin fermentation in A. terreus 
is benzophenone sulochrin (Couch and Gaucher, 2004). In order to be commercially 
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successful, statins produced by fermentation must be cost-competitive; therefore 
there is a constant need for improvement of the production processes. 
 Optimization of the biotechnological production of natural and semi-natural 
statins has mostly been based on two approaches; optimization of the 
bioprocessing conditions and improvement of the production organism (Barrios-
González and Miranda, 2010; Mulder et al., 2015; S. K. Singh and Pandey, 2013). 
However, strategies to improve secondary metabolite production can also include 
the transfer of the biosynthetic gene cluster to a heterologous host. Heterologous 
production of statins in a fast-growing host, such as S. cerevisiae, could bring new 
opportunities for optimization of this process, thus making it cost-competitive. 
Moreover, heterologous production of statins would provide a platform for future 
combinatorial biochemistry experiments aimed at the synthesis of novel statins with 
improved pharmacokinetic and pharmacodynamics properties.  
 The yeast S. cerevisiae, a unicellular eukaryotic organism from the kingdom 
of fungi, is one of the most widely used cell factories (Borodina and Nielsen, 2014; 
Nielsen and Jewett, 2008). S. cerevisiae is suitable for large-scale production of 
various products because of its high specific growth rates, and high biomass levels 
on simple and cheap media, and on complex (rich) and defined (minimal) media. 
Besides the ease of cultivation, S. cerevisiae is well characterized both 
physiologically and genetically, enabling optimization of existing biotechnological 
production processes using this organism as a heterologous production host. The 
broad range of available tools for genetic manipulation of S. cerevisiae allows for 
easier genetic engineering than it is possible in e.g. filamentous fungi (Da Silva and 
Srikrishnan, 2012). Advancements in synthetic biology and metabolic engineering 
tools have enabled and enhanced our ability to engineer S. cerevisiae to produce a 
wide variety of value-added products, including polyketides, e.g. 6-methylsalicylic 
acid (6-MSA) from Penicillium patulum (Kealey et al., 1998; Wattanachaisaereekul et 
al., 2008, 2007), (R)-monocillin II from Pochonia chlamydosporia (Zhou et al., 2010b), 
and rubrofusarin from Fusarium graminearum (Rugbjerg et al., 2013). Despite the 
 67 
obvious advantages of S. cerevisiae as a host for industrial applications, and its 
capacity to synthesize a diverse range of products, several requirements need to be 
considered when S. cerevisiae is intended for production of polyketides (e.g. 
statins). Firstly, heterologous production of polyketides requires the functional 
expression and correct posttranslational modifications of the large and complex 
enzymes, i.e. PKSs. In order to be functional, PKSs require posttranslational 
modification by 4'-phosphopantetheinyl transferase (PPTase), which covalently 
attaches the 4'-phosphopantetheine (P-pant) moiety of CoA to a conserved serine 
residue in the P-pant-dependent carrier protein of PKS. Therefore, co-expression of 
PPTase with PKSs is essential for the production of polyketides in S. cerevisiae 
(Wattanachaisaereekul et al., 2007). Secondly, building blocks for the polyketide 
biosynthesis must be available in sufficient quantities to sustain high production 
levels. Thirdly, S. cerevisiae must possess a resistance mechanism against any toxic 
effects the produced compound(s) may have. The subject of resistance was already 
introduced in Chapter 3, and will be further discussed in Chapters 5 and 6. Here I 
provide a summary of the work aiming at the heterologous expression of the 
compactin biosynthetic pathway (Figure 1) in S. cerevisiae. 
 
 
Figure 1: Compactin biosynthetic pathway as proposed by Abe et al (Abe et al., 2002b), and according to the new 
information regarding the lovastatin pathway (Xu et al., 2013). MlcA – nonaketide synthase, MlcB – diketide 
synthase, MlcC – P450 monooxygenase, MlcF – oxidoreductase, MlcG – enoyl reductase, MlcH – Transesterase, 
SAM – S-adenosylmethionine. 
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4.2 Results and discussion 
 
 The attempt to construct a S. cerevisiae based cell factory for compactin 
production involved the expression of the compactin biosynthetic genes from P. 
citrinum in S. cerevisiae using a chromosomal gene integration approach. Stable 
integration is more suitable for the introduction of multiple genes, and thus 
expression of metabolic pathways, compared to the autonomously replicating 
plasmid vectors, because it offers precise gene copy number control and long-term 
stability (Da Silva and Srikrishnan, 2012). The use of vectors, such as 2μ or 
CEN/ARS, can result in loss of the required genes, as two or more copies of these 
vectors can be difficult to stably maintain in a single cell (Futcher and Cox, 1983; 
Mead et al., 1986). Moreover, expression of multiple genes from integrative 
cassettes is more homogenous within the yeast population than expression from 
multiple plasmid vectors (Jensen et al., 2014). For genomic integration of the 
compactin biosynthetic genes, the yeast expression platform developed by 
Mikkelsen et al. (University of Copenhagen, Denmark) was applied (Mikkelsen et al., 
2012). Codon-optimized de novo synthesized compactin biosynthetic genes (mlcA, 
mlcC, mlcF and mlcG; Table 1) required for the synthesis of the nonaketide 
intermediate ML-236A (Figure 1) were expressed in S. cerevisiae CEN.PK113-11C 
as single copy genes from defined loci in the yeast genome (Table 1). Strong 
constitutive promoters TEF1 or PGK1 were used for expression of all genes, except 
for the PKS-encoding gene mlcA, which was expressed from the galactose-
inducible promoter GAL10 (Table 1). In order to avoid self-intoxication, two putative 
self-resistance genes mlcD and mlcE were co-expressed, resulting in a strain with 
six genes from the compactin biosynthetic gene cluster. To ensure efficient post-
transcriptional activation of the MlcA PKS, two genes encoding for PPTase with 
broad substrate specificity were co-expressed individually in the pathway-harboring 
yeast strain; either npgA from Aspergillus nidulans (Keszenman-Pereyra et al., 2003), 
or sfp from Bacillus subtilis (Mootz et al., 2001), resulting in strains AR22 and AR23, 
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respectively. The constructed strains (AR22 and AR23) were analyzed for the 
production of expected intermediates (4a,5-dihydro ML236-C, ML236-C or ML-
236A) in the compactin biosynthetic pathway (Figure 1) by LC-MS, however, we 
were not able to detect any new compounds in the analyzed strains (AR22 and 
AR23) (data not shown). The method used for extraction and analysis of the 
expected intermediates have been previously verified (Kildegaard, 2011), ruling out 
the possibility that the negative results were due to inadequate procedures to 
extract and detect the metabolites. 
 
Table 1 
List of genes integrated into the S. cerevisiae CEN.PK genome using the yeast expression platform developed by 
Mikkelsen et al (Mikkelsen et al., 2012). 
Gene 
name (Putative) function Promoter 
Integration 
sitea 
Genes from the P. citrinum compactin biosynthetic gene cluster 
mlcA Nonaketide synthase (Synthesis of the polyketide backbone) GAL10 X-4 
mlcC P450 monooxygenase (hydroxylation and dehydration of the backbone) TEF1 XII-1 
mlcF Oxidoreductase (Release of the intermediate from MlcA) PGK1 XII-1 
mlcG Enoyl reductase (Reduction of the nonaketide backbone) TEF1 XII-4 
mlcD HMG-CoA reductase-like (Resistance) PGK1 X-3 
mlcE Efflux pump (Resistance) TEF1 X-3 
Genes for posttranslational modification of MlcA 
npgA PPTase (activation of MlcA) TEF1 X-2 
sfp PPTase (activation of MlcA) TEF1 X-2 
a Roman numerals indicate the number of a chromosome, and whole numbers indicate the locus on a chromosome, 
in which the gene was integrated. 
 
 
 To test whether the gene-integration and induction regime allowed for the 
expression of the key-enzyme in the pathway, PKS MlcA, I tagged mlcA with RFP at 
its carboxylic terminus. Fluorescent microscopy of the resulting strain (AR30) 
revealed that MlcA indeed was expressed and that the fluorescent signal was 
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accumulated as bright foci in the cells (Figure 2). This result indicates that MlcA is 
either localized in a certain subcellular compartment or is accumulated as protein 
aggregates (inclusion bodies) in the cytosol, which may arise from improperly 
folded, and thus insoluble proteins (Fink, 1998; Y. Wang et al., 2009). Both situations 
could explain the inability of the recombinant strains (AR22 and AR23) to produce 
the intermediates of the compactin biosynthetic pathway. If the PKS MlcA is 
localized in a compartment separately from the rest of the required enzymes (i.e. 
PPTase), it is unable to synthesize the nonaketide backbone. More specifically, 
MlcA would be inactive in the absence of PPTase due to the lack of 
posttranslational modification. A similar phenotype could also be result from the 
incompatibility of the chosen PPTases with MlcA, however both NpgA and Sfp had 
previously been proven to be a suitable candidates for heterologous co-expression 
with various PKSs (Quadri et al., 1998; Wattanachaisaereekul et al., 2007), including 
the lovastatin nonaketide synthase LovB (Ma et al., 2009a). Moreover, insufficient 
availability of biosynthetic substrates (i.e. acetyl-CoA, malonyl-CoA and S-
adenosylmethionine) in specific cellular compartments may be insufficient. The 
precursor supply for polyketide production in S. cerevisiae has been shown to be 
important when establishing a S. cerevisiae cell factory for 6-MSA production 
(Wattanachaisaereekul et al., 2008). Improper folding of MlcA could also provide an 
explanation for the failure to produce compactin intermediates, as misfolded 
proteins may possess insufficient catalytic activity (Fink, 1998). The results shown in 
Figure 2 are very similar to those published by Siewers et al., where heterologous 
expression of a non-ribosomal peptide synthase (NRPS) in S. cerevisiae resulted in 
formation of protein aggregates that appeared as bright foci when the NRPS was 
fused with YFP at its C-terminus (Siewers et al., 2009). 
  One of the factors affecting the protein folding is the cultivation temperature, 
and its reduction can enable the cells to fold the proteins correctly (Gidijala et al., 
2008; Li et al., 2001). In our case, lowering the cultivation temperature from 30°C to 
25°C or 20°C did not result in production of compactin intermediates in the AR22 
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and AR23 strains, nor did it affect the observed intracellular distribution of RFP-
tagged MlcA (data not shown). These results did not resolve the question, why the 
constructed strains were not producing the expected compactin intermediates. 
Further investigation of the expression of the compactin biosynthetic genes, the 
intracellular localization of the heterologous proteins and their posttranslational 
modification (i.e. phosphopantetheinylation of MlcA) is required, and an alternative 
expression system could be considered. 
 
 
Figure 2: Fluorescence microscopy of S. cerevisiae expressing mlcA-RFP (strain AR30; X4::(pGAL10­mlcA-RFP)). 
Prior to microscopy the strain was cultured in liquid YPGal medium at 30°C with 150 rpm agitation overnight. DIC – 
differential interference contrast. 
 
4.3 Conclusions 
 
Heterologous production of statins in a fast-growing host, such as S. 
cerevisiae, has been an ambition of several research groups around the world. The 
intention to construct a S. cerevisiae cell factory for compactin production was not 
realized, as the yeast strains harboring the compactin biosynthetic genes did not 
produce any of the expected intermediates in the compactin pathway. At the time 
when I obtained the results described in this chapter, another research group, 
namely Xu et al. (University of California, Los Angeles, USA), succeeded in 
producing the first stable lovastatin intermediate dihydromonacolin L acid in S. 
cerevisiae (Xu et al., 2013). They used plasmid vectors to express LovB (nonaketide 
synthase), LovG (oxidoreductase) and LovC (enoyl reductase) in S. cerevisiae strain 
NpgA BJ5464-NpgA (Ma et al., 2009b), which is a vacuolar protease-deficient yeast 
strain with the A. nidulans npgA integrated chromosomally (Mootz, 2002). Besides 
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the different expression system, the deletion of two vacuolar proteases (PEP4 – 
vacuolar aspartyl proteinase A, and PRB1 – vacuolar proteinase B) in the expression 
strain that was used in their study could have a major impact on the successful 
expression of the lovastatin biosynthetic enzymes as proteases, especially luminal 
vacuolar proteases, can significantly affect protein production in yeast, and can 
generate artifacts concerning the structure, activity as well as localization of proteins 
in the cells (Jones, 1991). The results from Xu et. al showed that a future yeast-
based production of statins is possible. This achievement will open numerous 
opportunities for engineering S. cerevisiae strains aimed at improved production of 
statins. Solutions for tackling the problem with S. cerevisiae statin sensitivity could 
have an enormous impact on future production of statins in yeast, which is why I 
decided to switch focus from the cell-factory construction to establishing statin 
resistance and export in S. cerevisiae as described in the following two chapters. 
 
4.4 Materials and Methods 
 
4.4.1 Plasmid and yeast strain construction 
 
 Yeast codon-optimized versions of the biosynthetic genes from the P. 
citrinum compactin gene cluster (Table 1), de novo synthetized by Genscript, were 
PCR amplified from the relevant plasmids (Table 2) using primer pairs as listed in 
Table 4. PPTase-encoding genes npgA and sfp were amplified from plasmids 
pnpgATNT2 and p424sfp using primer pairs npgA-F/npgA-R and sfp-F/sfp-R, 
respectively. The PGK1 and TEF1 promoter sequences were amplified from plasmid 
pSP-G2, and GAL10 was amplified from pESC-Ura using primer pair GalP-F2 and 
GalP-R. Expression of MlcA was analyzed by tagging it C-terminally with monomeric 
red fluorescent protein (RFP). For this, the plasmid pX4-GalP-mlcA was constructed, 
by amplifying mlcA coding sequence lacking the stop codon, using the primer pair 
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mlcA-F/mlcA-CO-RFP-R, and yeast codon-optimized RFP was amplified from 
plasmid pWJ1350 using primer pair RFP_F+/RFPR+.  
 The amplified fragments were cloned into the targeting vectors (Table 2) 
(Mikkelsen et al., 2012) via the USER (uracil-specific excision reagent) cloning 
technique (Nour-Eldin et al., 2006) resulting in plasmids carrying the gene 
expression cassettes. All fragments were amplified by PCR using a 2-deoxyuridine 
compatible PfuX7 polymerase (Nørholm, 2010). Escherichia coli DH5α (Woodcock et 
al., 1989) was used as host for USER cloning experiments and for propagation of 
the constructed plasmid. The constructed plasmids were digested with the NotI 
enzyme (New England Biolabs), and the obtained linear fragments were introduced 
into yeast by lithium acetate/single-stranded carrier DNA/polyethylene glycol 
transformation (Gietz and Schiestl, 2007). The linear gene targeting cassettes were 
integrated into the different loci of the reference yeast strain, S. cerevisiae CEN.PK 
113-11C as described by Mikkelsen et al (Mikkelsen et al., 2012). Integration sites 
into which the individual genes were integrated are listed in Table 1. Correct 
integration of the substrates was verified by diagnostic colony PCR with one primer 
annealing outside of the integration site in the yeast genome (e.g. X-3-up-out-sq for 
confirmation of the correct integration of the expression cassette in the integration 
site 3 on chromosome X), and one substrate specific primer (C1_TADH1_F) 
annealing within the integrated targeting cassette. Strains used in this study are 
listed in Table 3. 
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Table 2 
List of plasmids used in this study. 
Plasmid name Description Reference or source 
pEN669 Template for amplifying mlcE (S. cerevisiae codon optimized) from Evolva Holding SA 
pEN668 Template for amplifying mlcD (S. cerevisiae codon optimized) from Evolva Holding SA 
pEN155 Template for amplifying mlcG (S. cerevisiae codon optimized) from Evolva Holding SA 
pEN156 Template for amplifying mlcF (S. cerevisiae codon optimized) from Evolva Holding SA 
pEN157 Template for amplifying mlcA (S. cerevisiae codon optimized) from Evolva Holding SA 
pEN158 Template for amplifying mlcC (S. cerevisiae codon optimized) from Evolva Holding SA 
pnpgATNT2 Template for amplifying npgA Louise Mølgaard, Novo Nordisk A/S , Denmark 
p424sfp Template for amplifying sfp (Wattanachaisaereekul et al., 2007) 
pWJ1350 Template for amplifying RFP (Lisby et al., 2003) 
pSP-G2 Template for amplifying TEF1 and PGK1 (Partow et al., 2010) 
pESC-Ura Template for amplifying GAL10 Tomas Strucko, Technical University of Denmark 
pX2 USER cloning vector equipped with the CYC1 and ADH1 terminators designed to target site 2 on chromosome X. (Mikkelsen et al., 2012) 
pX3 USER cloning vector equipped with the CYC1 and ADH1 terminators designed to target site 3 on chromosome X. (Mikkelsen et al., 2012) 
pX4 USER cloning vector equipped with the CYC1 and ADH1 terminators designed to target site 4 on chromosome X. (Mikkelsen et al., 2012) 
pXII1 USER cloning vector equipped with the CYC1 and ADH1 terminators designed to target site 1 on chromosome XII. (Mikkelsen et al., 2012) 
pXII4 USER cloning vector equipped with the CYC1 and ADH1 terminators designed to target site 4 on chromosome XII. (Mikkelsen et al., 2012) 
pX2-TEF1-sfp Plasmid carrying a gene-targeting cassette for expressing sfp in yeast. This study 
pX2-TEF1-npgA Plasmid carrying a gene-targeting cassette for expressing npgA in yeast. This study 
pX3-mlcD-PGK1-
TEF1-mlcE 
Plasmid carrying a gene-targeting cassette for 
expressing mlcD and mlcE in yeast. This study 
pX4-GalP-mlcA Plasmid carrying a gene-targeting cassette for expressing mlcA in yeast. This study 
pX4-GalP-mlcA-
RFP 
Plasmid carrying a gene-targeting cassette for 
expressing mlcA-RFP in yeast. This study 
pXII1-mlcF-PGK1-
TEF1-mlcC 
Plasmid carrying a gene-targeting cassette for 
expressing mlcC and mlcF in yeast. This study 
pXII4-TEF1-mlcG Plasmid carrying a gene-targeting cassette for expressing mlcG in yeast. This study 
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Table 3 
List of strains used in this study. 
Strain name Genotype Reference or source 
Escherichia coli 
DH5α 
F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 
hsdR17 (rK–, mK+) phoA supE44 λ– thi-1 gyrA96 
relA1 
(Woodcock et al., 1989) 
Saccharomyces cerevisiae 
CEN.PK113-11C 
(Wild type strain) 
 
MATα MAL2-8C SUC2 his3Δ ura3-52 
Dr. Petter Kötter, Institut für 
Mikrobiologie, der Johan Wolfgang 
Goethe-Universität, Frankfurt am 
Main, Germany 
AR22 
MATα MAL2-8C SUC2 his3Δ ura3-52 
X2::(pTEF1­npgA) X3::(pPGK1-mlcD, pTEF1­mlcE) 
X4::(pGAL10-mlcA) XII1::(pPGK1-mlcF, pTEF1-mlcC) 
XII-4::(pPGK1-mlcG) 
This study 
AR23 
MATα MAL2-8C SUC2 his3Δ ura3-52 X2::(pTEF1­sfp) 
X3::(pPGK1-mlcD, pTEF1­mlcE) X4::(pGAL10-mlcA) 
XII1::(pPGK1-mlcF, pTEF1-mlcC) XII-4::(pPGK1-mlcG) 
This study 
AR31 MATα MAL2-8C SUC2 his3Δ ura3-52 X2::(pTEF1­npgA) X4::(pGAL10­mlcA-RFP) This study 
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Table 4 
List of oligonucleotides used in this study. U = 2-deoxyuridine. 
Primer name Primer sequence (5`- 3`) Use 
mlcD-F ATCAACGGGUAAAAATGGTGGCTTCCT 
 
Amplification of mlcD from 
plasmid pEN668 mlcD-R CGTGCGAUTCAACGTCTGGCAC  
 mlcA-F ATCCGTAATACUAAAAATGGATCAAGCTAATTATC Amplification of mlcA from 
plasmid pEN157 mlcA-R CACGCGAUCTAAGCTAACTTAAGTC 
mlcE-F AGCGATACGUAAAAATGAGTGAACCATTACC 
 
Amplification of mlcE from 
plasmid pEN669 mlcE-R CACGCGAUTTATGCATCAGTCTCAG  
 mlcC-F AGCGATACGUAAAAATGTTGGGTCAAGTTTTATTGACTGTAG 
 
Amplification of mlcC from 
plasmid pEN158 mlcC-R CACGCGAUTTAGCATCTGTCATGTGGTAGTGGA    
mlcF-F ATCAACGGGUAAAAATGTCTCCAGCTAGAATTAC 
 
Amplification of mlcF from 
plasmid pEN156 mlcF-R CGTGCGAUCTACACGAAAGATCCACT    
mlcG-F AGCGATACGUAAAAATGGGTGTTGCTATGACTGA 
 
Amplification of mlcG from 
plasmid pEN155 mlcG-R CACGCGAUTTAGACAGAGAACCTTACAACG 
 npgA-F ATCAACGGGUAAAAATGGTGCAAGACACATC  Amplification of npgA from plasmid pnpgATNT2 
 npgA-R CGTGCGAUTTAGGATAGGCAATTACACA 
Sfp-F ATCAACGGGUAAAAATGAAGATTTACGGAAT Amplification of sfp from 
plasmid p424sfp Sfp-R CGTGCGAUTTATAAAAGCTCTTCG 
TEF1-d ACGTATCGCUGTGAGTCGTATTACGGATCCTTG 
Amplification of promoter 
sequences from plasmid pSP-
G2 
PGK1-s CGTGCGAUGCCGCTTGTTTTATATTTGTTG 
TEF1-s CACGCGAUGTGAGTCGTATTACGGATCCTTG 
 PGK1-d ACCCGTTGAUGCCGCTTGTTTTATATTTGTTG 
 GalP-F2 AGCCCTTTAGUGAGGGTTGAATTCGAAT Amplification of promoter 
sequence from plasmid pESC-
Ura Gal-R AGTATTACGGAUCCGGGGTTT 
RFP_F+ ATGGCCTCCUCCGAGGACGTCATCAAGGAG Amplification of RFP sequence 
from plasmid pWJ1350 RFPR+ CACGCGAUCTAGGCGCCGGTGGAGTGGCGG 
mlcA-CO-RFP-R AGGAGGCCAUAGCTAACTTAAGTGCAGGGTTCATA pX-4 GalP mlcA (CO Evolva) 
X-2-up-out-sq TGCGACAGAAGAAAGGGAAG 
Strain confirmation via colony 
PCR 
X-3-up-out-sq TGACGAATCGTTAGGCACAG 
X-4-up-out-sq CTCACAAAGGGACGAATCCT 
 XII-1-up-out-sq CTGGCAAGAGAACCACCAAT 
 XII-4-up-out-sq GAACTGACGTCGAAGGCTCT 
 C1_TADH1_F CTTGAGTAACTCTTTCCTGTA 
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4.4.2 Media 
 
 The E. coli transformants were selected on lysogeny broth (LB) medium 
containing 100 µg/mL of ampicillin. Yeast strains were cultivated in standard liquid 
or solid yeast peptone dextrose medium (YPD; 10 g/L of yeast extract, 20 g/L of 
peptone and 20 g/L of glucose), synthetic complete medium (SC), or YPD medium 
in which glucose was replaced by 2% galactose as a carbon source, thus named 
YPGal. SC medium was prepared according to Sherman et al. (Sherman et al., 
1986), with the minor modification that the L-leucine concentration was doubled to 
60 mg/L. Yeast transformants were selected on SC medium lacking uracil. Removal 
of the URA3 marker, via direct repeat recombination, was achieved by growing the 
strain on SC medium containing 5-fluororotic acid (5-FOA; 740 mg/L, Melford) and 
uracil (30 mg/L). 
 
4.4.3 Fluorescent Microscopy 
 
 For fluorescent microscopy the mlcA-RFP expressing strain (AR31; 
X4::(pGAL10­mlcA-RFP)) was cultured in liquid YPGal medium at 30°C, 25°C or 
20°C with 150 rpm agitation overnight and analyzed by fluorescence and visible light 
microscopy using a Nikon Eclipse E1000 microscope equipped with an oil-
immersed objective at 100 x magnification. The images were captured with 
QImaging Retiga Exi digital camera using Image Pro Plus 5.1 software. The 
brightness of images to be compared was adjusted pairwise using Adobe 
Photoshop CS6. 
 
4.4.4 Metabolite extraction and detection 
 
 Yeast strains were grown in 100 mL YPGal medium in 500 mL shake flasks 
at 30°C, 25°C or 20°C and 150 rpm for 2 days. After incubation, 50 mL of the culture 
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broth were transferred to 50 mL Falcon tubes, and the cells were separated form the 
broth by centrifugation (10 min, 4500 rpm). Metabolites were extracted both from 
the supernatant and the cell pellet. Supernatant (10 mL) was first acidified to pH 3 
with 2 M HCl and then extracted with 10 mL of ethyl acetate containing 0.5 % 
formic acid at room temperature for 4 hours (lightly shaking on an orbital shaker). 
After extraction, 5 mL of the ethyl acetate phase was transferred to a new Falcon 
tube, the extract was dried under a stream of nitrogen, re-dissolved in 0.5 mL 
methanol and ultrasonicated for 10 min. Finally, the dissolved extract was filtered 
through a 0.45 μm Minisart RC4 filter (Sartorius, Germany) and subjected to LC-MS 
analysis. For extraction of metabolites from the cells, the cell pellet was first re-
dissolved in 1 mL of MilliQ water and then disrupted using glass beads and a 
Savant FastPrep FP120 cell disrupter system. 1 mL of ethyl acetate containing 0.5 
% formic acid were added to the disrupted cells, and the extraction took place at 
room temperature for 4 hours (lightly shaking on an orbital shaker). The cells and 
glass beads were separated from the extraction solvent by centrifugation (10 min, 
4500 rpm), and 0.5 mL of the ethyl acetate phase were subjected to the drying, re-
dissolving, sonication and filtering procedure as described above. LC-MS was 
carried out on Ultima 3000 UHPLC (Dionex, Sunnyvale, CA) coupled to a MaXis G3 
(Bruker Daltronics, Bremen, Germany) high-resolution mass spectrometer. 
Separation was achieved on a Kinetic C18 column (Phenomenex, Torrance, CA). 
The column was eluted using A: Water containing 20 mM formic acid and B: MeCN 
containing 20 mM formic acid using a linear gradient from 10 % B to 100 % B in 10 
min. All samples were calibrated by infusing of NaHCOO prior to all injections using 
Bruker HPC calibration algorithm achieving a mass accuracy < 1 ppm. The MS was 
operated in positive ESI mode. 
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CHAPTER 5 
5.MlcD – a metabolic backup system to the standard 
3-hydroxy-3-methylglutaryl coenzyme A 
reductase in statin producing fungi 
 
5.1 Introduction 
 
 In their natural habitats filamentous fungi face tough competition for the 
limited nutrition resources that are available. Prokaryotic competitors are typically 
combatted by fungi through excretion of potent antibiotics, which target unique 
prokaryotic molecular features to give the producing fungi a competitive advantage. 
The large differences in essential enzymatic systems that exist between prokaryotes 
and eukaryotes offers plenty of opportunities for the development of bioactive 
secondary metabolites that can inhibit prokaryotes without negatively affecting the 
eukaryotic producer. Penicillin, a secondary metabolite synthesized by Penicillium 
spp. is the cardinal example of this. In addition to the prokaryotic competitors, fungi 
often also face eukaryotic adversaries in the fight for survival, either in the form of 
other fungi adapted to utilize the same nutritional sources, or invertebrates that eat 
fungi. In these cases, the effective use of bioactive compounds in the confrontation 
is a bit more complex, and challenging in an evolutionary perspective, as both 
partners are eukaryotes and hence share many fundamental cellular processes. This 
situation significantly reduces the number of unique targets that exist in either of the 
adversaries, reducing the likelihood that biosynthetic pathways for the formation of 
efficient bioactive compounds will evolve (it will take longer time).   
 One way of escaping this curse of shared ancestry is for the organism to 
produce bioactive compounds that affect shared molecular targets, but which affect 
the competitor(s) at least marginally more than they affect the producing organism, 
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or which are first activated upon release from the producer. This will allow the 
producer to subsequently gain an additional competitive advantage by 
evolving/gaining a mechanism to avoid self-intoxication, which in turn will give room 
for the evolution of higher production levels.  
 Currently only a limited number of examples of this evolutionary solution has 
been documented in the fungal world4. In the published cases, the gene encoding 
for the self-resistance mechanism have been found to cluster together with the 
genes encoding the biosynthetic machinery for formation of the bioactive secondary 
metabolites (Brakhage, 2013; Smith et al., 1990). One example of this is Penicillium 
brevicompactums production of mycophenolic acid (MPA), an inhibitor of eukaryotic 
inosine-5`-monophosphate dehydrogenase (IMPD). P. brevicompactum contains 
two genes encoding for IMPD, PbIMPDH-A and PbIMPDH-B (also called mpaF), the 
latter being located within the MPA biosynthetic gene cluster (Regueira et al., 2011). 
Interestingly, MpaF is remarkably resistant to MPA, therefore it has been suggested 
that it is the key component of MPA self-resistance mechanism in P. 
brevicompactum (Hansen et al., 2011; Sun et al., 2011). Statins are another example 
of a eukaryotic toxin produced by fungi. The exact function of these compounds in 
nature has not been proven, but it is well known that statins are inhibitors of 3-
hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), an enzyme that 
catalyzes the rate-limiting step in the mevalonate pathway-derived biosynthesis of 
nonsterol isoprenoids and sterols, such as cholesterol and ergosterol (Maury et al., 
2005). The first statin to be isolated was compactin (also called compactin or ML-
236B) from cultures of Penicillium citrinum (Endo et al., 1976b). Since the target of 
compactin, HMGCR, is also present in the producing fungus, the latter must 
possess a mechanism of self-protection to overcome the inhibition of the 
mevalonate pathway. Characterization of the compactin biosynthetic gene cluster 
revealed the presence of a putative self-resistance gene encoding for an HMGCR-
like protein, namely mlcD (Abe et al., 2002b). The involvement of this gene in the 
                                                
4 A large number of secondary metabolites produced by fungi are toxic to vertebrates (mycotoxin group), however in 
the majority of cases this situation should likely be considered as collateral damage (as unfortunate side effect) as 
non-pathogenic fungi would not gain (in an evolutionary perspective) from killing vertebrates.  
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self-resistance mechanism was suggested when a P. citrinum compactin-sensitive 
mutant was isolated after cosmid-mediated recombination aimed at improved 
production of compactin (Abe et al., 2002a). Characterization of this mutant showed 
that a region containing the mlcD locus was not present in the sensitive strain. 
Homologs of mlcD, lvrA and mokG are found in the lovastatin gene cluster from 
Aspergillus terreus (Alberts et al., 1980) and Monascus pilosus (Chen et al., 2008), 
respectively. MlcD (1173 aa) and LvrA (1068 aa) display 40.1% identity and 55.1% 
similarity5 at amino acid levels. Protein identity (73%) and similarity (82%) are even 
higher between LvrA and MokG (1052 aa). All three enzymes possess the same 
domain organization (Figure 1). Hutchinson et al. reported that introduction of lvrA 
into the lovastatin sensitive Aspergillus nidulans resulted in increased lovastatin 
resistance, however, this statement was not supported by experimental data in the 
publication (unpublished results) (Hutchinson et al., 2000). Collectively, the available 
information leaves the molecular basis of the compactin self-resistance mechanism 
unresolved. 
 
 
Figure 1: Domain organization of HMGCRs; MlcD from P. citrinum, LvrA from A. terreus, and MokG from M. pilosus 
HPIH – N-terminal domain with HPIH motif (PF13323.1; function unknown); SS – sterol sensing domain (PF12349.3); 
CD – catalytic domain (PF00368.13; “HMG-CoA reductase”). Domains were identified using Pfam protein family 
database version 27.0 (Finn et al., 2014). 
 
 The discovery that statins can be used to modify and control cholesterol 
levels in vertebrates, by inhibiting de novo synthesis, has had an enormous impact 
on human health and treatment of cardiovascular diseases (Corsini et al., 1995). 
                                                
5Identity and similarity were calculated using EMBOSS Needle pairwise global sequence alignment tool (Rice et al., 
2000). 
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Industrial scale production of natural statins is based on fermentation of Aspergillus 
and Penicillium spp., and many different strategies to increase the fermentation 
titers have already been applied (Barrios-González and Miranda, 2010). With respect 
to production-strain engineering aimed at increased production of secondary 
metabolites in the natural producer, understanding of the mechanisms of self-
resistance has in several instances been shown to be important (Lomovskaya et al., 
1996; Malla et al., 2010; Ullán et al., 2002; Zhang et al., 2002b). This is also the case 
for statin formation where one of the attempts to improve lovastatin production in A. 
terreus lead to the isolation of a mutant which showed a 3-fold increase in the 
production of lovastatin compared to the parental strain caused by increased 
resistance to lovastatin (Jia et al., 2011). This suggests that a better understanding 
of the mechanisms underlying the statin self-resistance likely can provide novel 
genetic engineering strategies to reach higher statin titer. In addition, it also opens 
up for the possibility to produce statins in a heterologous host, such as 
Saccharomyces cerevisiae, that is sensitive. 
 In this work we aimed to elucidate the function of mlcD gene from the P. 
citrinum compactin biosynthetic gene cluster. We used the statin-sensitive 
Saccharomyces cerevisiae as a model host to examine if MlcD can confer the statin-
resistance, and in hope of gaining insight into the molecular basis behind the 
resistance. 
 
5.2 Results and Discussion 
 
5.2.1 mlcD confers the resistance to statins in yeast 
 
 S. cerevisiae has previously been shown to be sensitive to statins present in 
the growth medium (Formenti and Kielland-Brandt, 2011; Rine et al., 1983), leading 
to the use of S. cerevisiae as a model organism for mapping the mode of action for 
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statins at the cellular level (Callegari et al., 2010). Statins inhibit the activity of yeast 
HMGCRs, ultimately resulting in ergosterol starvation and lack of protein 
prenylation, causing reduced cell viability and mitochondrial dysfunction (Callegari 
et al., 2010). To confirm the hypothesis that the mlcD gene from the P. citrinum 
compactin biosynthetic gene cluster can confer the resistance to statins, we 
expressed mlcD as a single copy gene under the constitutive promoter TEF1 from a 
defined genomic locus in S. cerevisiae (ARX4 strain). The strain’s sensitivity to 
statins was assayed via a growth experiment on solid YPD medium with increasing 
concentrations of lovastatin, the compactin structural analog. The mlcD-expressing 
strain displayed an increased resistance to lovastatin present in the medium, 
compared to the reference wild-type strain (Figure 2). This result shows that MlcD 
can confer the resistance to the compactin structural analog, lovastatin, when 
expressed in a heterologous host S. cerevisiae. This also supports the hypothesis by 
Abe et al. that mlcD encodes for a statin-resistance mechanism in its native host.  
 
5.2.2 MlcD is an HMG-CoA reductase (HMGCR) 
 
 MlcD and LvrA have previously been suggested to be HMGCRs capable of 
converting HMG-CoA into mevalonate, based on sequence similarity and domain 
architecture, however this suggestion has not been confirmed experimentally so far. 
To test whether mlcD encodes an HMGCR, we conducted a complementation 
assay in S. cerevisiae. S. cerevisiae contains two genes encoding HMGCRs, called 
HMG1 and HMG2, respectively. HMG1 was shown by Basson et al. to be 
responsible for approximately 83% of the HMGCR catalytic activity found in wild 
type cells (Basson et al., 1986a).  
 Firstly, we were interested in the effect that deletion of either HMG1 or 
HMG2 would have on yeast’s statin sensitivity. We deleted the two genes in S. 
cerevisiae CEN.PK strain using the strategy described by Reid et al. (Reid et al., 
2002b), resulting in the strains AR31 for the HMG1 deletion and AR32 for the HMG2 
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deletion. The growth of the two strains on rich medium was not affected (Figure 2), 
results that are similar to those published by Basson et al. showing that cells 
containing a mutant allele of either HMG1 or HMG2 are viable, and have only a 
subtle growth effect (Basson et al., 1987, 1986a). However, when the strain 
sensitivity to statins was assayed, it showed that the AR31 strain was considerably 
more sensitive to extracellular lovastatin than the wild-type strain (Figure 2). The 
growth of the AR31 strain was completely inhibited already at the lowest tested 
lovastatin concentration (0.25 mM). In contrast, deletion of HMG2 had very little 
effect on the lovastatin-sensitivity, as the AR32 strain behaves similarly to the wild-
type strain on medium containing lovastatin (Figure 2). The hyper sensitivity of the 
hmg1Δ strain is in good agreement with the fact that HMG1 isozyme is responsible 
for the majority of the HMGCR activity in the cells (Basson et al., 1986b). Next, we 
investigated whether expression of mlcD in the hmg1Δ strain would rescue the 
observed statin hypersensitive phenotype. For this, mlcD was integrated into the 
two deletion strains as described in the previous section, resulting in strains AR33 
(hmg1Δ X3::PTEF1­mlcD) and AR34 (hmg2Δ X3::PTEF1­mlcD). Testing of the two 
strains statin sensitivity levels showed that they behaved as the ARX4 strain 
(X3::PTEF1­mlcD) (Figure 2), indicating that mlcD was not only capable of 
complementing hmg1Δ mutation, but in addition made both strains less sensitive 
compared to the wild type reference. Lovastatin sensitivity of the constructed 
strains is summarized in Table 1. 
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Figure 2: Susceptibility assay. (A) Overview of the constructed and tested strains. (B) Susceptibility assay: five-fold 
dilution series of the strains starting with and OD600 of 0.01 were prepared from overnight cultures and plated on a 
set of YPD agar plates containing activated lovastatin (0, 0.25 or 1.24 mM). The plates were incubated at 30°C for 3 
days, after which the growth of the strains was recorded by photography. Strains: WT (CEN.PK113-11C); ARX4 
(X3::pTEF1­mlcD); AR31 (hmg1Δ); AR32 (hmg2Δ); AR33 (hmg1Δ X3::pTEF1­mlcD); AR34 (hmg2Δ X3::pTEF1­mlcD). 
 
 
 To determine whether MlcD is an HMGCR or mediates its statin resistance 
via an alternative activity (e.g. binding of stains) we performed a complementation 
experiment by deleted both HMGCR isozymes in S. cerevisiae. However, as the 
double deletion (hmg1 and hmg2) has previously been shown to be nonviable 
(Basson et al., 1986a), we deleted the two genes in a strain expressing mlcD (strain 
ARX4). If the resulting strain was viable, then MlcD must be an HMGCR, as it would 
be the only enzyme present in the cells capable of reducing HMG-CoA to 
mevalonate and HMG-CoA. Deletion of both HMG1 and HMG2 in the mlcD-
expressing strain (resulting strain is named ARX5) only had a minimal effect on the 
growth of the yeast cells on YPD plates compared to the wild-type strain (Figure 3), 
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echoing the results from Basson et al. that expression of either human or hamster 
HMGCR restored the viability of hmg1 hmg2 yeast cells lacking this enzyme 
(Basson et al., 1988). The performed complementation experiment shows that MlcD 
is able to provide sufficient catalytic capacity to replace both HMGCR isozymes in 
yeast, confirming the hypothesis that mlcD encodes for an HMGCR. Moreover, the 
mlcD-expression setup in S. cerevisiae confers high-level lovastatin resistance even 
in the strain lacking both native HMGCRs (Figure 3). 
 
 
Figure 3: Susceptibility assay of the S. cerevisiae strain lacking native HMGCRs (HMG1 and HMG2) and expressing 
mlcD (ARX5; hmg1Δ hmg2Δ X3::pTEF1­mlcD). (A) Schematic representation of the constructed strain. (B) 
Susceptibility assay. Ten-fold dilution series of the ARX5 and wild-type strain (WT; CEN.PK113-11C) strains starting 
with and OD600 of 0.02 were prepared from overnight cultures and plated on a set of YPD agar plates containing 
lovastatin (0, 0.7 or 2 mM). The plates were incubated at 30°C for 3 days, after which the growth of the strains was 
recorded by photography. 
 
Table 1  
Summary of the susceptibility assays.  
Strain Genotype Statin sensitivity 
CEN.PK113-11C 
(Wild type) 
 
MATα MAL2-8C SUC2 his3Δ ura3-52 Reference 
AR31 MATα MAL2­8C SUC2 his3Δ ura3-52 hmg1Δ High 
AR32 MATα MAL2-8C SUC2 his3Δ ura3-52 hmg2Δ As reference 
ARX4 MATα MAL2-8C SUC2 his3Δ ura3-52 X3::pTEF1­mlcD Low 
AR33 MATα MAL2­8C SUC2 his3Δ ura3-52 hmg1Δ X3::pTEF1­mlcD Low 
AR34 MATα MAL2­8C SUC2 his3Δ ura3-52 hmg2Δ X3::pTEF1­mlcD Low 
- hmg1Δ hmg2Δ Not viable 
ARX5 MATα MAL2­8C SUC2 his3Δ ura3-52 hmg1Δ hmg2Δ X3::pTEF1-mlcD Low 
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5.2.3 Do statin-producing fungi contain a unique HMGCR type? 
 
 We showed that MlcD is an HMGCR and that it can confer the resistance to 
statins, but what is the molecular basis for the statin resistance? We were interested 
whether the statin resistance is based on the overproduction of the statin target, 
which would suggest that statin producers have more than one HMGCR-encoding 
gene. Or do the statin producers contain a unique HMGCR, which is somehow 
resistant to statins, a situation similar to the presence of MPA-resistant IMPDH in P. 
brevicompactum? In the hope of gaining an insight into the molecular basis behind 
the resistance we used a bioinformatics approach. 
 
5.2.3.1 Analysis of HMGCR copy number 
 
 The lovastatin and compactin gene clusters both include an HMGCR-
encoding gene, however it is currently unknown how many HMGCRs fungi typically 
encode. To determine this, we performed a BlastP against the Join Genome 
Institute (JGI) fungal genome database (Nordberg et al., 2014) and the resulting hits 
were manually curated by eliminating doubtful gene models, missing data, and 
sequences, in which the conserved domain structure was not found (see section 
5.4.4. for detailed description of the curating procedure). The resulting database 
included 583 HMGCR sequences, originating from 447 different genomes, and all 
the sequences included an ‘HMG-CoA_red’ (PF00368) domain, which is 
characteristic HMGCRs. To all the sequences in our database, information about the 
phyla/division was attributed, the redundancy was eliminated, e.g. species for which 
multiple different genomes were present such as S. cerevisiae (see section 5.4.5. for 
detailed description of the procedure), and the resulting dataset contained 551 
unique sequences divided between 435 species from 319 different genera. We 
sorted the list based on species names and counted the number of putative 
HMGCR copies in the individual species (data not presented), showing that 82% of 
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the species across the entire taxonomic range encoded a single copy of the gene. 
The highest copy number found was 5, which were present in five species of 
ascomycetes and one of basidiomycetes. Sorting the list based on species name 
also revealed that our dataset is not taxonomically balanced as it includes 
enrichment for species within specific genera, for example twenty-one Aspergillus 
species. To compensate for this, a representative species (with respect to gene 
copy number) was selected from each genus. The final dataset was used for the 
copy-number count (Table 2). While this correction eliminated the ‘multi-species per 
genera’ problem, it did not remove the bias for Ascomycota and Basidiomycota6. 
The corrections only had a minor impact on the data and did not change the general 
trend with the majority (85%) of species containing a single copy of the HMGCR 
enzyme, and the highest copy number being 5 (Table 2). 
 
Table 2 
Number of putative HMGCRs per genome sorted by taxonomic phylum/division with a single representative for 
each genus. 
Phylum/Division 
Number of Putative HMGCR copy-number 
Genera Species Seq. 1 2 3 4 5 
Ascomycota 178 178 219 153 (86.0%) 16 (9.0%) 4 (2.2%) 3 (1.7%) 2 (1.1%) 
Basidiomycota 122 122 142 106 (86.9%) 14 (11.5%) 1 (0.8%)  -  1 (0.8%) 
Zygomycota 12 12 22 5 (41.7%) 4 (33.3%) 3 (25.0%)  -  - 
Blastocladiomycota 1 1 1 1 (100%)  -  -  -  - 
Chytridiomycota 2 2 2 2 (100%)  -  -  -  - 
Cryptomycota 1 1 1 1 (100%)  -  -  -  - 
Glomeromycota 1 1 1 1 (100%)  -  -  -  - 
Microsporidia 2 2 2 2 (100%)  -  -  -  - 
 Total   319 319 390 271 (85.8%) 34 (10.8%) 8 (2.5%) 3 (0.9%) 3 (0.9%) 
 
 
5.2.3.2 Phylogenetic analysis of putative HMGCRs 
 
                                                
6 The bias is due to the available genome sequences where focus has been on ascomycetes and basidiomycetes.  
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 Next, we performed a phylogenetic analysis of the putative HMGCRs. The 
dataset with 551 putative HMGCR sequences was aligned using MUSCLE (Edgar, 
2004) to create higher quality alignments for the phylogenetic analysis. This showed 
that only the predicted ‘HMG-CoA_red’ region was shared between all the 
sequences. Unaligned regions were removed, only retaining the approximately 340 
aa long ‘HMG-CoA_red’ domain in each sequence, which was used for the 
phylogenetic tree (Maximum Likelihood tree) construction. HMGCR from Sulfolobus 
tokodaii (Archaea)7 was used as an out-group. Analysis of the resulting tree (Figure 
4) showed that the majority of sequences grouped into five clades with good 
support (bootstrap values above 67) 8 , which for the major part followed the 
taxonomy of the included species at the phylum level (Figure 4A).  One significant 
exception from this grouping was that the sequences from ascomycetes were 
between two separate clades (Group A and Group B) with 100% bootstrap support. 
 The two clades proved to be very different (Figure 4B), with Group A 
sequences being characterized by containing three specific domains: (i) HPIH 
membrane spanning domain (PF13323.1; function unknown), (ii) sterol-sensing 
domain (PF12349.3) and (iii) ‘HMG-CoA reductase’ domain (PF00368.13) (Figure 5). 
In contrast, Group B sequences only contained an HMG-CoA reductase domain, 
similar to the situation in Cryptomycota, Microsporidia and Archaea HMGCRs 
(Figure 5). Group A (289 sequences) included representatives for all 266 analyzed 
ascomycete species (surplus of 22 sequences), while Group B (59 sequences) only 
included 35 different species. The domain structure and universal distribution of the 
HMGCRs in the Ascomycota Group A suggests that this is the ancestral HMGCR 
that is involved in central metabolism, catalyzing the conversion of HMG-CoA to 
mevalonate. The function of the previously unrecognized subgroup B is unknown, 
however the lack of transmembrane and sterol-sensing domains suggests that 
                                                
7 HMGCRs are divided into two classes, where class I includes eukaryotic and archaeal enzymes, while class II 
consists of enzymes from eubacteria (Bochar et al., 1999). Class II HMGCRs also catalyzes the reverse reaction of 
class I enzymes (Hedl et al., 2004). 
8 The phylogeny also included three additional smaller clades. Analysis of these clades revealed that they contained 
sequences form different phyla. 
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these HMGCRs are soluble and serve a different function than Group A. Though 
they share domain structure with the Cryptomycota and Achaea HMGCRs, Group B 
is as distantly related to these as it is to the Group A, and the origin of the Group B 
remains elusive9. The three HMGCRs known to be involved in statin resistance 
(MlcD, LvrA and MokG) were all found to belong to the clade Ascomycota Group A 
(Figure 4A).   
 
 
                                                
9 Requires dedicated study to be resolved – either BlastP against complete non-redundant database or by including 
additional groups of eukaryotes.  
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Figure 4: Phylogenetic analysis of putative HMGCRs. (A) Circular cladogram showing the maximum likelihood tree 
for the putative fungal HMGCRs with an Archaea HMGCR as outgroup. Arrows are indicating placement of MlcD 
(from P. citrinum compactin gene cluster; left quare) and LvrA and MokG (from A. terreus and M. ruber lovastatin 
gene cluster, respectively; right square) in the phylogeny. (B) Radial display of the phylogenetic tree shows the 
distances between the different groups. Abbreviations of the groups: B-basidiomycota, Z-zygomycota, A-
ascomycota, Ch-chytridiomycota. 
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Figure 5: Domain architecture representative HMGCRs for the different clades highlighted in the phylogeny. Proteins 
are drawn to scale. The identified domains included ‘HMG-CoA reductase’ (HMG-COA_red; PF00368.13), HPIH 
(PF13323.1) and Sterol-sensing (SS; PF12349.3) domains. For the Microsporidia, Chytridiomycota and 
Cryptomycota groups only few sequences were available and it is unknown whether the included sequences are 
representative for the HMGCRs in these groups. Domains were identified using Pfam protein family database 
version 27.0 (Finn et al., 2014). 
 
5.2.3.3 Analysis of the Ascomycota Group A HMGCRs 
 
 The clade Ascomycota Group A contains twenty-one species with two or 
more copies of the HMGCR from Group A, as shown in Table 3. Seventeen of these 
species belong to the Asperillus genus, revealing local enrichment for this enzyme 
class, supporting a model, where one or several gene duplication events have 
occured. 
 
  
 97 
Table 3 
Ascomycetes that possess more than one HMGCR-domain containing protein, sorted based on the number of 
enzymes belonging to Group A. Especially members of the Aspergillus genus (shown in blue) are enriched for 
HMGCRs belonging to Group A. Enrichment for group B HMGCRs is also seen.  
 Number of HMGCRs 
Species in Group A In Group B Total 
Aspergillus carbonarius  3 1 4 
Aspergillus flavus, Aspergillus oryzae  2 3 5 
Aspergillus brasiliensis,  Aspergillus acidus, 
Aspergillus kawachii, Aspergillus niger, Aspergillus 
phoenicis, Aspergillus terreus, Aspergillus tubingensis 
2 2 4 
Neosartorya fischeri  2 1 3 
Aspergillus fumigatus , Aspergillus novofumigatus, 
Aspergillus sydowii, Aspergillus versicolor, Monascus 
ruber, Penicillium expansum, Saccharomyces cerevisiae, 
Kazachstania africana, Lindgomyces ingoldianus, 
Colletotrichum eremochloae, Colletotrichum eremochloae 
2 0 2 
Fusarium oxysporum  1 4 5 
Corynespora cassiicola, Periconia macrospinosa 1 3 4 
Aspergillus wentii, Colletotrichum zoysiae, Myriangium 
duriaei, Penicillium bilaiae 
1 2 3 
Penicillium brevicompactum, Penicillium chrysogenum, 
Aspergillus glaucus, Aspergillus nidulans, Aspergillus 
steynii, Aureobasidium pullulans Byssothecium circinans, 
Colletotrichum higginsianum, Colletotrichum 
somersetensis, Glonium stellatum, Ilyonectria sp., 
Marssonina brunnea, Mytilinidion resinicola, Niesslia exilis, 
Penicillium glabrum, Phialocephala scopiformis, 
Pyrenochaeta sp., Stanjemonium grisellum 
1 1 2 
 
  
To further investigate the genera that contain statin-producing species, a 
MUSCLE alignment and Maximum Likelihood tree were calculated for members of 
the Aspergillus, Penicillium and Monascus genera. The resulting phylogeny (Figure 6) 
includes a subgroup (termed Primary HMGCR in the figure) supported by a 
bootstrap value of 100, which contains HMGCR sequences from all the included 
species. Though parts of the subtree topology (Aspergillus clade) did not reach 
significant support, Aspergillus, Monascus and Penicillium sequences (shown in 
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blue) were separated with bootstrap values of 84 and 100. This clade (Primary 
HMGCR) likely represents the HMGCR’s that participate in primary metabolism. A 
second subgroup was separated from the ‘Primary HMGCR’ clade with a bootstrap 
support of 100. This group included the LvrA and MokG sequences from the 
lovastatin clusters in A. terreus and M. rubrum, respectively, and a second copy of 
HMGCR from A. flavus and A. carbonarius. The MlcD protein is found in a third 
clade where it clusters together with a second HMGCR from Penicillium expansum 
with a 100% support. The split of the LvrA/MokG and MlcD HMGCRs into two 
different clades could suggest that they have evolved by two independent events 
(separate duplication events; further discussed in the next section). Though P. 
expansum, A. flavus and A. carbonarius possess HMGCRs that cluster together with 
HMGCRs associated with statin-gene clusters, production of statins by these 
organisms have not been reported to our knowledge.  
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Figure 6: Phylogenetic analysis of the Ascomycota Group A HMGCRs. Subtree of the maximum likelihood tree for 
putative HMGCRs from the Aspergillus (including Neosartorya), Monascus and Penicillium genera, showing 
sequences from the Ascomycetes Group A. Blue color represents the “primary HMGCRs” and red color represents 
clades where HMGCRs from the statin gene clusters can be found (highlighted with bold font). Detailed list of 
sequences used for the analysis is shown in Table 6. 
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5.2.3.4 Gene duplication and evolving a new function 
 
 Gene duplication events result in a functional/genetic redundancy, which is 
an inherently unstable situation in an evolutionary perspective (Hartman et al., 2001). 
This can either be resolved by eliminating one of the genes or by one of the genes 
coming to serve a new function (catalytic or expression pattern). As the HMGCRs 
from the statin gene clusters do not cluster together with the primary HMGCRs 
found in the producing species (Figure 6), but with separate clades, they are likely 
not the result of recent duplication of the primary HMGCR. In addition, the tree 
presented in Figure 6 suggests that mlcD and lvrA/mokG have arisen from separate 
duplication events. The genetic redundancy has likely allowed for the adaptation to 
serve a new function in protecting the cell from the toxic effects of statin. We 
propose that the HMGCR-encoding gene at some time during evolution was 
duplicated, and genome shuffling has resulted in relocation of the gene into the 
gene clusters. The selective advantage of this genetic setup was then preserved 
throughout time/evolution as it posed a selective advantage. 
 If HMGCRs encoded in the statin gene clusters arose from the recruitment of 
the gene into the gene cluster by a gene duplication event, then the statin self-
resistance mechanism is likely based on the increased concentration of HMGCR in 
the cell at the time when statins are being synthesized. Alternatively, HMGCRs from 
the statin gene clusters are unique versions of the enzyme that developed during 
evolution in a way to become insensitive to statins. It has been previously shown 
that some of the amino acid residues in human HMGCR are associated with statin 
sensitivity of the enzyme; i.e. Q766H mutation incresed statin sensitivity of the 
enzyme (Wysocka-Kapcinska et al., 2009). To look for possible substitutions in 
HMGCRs associated with the statin clusters, which might indicate their statin 
insensitivity, a protein sequence alignement of their catalytic region (HMG-COA_red; 
PF00368.13) was created using Clustal Omega program (Sievers et al., 2011) (Figure 
7). Human HMGCR was used as a reference to identify the residues that participate 
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in binding of HMG-CoA (the residues were defined experimetally (Istvan, 2000)), and 
that were previously suggested to be associated with statin sensitivity (i.e. position 
766). 
 
                                            548 
H. sapiens HMGCR                      EKEFQVPMATTEGCLVASTNRGCRAIGLGGGASSRVLADGMTRGPVVRLPRACDSAEVKA 
A. terreus HMGCR1                     GQNYFIPMATTEGVLVASASRGAKAINAGGGAVTVLTGDGMTRGPCVGFPTLARAAAAKV 
A. terreus HMGCR2 (LvrA)              GQALFIPMATTEGVLVASASRGCKAINAGGGATTMLKGDGMTRGPCLRFPSAQRAAEAQR 
M. ruber HMGCR1                       GQSYFIPMATTEGVLVASTSRGAKAINAGGGAVTVLTGDGMTRGPCVGFPTLARAAAAKV 
M. ruber HMGCR2 (MokG)                GQAYFIPMATTEGVLVASASRGCKAINTGGGAVTMLKGDGMTRGPCLGFPSAKRAAEAQR 
P. citrinum MlcD                      GKSYFIPMATTEGVLVASASRGSKAINLGGGAVTVLTGDGMTRGPCVKFDVLERAGAAKI 
                                       :   :******* ****:.**.:**  **** : : .******* : :     :. .:  
                                      608 
H. sapiens HMGCR                      WLETSEGFAVIKEAFDSTSRFARLQKLHTSIAGRNLYIRFQSRSGDAMGMNMISKGTEKA 
A. terreus HMGCR1                     WLDSEEGRNIMTTAFNSTSRFARLQSMKTALAGTYLYIRFKTTTGDAMGMNMISKGVEKA 
A. terreus HMGCR2 (LvrA)              WVESPLGHEVLAAAFNATSRFARLQTLTVAQAGIYLYIRFRTTTGDAMGMNMISKGVEKA 
M. ruber HMGCR1                       WLDSEEGRSIMTAAFNSTSRFARLQSMKTALAGTYLYIRFKTTTGDAMGMNMISKGVEKA 
M. ruber HMGCR2 (MokG)                WVESPVGHQVLTDAFNATSRFARLQTLTVAQAGTYLYIRFRTTTGDAMGMNMISKGVEKA 
P. citrinum MlcD                      WLDSDVGQTVMKEAFNSTSRFARLQSMRTTIAGTHLYIRFKTTTGDAMGMNMISKGVEHA 
                                      *:::  *  ::  **::********.: .: **  *****:: :************ *:* 
                                      668 
H. sapiens HMGCR                      LSKLH--EYFPEMQILAVSGNYCTDKKPAAINWIEGRGKSVVCEAVIPAKVVREVLKTTT 
A. terreus HMGCR1                     LHVMSTECGFDDMATISVSGNFCTDKKSAALNWIDGRGKSVVAEAIIPGDVVRSVLKSDV 
A. terreus HMGCR2 (LvrA)              LEAMAAEGGFPDMHTVTLSGNFCSDKKSAAINWIGGRGKSVIAEATIPAETVRQVLKTDV 
M. ruber HMGCR1                       LHVMATECGFDDMATISVSGNFCIDKKPAAINWIDGRGKSVVAEAIIPGDVVKSVLKSDV 
M. ruber HMGCR2 (MokG)                LQAMTA-HGFPDMNTITLSGNFCADKKSAAINWIGGRGKSVIAEATIPADTVRKVLKTDI 
P. citrinum MlcD                      LNVMATEAGFSDMNIITLSGNYCTDKKPSALNWIDGRGKGIVAEAIIPANVVRDVLKSDV 
                                      *  :     * :*  :::***:* *** :*:**  ****.::.** **...*:.***:   
                                      726 
H. sapiens HMGCR                      EAMIEVNINKNLVGSAMAGSIGGYNAHAANIVTAIYIACGQDAAQNVGSSNCITLMEASG 
A. terreus HMGCR1                     NALVELNTSKNLIGSAMSGSLGGFNAHASNLVTAVFLATGQDPAQNVESSSCITTMKN-- 
A. terreus HMGCR2 (LvrA)              DALVELNTAKNLVGSAMAGSLGGFNAHASNLVQAVFLATGQDPAQNVESSSCITTMKN-- 
M. ruber HMGCR1                       NALVELNTSKNLIGSAMAGSLGGFNAHASNIVTAIFLATGQDPAQNVESSNCITTMRN-- 
M. ruber HMGCR2 (MokG)                DALVELNTAKNLVGSAMAGSMGGFNAHASNLVQAVFLATGQDPAQNVESSSCITTMKK-- 
P. citrinum MlcD                      DSMVQLNISKNLIGSAMAGSVGGFNAQAANLAAAIFIATGQDPAQVVESANCITLMNN-- 
                                      ::::::*  ***:****:**:**:**:*:*:. *:::* *** ** * *:.*:* *.    
                                      786 
H. sapiens HMGCR                      PTNEDLYISCTMPSIEIGTVGGGTNLLPQQACLQMLGVQGACKDNPGENARQLARIVCGT 
A. terreus HMGCR1                     -VDGNLQIAVSMPAIEVGTIGGGTILEGQSAMLDLLGVRGSHPTNPGDNARQLARIVAAA 
A. terreus HMGCR2 (LvrA)              -IDGNLHIAVSMPSMEVGTIGGGTILEAQGAMLDLLGVRGAHATEPGANARRLARIVAAA 
M. ruber HMGCR1                       -INGNLQIAVSMPSIEVGTIGGGTILEGQSAMLDLLGVRGSHPTDPGENARRLARIVAAA 
M. ruber HMGCR2 (MokG)                -IDGNLHIAVSMPSMEVGTIGGGTILEAQGAMLDLLGVRGAHPTDPGANARRLARIVAAA 
P. citrinum MlcD                      -LRGSLQISVSMPSIEVGTLGGGTILEPQGAMLDMLGVRGSHPTTPGENARQLARIIGSA 
                                          .* *: :**::*:**:**** *  * * *::***:*:    ** *:*:*:**: .: 
                                      846 
H. sapiens HMGCR                      VMAGELSLMAALAAGHLVKSHMIHNRS 
A. terreus HMGCR1                     VLAGELSLCSALAAGHLVRAHMAHNRS 
A. terreus HMGCR2 (LvrA)              VLAGELSTCAALAAGHLVNAHMQHNRS 
M. ruber HMGCR1                       VLAGELSLCSALAAGHLVRAHMAHNRG 
M. ruber HMGCR2 (MokG)                VLAGELSTCSALAAGHLVNAHMRHNRS 
P. citrinum MlcD                      VLAGELSLCAALAAGHLVKAHMAHNRS 
                                      *:*****  :********.:** ***.                                   
 
     
Figure 7: Sequence alignment of the catalytic domains of HMG-CoA reductases (HMGCRs). The region including 
the residues that participate in the binding of HMG-CoA is presented in the figure. The numbers on top of the 
alignment correspond to the amino acid positions in human HMGCR (Homo sapiens HMGCR). The HMG-CoA-
binding residues in human HMGCR (marked with yellow) were identified prior to this work (Istvan, 2000). Position 
766 that was prveviously shown to be important for statin sensitivity is marked witjh blue (Wysocka-Kapcinska et 
al., 2009). Non-conserved residues are shown in red. Sequences were aligned with Clustal Omega program (Sievers 
et al., 2011). Symbols below the alignment: * (asterisk)-positions, which have a single, fully conserved residue. : 
(colon)-conservation between groups of strongly similar properties (scoring > 0.5 in the Gonnet PAM 250 matrix) . 
(period)-conservation between groups of weakly similar properties (scoring =< 0.5 in the Gonnet PAM 250 matrix). 
 
 Sequence comparison revealed that the residue at position 766 (shown in 
blue in Figure 7), which was proposed to be associated with the enzyme`s statin 
sensitivity (Wysocka-Kapcinska et al., 2009), is conserved in all the aligned HMGCR 
sequences. Most of the residues that participate in the binding of HMG-CoA, and 
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thus also statins (shown in yellow in Figure 7), are too conserved, however, few 
residues (shown as red in Figure 7) in A. terreus LvrA, and in M. ruber HMHCRs are 
substituted, suggesting that these HMGCRs could possess altered binding affinity 
for statins. If these substitutions would render the HMGCRs stain-insensitive, than 
one would expect that the substitutions would be also present in MlcD. The fact that 
not all the statin-associated HMGCRs possess similar substitutions, combined with 
the finding that MlcD and LvrA/MokG clades arose from separate duplication 
events, favor the hypothesis that the statin self-resistance mechanism is based on 
the increased concentration of HMGCR and not on the expression of the statin-
insensitive version of HMGCR. Nevertheless, the question whether the HMGCRs 
encoded in the statin gene clusters are statin insensitive can only be resolved via an 
in vitro biochemical characterization of the HMGCRs from the statin-clusters. 
 
5.3 Conclusions 
 
 This study shows that mlcD from the P. citrinum compactin gene cluster can 
mediate statin resistance when expressed heterologously in S. cerevisiae, 
supporting the suggestions made by Alberts et al. concerning the function of the 
orthologues function in A. terreus. Successful complementation of HMG1 and 
HMG2 in yeast, in addition, for the first time provides direct evidence for the 
mechanism by which MlcD mediates resistance, as it functions as HMGCR. With the 
ability to confer the statin resistance in S. cerevisiae, MlcD has a potential to 
improve future yeast based production of statins. To gain insight into the molecular 
biological basis of statin resistance, a bioinformatics approach was used. Our 
phylogenetic analysis showed that HMGCRs from the statin clusters split between 
two different clades (MlcA in one clade and LvrA/MokA in another clade), which 
could suggest that they have evolved by two independent events (separate 
duplication events). HMGCR-encoding gene at some time during evolution was 
likely duplicated, and genome shuffling has resulted in relocation of the gene into 
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the statin gene clusters. Moreover, protein sequence alignment did not reveal any 
unique amino acid substitutions, which would suggest that the HMGCRs from the 
statin gene clusters are statin-insensitive. We propose that the statin self-resistance 
mechanism is based on the increased concentration of HMGCR in the cell and not 
on the expression of the statin-insensitive version of HMGCR, however, further 
biochemical characterization of the HMGCRs from the statin-clusters is required to 
validate the proposed model. Understanding the molecular biological basis for statin 
resistance may aid the strain optimization processes for efficient production of 
statins in both, native and heterologous hosts. 
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5.4 Materials and methods 
 
5.4.1 Construction of plasmids and strains 
 
 A yeast codon-optimized version of the mlcD gene, de novo synthetized by 
Genscript, was PCR amplified from the plasmid pEN668 with primers mlcD-F and 
mlcD-R. The S. cerevisiae TEF1 promoter was amplified from the plasmid pSP-G2 
(Partow et al., 2010) using primers TEF1-d and PGK1-s. The amplified fragments 
were cloned into the pX-3 targeting vector (Mikkelsen et al., 2012) via the USER 
cloning technique (Nour-Eldin et al., 2006) resulting in plasmid pX3-TEF1-mlcD-
CYC1. All fragments were amplified by PCR using a USER cloning compatible 
PfuX7 polymerase (Nørholm, 2010). Escherichia coli DH5α (Woodcock et al., 1989) 
was used as host for USER cloning experiments and for the propagation of the 
constructed plasmid. The inserts of the resulting plasmid were verified by 
sequencing (StarSEQ). The constructed plasmid was digested with the NotI enzyme 
(New England Biolabs), and the obtained linear fragment was used for yeast 
transformation using the lithium acetate/single-stranded carrier DNA/polyethylene 
glycol transformation method (Gietz and Schiestl, 2007). The linear gene targeting 
cassette was integrated into the X-3 locus of the reference yeast strain, S. cerevisiae 
CEN.PK 113-11C as described by Mikkelsen et al (Mikkelsen et al., 2012). Correct 
integration of the substrate was verified by diagnostic colony PCR with one primer 
annealing outside of the integration site in the yeast genome (X-3-up-out-sq), and 
one substrate specific primer (C1_TADH1_F). 
 For the deletion of the HMGCR-encoding genes in S. cerevisiae we used a 
gene targeting strategy (Reid et al., 2002a, 2002b), in which the targeted genes 
(HMG1 and HMG2) were replaced by the Kluyveromyces lactis URA3 marker that 
was flanked by a direct repeat allowing for iterative gene targeting (Figure 8). Four 
PCR fragments for each knockout were generated. Two fragments represented the 
upstream and downstream regions of the gene to be deleted (HMG1/HMG2 
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upstream and HMG1/HMG2 downstream, respectively), and two fragments 
represented the 5` 2/3 of K. lactis URA3 and the 3` 2/3 of K. lactis URA3 marker 
(URA 1 and URA2 respectively). The URA1 and URA2 fragments were amplified 
from plasmid pWJ1042 (Reid et al., 2002a, 2002b) using primer pairs 5`-
int/cKL3`and 3`-int/dKL5`, respectively. The HMG1 upstream and HMG1 
downstream fragments were amplified from genomic DNA of the WT strain using 
primer pairs HMG1-Up-Fv/HMG1-Up-Rv and HMG1-Dw-Fv/HMG1-Dw-Rv, 
respectively, and the HMG2 fragments were obtained in the same way using the 
according primers. Next, gene-targeting substrates were generated by PCR-
mediated fusion, in which HMG1 upstream fragment was fused with URA2, and 
HMG1 downstream with URA1. Similarly, HMG2 upstream and HMG2 downstream 
fragments were fused with URA2 and URA1 fragments, respectively. This resulted in 
four gene targeting substrates, which were used for yeast transformation using the 
lithium acetate/single-stranded carrier DNA/polyethylene glycol transformation 
method (Gietz and Schiestl, 2007). Correct integration of substrates was verified by 
diagnostic colony PCR. Primer pairs HMG1-Up-out/HMG1-Dw-out and HMG2-Up-
out/HMG2-Dw-out were used to confirm the deletion of the HMG1 and HMG2 gene, 
respectively. 
 
Figure 8: Schematic representation of the gene targeting strategy used to delete the HMGCR-encoding genes, 
HMG1 and HMG2, in S. cerevisiae. The targeting substrates, each composed of the targeting sequence (HMG1/2 
upstream or HMG1/2 downstream) and 2/3 of K. lactic URA3 marker, were used to replace the targeted genes with 
the marker via homologous recombination (indicated with crosses). The URA3 marker was flanked by direct 
repeats, enabling removal of the marker by direct repeat recombination. 
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 The URA3 markers in all the constructed strains were removed by direct 
repeat recombination using 5-FOA (Melford) counter selection. Oligonucleotides 
used in this study are listed in Table 4, and plasmids and strains are listed in Table 
5. 
 
Table 4 
Oligonucleotides used in this study. U = 2-deoxyuridine. 
Primer name Primer sequence (5`- 3`) Use 
mlcD-F ATCAACGGGUAAAAATGGTGGCTTCCT 
 
Amplification of mlcE from 
plasmid pEN669 mlcD-R CGTGCGAUTCAACGTCTGGCAC  
 TEF1-d ACGTATCGCUGTGAGTCGTATTACGGATCCTTG Amplification of promoter 
sequence from plasmid 
pSP-G2 PGK1-s CGTGCGAUGCCGCTTGTTTTATATTTGTTG 
X-3-up-out-sq TGACGAATCGTTAGGCACAG Strain confirmation via 
colony PCR C1_TADH1_F CTTGAGTAACTCTTTCCTGTA 
cKL3` CACGGCGCGCCTAGCAGCGGTAACGCCAGGGTTTTCCCAGTCAC Amplification of URA1 
fragment from plasmid 
pWJ1042 5`-int CTTGACGTTCGTTCGACTGATGAGC 
3`-int GAGCAATGAACCCAATAACGAAATC Amplification of URA2 
fragment from plasmid 
pWJ1042 dKL5 GTCAGCGGCCGCATCCCTGCTTCGGCTTCATGGCAATTCCCG 
HMH1-Up-Fv GAAACTTTTTGGTCGGTC Amplification of HMG1 
upstream fragment from 
gDNA of WT strain HMG1-Up-Rv GCAGGGATGCGGCCGCTGACCCTAAACTTAGTCATACGTC 
HMH1-Dw-Fv CCGCTGCTAGGCGCGCCGTGCGGCATGCTTGTTTTATG Amplification of HMG1 
downstream fragment 
from gDNA of WT strain HMG1-Dw-Rv AAACGGAATTTCAAAGGGC 
HMH2-Up-Fv TATTTAGTGATATAGCCGCCCA Amplification of HMG2 
upstream fragment from 
gDNA of WT strain HMG2-Up-Rv GCAGGGATGCGGCCGCTGACGAAGTGACATTTGAGGTTG 
HMH2-Dw-Fv CCGCTGCTAGGCGCGCCGTGCCCTGTAAAACCTCAGCATTAT Amplification of HMG2 
downstream fragment 
from gDNA of WT strain HMG2-Dw-Rv GGACATTCTTTTTAGCACAC 
HMG1-Up-out TTGTGTGGCCTTATCTATGC Strain confirmation via 
colony PCR HMG1-Dw-
out TTCTCTTCCAACCCCTTTTAC 
HMG2-Up-
Out TCCATGAAATAGGGTCCTT Strain confirmation via 
colony PCR HMG2-Dw-
Out TCTCGGTTCTATTTCTGTCGT 
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Table 5 
Plasmids and strains used in this study. 
Plasmid name Description Reference or source 
pEN668 Template for amplifying mlcD (S. cerevisiae codon optimized) from Evolva Holding SA 
pWJ1042 Template for amplifying URA3 marker (Reid et al., 2002b) 
pSP-G2 Template for amplifying TEF1 (Partow et al., 2010) 
pX3 
USER cloning vector equipped with the CYC1 
terminator designed to target site 3 on 
chromosome X. 
(Mikkelsen et al., 2012) 
pX3-TEF1-mlcD-
CYC1 
Plasmid carrying a gene-targeting cassette for 
expressing mlcD in yeast. This study 
Strain name Genotype Reference or source 
Escherichia coli 
DH5α 
F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 
recA1 endA1 hsdR17 (rK–, mK+) phoA 
supE44 λ– thi-1 gyrA96 relA1 
(Woodcock et al., 1989) 
Saccharomyces cerevisiae 
CEN.PK113-11C 
(Wild type strain) 
 
MATα MAL2-8C SUC2 his3Δ ura3-52 
Dr. Petter Kötter, Institut für Mikrobiologie, 
der Johan Wolfgang Goethe-Universität, 
Frankfurt am Main, Germany 
ARX4 MATα MAL2-8C SUC2 his3Δ ura3-52 X3::PTEF1-mlcD-Tcyc1 This study 
AR31 MATα MAL2­8C SUC2 his3Δ ura3-52 hmg1Δ This study 
AR32 MATα MAL2-8C SUC2 his3Δ ura3-52 hmg2Δ This study 
AR33 MATα MAL2­8C SUC2 his3Δ ura3-52 hmg1Δ X3::PTEF1­mlcD-Tcyc1 This study 
AR34 MATα MAL2­8C SUC2 his3Δ ura3-52 hmg2Δ X3::PTEF1-mlcD-Tcyc1 This study 
ARX5 MATα MAL2­8C SUC2 his3Δ ura3-52 hmg1Δ hmg2Δ X3::PTEF1-mlcD-Tcyc1 This study 
 
 
5.4.2 Media 
 
 The E. coli transformants were selected on lysogeny broth (LB) medium 
containing 100 µg/mL of ampicillin. Yeast strains were cultivated in standard liquid 
or solid yeast peptone dextrose medium (YPD), synthetic complete medium (SC), or 
synthetic medium (SM). SC medium was prepared according to Sherman et al. 
(Sherman et al., 1986), with the minor modification that the L-leucine concentration 
was doubled to 60 mg/L. Yeast transformants were selected on SC medium lacking 
uracil. Removal of the URA3 marker, via direct repeat recombination, was achieved 
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by growing the strain on SC medium containing 5-fluororotic acid (5-FOA; 740 
mg/L, Melford) and uracil (30 mg/L). 
 For susceptibility experiments strains were grown aerobically on YPD plates, 
supplemented with activated lovastatin (Tokyo Chemical Industry). Lovastatin stock 
solution (50 mM) was prepared as described previously (Morimoto et al., 2013). 
Briefly, solid lovastatin was dissolved in 1 mL of 99% ethanol, preheated to 50°C, 
alkalinized with 0.5 mL of 0.6 M NaOH and incubated at 50°C for 2 hours. The pH of 
the solution was then adjusted to 7.2 by adding 0.4 M HCl. The final volume of the 
solution was adjusted to 2 mL with water, resulting in stock solutions of 50 mM. All 
stock solutions were filter-sterilized and stored at -20°C. 
 
5.4.3 Susceptibility assays  
 
 For susceptibility assays on solid media five- or tenfold dilution series of S. 
cerevisiae strains, starting with an OD600 of 0.01 or 0.02 were prepared from 
overnight cultures in YPD medium (30°C/150 rpm). 4.5 µL of each dilution were 
plated on a set of YPD agar plates containing different cytotoxic compounds. The 
plates were incubated at 30°C for 3 days, after which the growth of the yeast strains 
was recorded by photography. 
 
5.4.4 Identification of HMGCR candidates 
 
 To determine the number of HMGCR-encoding genes across fungal 
genomes we performed a BlastP against the JGI Genome Portal (Nordberg et al., 
2014), which resulted in 649 hits, all with an E-value below e-7 and a bit score 
higher than 148, originating from 447 different genomes belonging to 346 different 
genera. The full-length sequences of the hits were retrieved and the sequences were 
manually curated to identify doubtful gene models and missing data. This was done 
by tentatively aligning the putative HMGCRs using the CLC Main Workbench 
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alignment algorithm and manually removing sequences with large stretches of 
missing information (gaps) in parts that were found in 95% of the other sequences. 
The eliminated sequences likely included both true pseudogenes and low quality 
gene models, however, no further effort was made to improve or test the validity of 
the underlying gene models. The remaining 602 amino acid sequences were 
analyzed for the presence of conserved domains using the build-in Pfam (Finn et al., 
2014) annotation tool in CLC Main Workbench. Following the Pfam analysis the 
dataset was tentatively aligned again and clustered using the ‘RapidNJ tree’ tool in 
CLC Main Workbench, to allow for manual identification and elimination of 
sequences that did not show the same domain structure as closely related 
sequences. This reduced the total number of sequence hits to 583 representing 435 
different genomes. All the retained sequences included a ‘HMG-CoA_red’ (PF00368) 
domain characteristic of HMGCRs. 
 
5.4.5 Analysis of the HMGCR copy-number in fungal genomes 
 
 Complete lineages for the individual hits were retrieved from the National 
Center for Biotechnology Information (NCBI) taxonomy database (Federhen, 2002) 
and information about the phyla/division (ascomycota (A), basidiomycota (B), 
blastocladiomycota (Bl), chytridiomycota (Ch), cryptomycota (Cy), glomeromycota 
(G), microsporidia (M) and zygomycota (Z)) for the individual sequence belonged to 
was added to the sequence name. Using Microsoft Excel the putative HMGCRs 
were sorted based on first ‘division name’, secondly ‘genera name’ and thirdly 
‘species name’. The list was inspected and redundancy was eliminated, e.g. species 
for which multiple different genomes were present such as S. cerevisiae, resulting in 
a dataset containing 551 unique sequences divided between 435 species from 319 
different genera. Sorting of the sequence list based on species names allowed for 
counting the number of putative HMGCR copies in the individual species. 
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5.4.6 Phylogenetic analysis of putative HMGCRs and Ascomycota Group A 
HMGCRs 
 
 The dataset with 551 putative HMGCR sequences was aligned using 
MUSCLE (Edgar, 2004) to create higher quality alignments for the phylogenetic 
analysis. The sequences fell within three groups based on sequence length and 
predicted domain structure, which was reflected in the MUSCLE alignments where 
only the predicted ‘HMG-CoA_red’ region was shared between all sequences. 
Unaligned regions were removed, only retaining the approximately 340 aa long 
‘HMG-CoA_red’ domain in each sequence. To allow for rooting of the constructed 
phylogentic tree, the sole HMGCR from Sulfolobus tokodaii (Archaea) was included 
in the dataset to serve as an out-group. The sequences were realigned with 
MUSCLE and a Maximum likelihood phylogeny was built using MEGA 6 (Tamura et 
al., 2013). The latter approach was used for generation of phylogenetic trees in both, 
Figure 4 and Figure 6. 
 
5.4.7 Protein sequence alignment 
 
Protein sequences were obtained from either JGI Genome Portal or NCBI. 
Reference numbres of the aligned fungal proteins are listed in Table 6. Human 
HMGCR was used as a reference (H. sapiens HMGCR; NCBI Accession   
NP_000850). Protein sequences were aligned with Clustal Omega program (Sievers 
et al., 2011) using the default settings. 
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Table 6 
List of protein sequence used for the phylogenetic analysis of the Ascomycota Group A HMGCRs (presented in 
Figure 6). Sequences are listed in the same order as they appear in the phylogenetic tree from top to bottom. Where 
Protein ID from JGI is not available, an NCBI GenBank number (*), or Reference Sequence number (**) is provided. 
Organism 
Protein name 
used in the tree 
JGI Protein ID 
Neosartorya fischeri NRRL 181 HMGCR1 1520 
Aspergillus novofumigatus IBT 16806 v1.0 HMGCR1 456029 
Aspergillus fumigatus A1163 HMGCR1 100206 
Aspergillus clavatus NRRL 1 HMGCR1 3868 
Aspergillus versicolor v1.0 HMGCR1 132429 
Aspergillus sydowii v1.0 HMGCR1 149226 
Aspergillus nidulans from aspGD HMGCR1 2327 
Aspergillus ochraceoroseus IBT 24754 HMGCR1 513848 
Aspergillus phoenicis ATCC 13157 v1.0 HMGCR1 133230 
Aspergillus niger CBS 513.88 HMGCR1 4864 
Aspergillus brasiliensis HMGCR1 123745 
Aspergillus kawachii IFO 4308 HMGCR1 15042 
Aspergillus acidus v1.0 HMGCR1 141251 
Aspergillus tubingensis v1.0 HMGCR1 125382 
Aspergillus carbonarius ITEM 5010 v3 HMGCR1 207403 
Aspergillus terreus NIH 2624 HMGCR1 3658 
Aspergillus steynii IBT 23096 v1.0 HMGCR1 364578 
Aspergillus flavus NRRL3357 HMGCR1 27661 
Aspergillus wentii v1.0 HMGCR1 51536 
Aspergillus glaucus v1.0 HMGCR1 119821 
Aspergillus campestris IBT 28561 v1.0 HMGCR1 316459 
Monascus ruber NRRL 1597 v1.0 HMGCR1 389114 
Monascus Purpureus v1.0 HMGCR1 512502 
Penicillium bilaiae ATCC 20851 v1.0 HMGCR1 392097 
Penicillium glabrum DAOM 239074 v1.0 HMGCR1 385979 
Penicillium fellutanum ATCC 48694 v1.0 HMGCR1 350461 
Penicillium oxalicum 114-2 HMGCR1 5304 
Penicillium janthinellum ATCC 10455 v1.0 HMGCR1 373341 
Penicillium raistrickii ATCC 10490 v1.0 HMGCR1 315658 
Penicillium Brevicompactum v2.0 HMGCR1 41253 
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Penicillium expansum ATCC 24692 v1.0 HMGCR1 380985 
Penicillium digitatum PHI26 HMGCR1 5769 
Penicillium lanosocoeruleum ATCC 48919 v1.0 HMGCR1 368062 
Penicillium chrysogenum Wisconsin 54-1255 HMGCR1 142996 
Penicillium canescens ATCC 10419  v1.0 HMGCR1 364500 
Penicillium citrinum MlcD BAC20567.1* 
Penicillium expansum ATCC 24692 v1.0 HMGCR2 372222 
Aspergillus kawachii IFO 4308 HMGCR2 12145 
Aspergillus acidus v1.0 HMGCR2 132582 
Aspergillus tubingensis v1.0 HMGCR2 58795 
Aspergillus phoenicis ATCC 13157 v1.0 HMGCR2 280144 
Aspergillus niger NRRL3 HMGCR2 8211 
Aspergillus brasiliensis v1.0 HMGCR2 44387 
Aspergillus carbonarius ITEM 5010 v3 HMGCR2 163555 
Periconia macrospinosa DSE2036 v1.0 HMGCR1 28317 
Monascus ruber NRRL 1597  v1.0 HMGCR2 390686 
Aspergillus flavus NRRL3357 HMGCR2 33547 
Aspergillus carbonarius ITEM 5010 v3 HMGCR3 204491 
Aspergillus terreus NIH 2624 HMGCR2 4103 
Neosartorya fischeri NRRL 181 HMGCR2 2813 
Aspergillus novofumigatus IBT 16806 v1.0 HMGCR2 504007 
Aspergillus fumigatus A1163 HMGCR2 101185 
Aspergillus wentii v1.0 HMGCR2 119346 
Aspergillus glaucus v1.0 HMGCR2 129472 
Neosartorya fischeri NRRL 181 HMGCR3 2369 
Aspergillus nidulans from aspGD HMGCR2 7253 
Penicillium bilaiae ATCC 20851 v1.0 HMGCR2 391090 
Aspergillus versicolor v1.0 HMGCR2 38907 
Aspergillus sydowii v1.0 HMGCR2 194492 
Aspergillus terreus NIH 2624 HMGCR3 5708 
Sulfolobus tokodaii  HMGCR WP_010979393.1** 
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Abstract 
 
 Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, 
the key enzyme in cholesterol biosynthesis. Their extensive use in treatment and 
prevention of cardiovascular diseases placed statins among the best selling drugs. 
Construction of Saccharomyces cerevisiae cell factory for the production of high 
concentrations of natural statins will require establishment of a non-destructive self-
resistance mechanism to overcome the undesirable growth inhibition effects of 
statins. To establish active export of statins from yeast, and thereby detoxification, 
we integrated a putative efflux pump-encoding gene mlcE from the mevastatin-
producing Penicillium citrinum into the S. cerevisiae genome. The resulting strain 
showed increased resistance to both natural statins (mevastatin and lovastatin) and 
semi-synthetic statin (simvastatin) when compared to the wild type strain. 
Expression of RFP-tagged mlcE showed that MlcE is localized to the yeast plasma 
and vacuolar membranes. We provide a possible engineering strategy for 
improvement of future yeast based production of natural and semi-synthetic statins.  
 
Keywords: 
Polyketide; Statins; Saccharomyces cerevisiae; Transport; Cell factory; Resistance 
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6.1 Introduction 
 
 Statins are used as cholesterol-lowering drugs in treatment and prevention 
of coronary heart diseases, and their extensive worldwide usage placed them 
among the best selling pharmaceuticals in the past decade (GBI Research, 2013). 
The application of statins in medicine is based on their ability to inhibit the catalytic 
action of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR). HMGCR 
constitutes the rate-limiting enzyme in the mevalonate pathway, which is 
responsible for the production of sterols, such as cholesterol in animal cells, and 
ergosterol in fungi (Maury et al., 2005). Natural statins are synthesized as secondary 
metabolites by filamentous fungi; mevastatin (Fig. 1A) by Penicillium citrinum (Endo 
et al., 1976a), and lovastatin (Fig. 1B) by Aspergillus terreus (Alberts et al., 1980) and 
Monascus ruber (Endo, 1979). Industrial scale production of natural statins and their 
semi-synthetic derivatives (e.g. simvastatin and pravastatin) is based on 
fermentation of statin-producing filamentous fungi (Manzoni and Rollini, 2002; S. K. 
Singh and Pandey, 2013). Production limitations associated with the unique 
physiology and morphology of these natural producers can be overcome by 
heterologous expression of the biosynthetic pathway in a fast-growing host, such as 
Saccharomyces cerevisiae. It will, however be crucial to establish a nondestructive 
resistance mechanism in yeast to overcome the undesirable growth inhibition 
effects of statins. One such mechanism could be active export of statins. 
 Secondary metabolite gene clusters, in addition to the catalytic enzymes, 
often encode proteins for secretion of the produced bioactive compounds and 
thereby also a self-resistance mechanism (reviewed in (Martín et al., 2005)). This is 
also likely the case for the known statin clusters, where putative efflux pump 
encoding genes are present; mlcE in the mevastatin cluster (Fig. 1A) (Abe et al., 
2002b), and lovI or mokI in the lovastatin cluster of A. terreus (Kennedy et al., 1999) 
or M. ruber (Chen et al., 2008), respectively (Fig. 1B). Given the industrial importance 
of the microbial statin-producing cell factories it is surprising that only limited 
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evidence concerning the function of the putative efflux pumps in the statin gene 
clusters has been provided so far. Hutchinson et al. found that A. terreus lovI 
mutants did not produce lovastatin or any of its known precursors, and that 
heterologous expression of lovI in Aspergillus nidulans, a lovastatin sensitive 
species, did not result in increased lovastatin resistance (unpublished result in 
(Hutchinson et al., 2000)). These findings did not clarify the function of the putative 
efflux pumps in the statin-producing fungi. Nevertheless, understanding the statin 
transport mechanism could open up an alternative avenue to classical metabolic 
engineering strategies aimed at increased productivity of the natural statin-
producing strains (Barrios-González and Miranda, 2010). Moreover, genes encoding 
for the statin transporters can represent a pool of candidates for co-expression in a 
heterologous host, such as S. cerevisiae, thus open up a possibility to establish the 
necessary self-resistance mechanism for the production of statins in yeast. 
 In this study, we investigate the function of the putative efflux pump MlcE 
from the P. citrinum mevastatin gene cluster and explore its potential to confer 
statin resistance in S. cerevisiae. 
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Fig. 1. Natural statins and their biosynthetic gene cluster. (A) Mevastatin and its gene cluster from P. citrinum. (B) 
Lovastatin and its gene clusters from M. ruber (mok genes) and A. terreus (lov genes). The putative efflux pump 
genes are shown in grey. 
 
6.2 Materials and methods 
 
6.2.1 Bioinformatics 
 
 Protein sequences were obtained from UniProtKB (Consortium, 2013). 
Protein topology prediction was carried out using TOPCONS web server (Bernsel et 
al., 2009). Prediction of subcellular localization was performed with CELLO v.2.5 (Yu 
et al., 2006). For phylogenetic tree construction the protein sequences were aligned 
with the multiple sequence alignment tool MAFFT (Multiple sequence Alignment 
using Fast Fourier Transform) (Katoh et al., 2009) available at the European 
Bioinformatics Institute (EMBL-EBI) (McWilliam et al., 2013). See Supplementary 
Table S1 for the list of protein sequences used for the tree construction. The 
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phylogenetic tree was generated with the ClustalW2 alignment extension (Larkin et 
al., 2007) at EMBL-EBI using the Neighbor joining clustering method, with the 
following setting: distance correction on, exclude gaps on. FigTree software, version 
1.4 was used for displaying the tree. 
 
6.2.2 Construction of plasmids and strains 
 
 A yeast codon-optimized version of the mlcE gene, de novo synthetized by 
Genscript, was PCR amplified from the plasmid pEN669 with primers mlcE-F and 
mlcE-R. The S. cerevisiae TEF1 promoter was amplified from the plasmid pSP-G2 
(Partow et al., 2010) using primers TEF1-d and PGK1-s. The amplified fragments 
were cloned into the pX-3 targeting vector (Mikkelsen et al., 2012) via the USER 
cloning technique (Nour-Eldin et al., 2006) resulting in plasmid pX3-TEF1-mlcE-
CYC1. The subcellular localization of MlcE was determined by tagging it C-
terminally with monomeric red fluorescent protein (RFP). For that plasmid pX3-
TEF1-mlcE-RFP-CYC1 and a control plasmid pX3-TEF1-RFP-CYC1 were 
constructed as follows: the coding sequence of mlcE lacking the stop codon was 
amplified using the primer pair mlcE-F and mlcE-RFP-R, and a yeast codon-
optimized RFP was amplified from plasmid pWJ1350 (Lisby et al., 2003) using the 
primers RFP_R+ and either RFP-F (for tagging mlcE) or RFP_F+ (for the control 
plasmid). All fragments were amplified by PCR using a USER cloning compatible 
PfuX7 polymerase (Nørholm, 2010). Escherichia coli DH5α (Woodcock et al., 1989) 
was used as host for USER cloning experiments and for the propagation of the 
constructed plasmids. The inserts of the resulting plasmids were verified by 
sequencing (StarSEQ). The constructed plasmids were digested with the NotI 
enzyme (New England Biolabs), and the obtained linear fragments were used for 
yeast transformation using the lithium acetate/single-stranded carrier 
DNA/polyethylene glycol transformation method (Gietz and Schiestl, 2007). The 
linear gene targeting cassettes were integrated into the X-3 locus of the reference 
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yeast strain, S. cerevisiae CEN.PK 113-11C as described by Mikkelsen et al 
(Mikkelsen et al., 2012). The URA3 markers in the constructed strains were removed 
by direct repeat recombination using 5-FOA (Melford) counter selection. Correct 
integration of substrates was verified by diagnostic colony PCR with one primer 
annealing outside of the integration site in the yeast genome (X-3-up-out-sq), and 
one substrate specific primer (C1_TADH1_F). Oligonucleotides, plasmids and strains 
used in this study are listed in Table 1. 
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Table 1  
Oligonucleotides, plasmids and strains used in this study. U = 2-deoxyuridine. 
Primer name Primer sequence (5`- 3`) Use 
mlcE-F AGCGATACGUAAAAATGAGTGAACCATTACC 
Amplification of mlcE from 
plasmid pEN669 
mlcE-R CACGCGAUTTATGCATCAGTCTCAG 
TEF1-d ACGTATCGCUGTGAGTCGTATTACGGATCCTTG Amplification of promoter 
sequence from plasmid pSP-
G2 PGK1-s CGTGCGAUGCCGCTTGTTTTATATTTGTTG 
RFP_F+ ATGGCCTCCUCCGAGGACGTCATCAAGGAG 
Amplification of RFP from 
plasmid pWJ1350 
RFP_R+ CACGCGAUCTAGGCGCCGGTGGAGTGGCGG 
mlcE-RFP-R AGGAGGCCAUTGCATCAGTCTCAGGGAC Amplification of mlcE from plasmid pX3-TEF1-mlcE-CYC1 
RFP-F AGCGATACGUAAAAATGGCCTCCTCCGAG 
Amplification of RFP from 
plasmid pX3-TEF1-mlcE-RFP-
CYC1 
X-3-up-out-sq TGACGAATCGTTAGGCACAG 
Strain confirmation via colony 
PCR 
C1_TADH1_F CTTGAGTAACTCTTTCCTGTA 
Plasmid name Description Reference or source 
pEN669 Template for amplifying mlcE (S. cerevisiae codon optimized) from Evolva Holding SA 
pWJ1350 Template for amplifying RFP (Lisby et al., 2003) 
pSP-G2 Template for amplifying TEF1 (Partow et al., 2010) 
pX3 USER cloning vector equipped with the CYC1 terminator designed to target site 3 on chromosome X. (Mikkelsen et al., 2012) 
pX3-TEF1-mlcE-
CYC1 
Plasmid carrying a gene-targeting cassette for expressing 
mlcE in yeast. This study 
pX3-TEF1-RFP-
CYC1 
Plasmid carrying a gene-targeting cassette for expressing 
RFP-tagged mlcE in yeast. This study 
pX3-TEF1-mlcE-
RFP-CYC1 
Plasmid carrying a gene-targeting cassette for expressing 
RFP in yeast. This study 
Strain name Genotype Reference or source 
Escherichia coli 
DH5α F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK–, mK+) phoA supE44 λ– thi-1 gyrA96 relA1 (Woodcock et al., 1989) 
Saccharomyces cerevisiae 
CEN.PK113-11C 
(Wild type strain) 
 
MATα MAL2-8C SUC2 his3Δ ura3-52 
Dr. Petter Kötter, Institut für 
Mikrobiologie, der Johan 
Wolfgang Goethe-Universität, 
Frankfurt am Main, Germany 
ARX1 MATα MAL2-8C SUC2 his3Δ ura3-52 X3::PTEF1­mlcE-RFP-Tcyc1 This study 
ARX2 MATα MAL2­8C SUC2 his3Δ ura3-52 X3::PTEF1-RFP-Tcyc1 This study 
ARX3 MATα MAL2-8C SUC2 his3Δ ura3-52 X3::PTEF1-mlcE-Tcyc1 This study 
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6.2.3 Media 
 
 The E. coli transformants were selected on lysogeny broth (LB) medium 
containing 100 µg/mL of ampicillin. Yeast strains were cultivated in standard liquid 
or solid yeast peptone dextrose medium (YPD), synthetic complete medium (SC), or 
synthetic medium (SM). SC medium was prepared according to Sherman et al. 
(Sherman et al., 1986), with the minor modification that the L-leucine concentration 
was doubled to 60 mg/L. Yeast transformants were selected on SC medium lacking 
uracil. Removal of the URA3 marker, via direct repeat recombination, was achieved 
by growing the strain on SC medium containing 5-fluororotic acid (5-FOA; 740 
mg/L, Sigma-Aldrich) and uracil (30 mg/L). 
 For susceptibility experiments strains were grown aerobically either on YPD 
plates or in SM, supplemented with compounds as described below. SM was 
prepared according to Verduyn (Verduyn et al., 1992), but concentrations of 
(NH4)2SO4  and KH2PO4 were modified to 7.5 g/L and 14.4 g/L, respectively. SM was 
supplemented with uracil (150 mg/L; Sigma-Aldrich) and L-Histidine (125 mg/L; 
Sigma-Aldrich) (Pronk, 2002). The pH was adjusted to 6.5 with a 2M NaOH solution. 
Glucose was added as carbon source to a final concentration of 20 g/L. The 
compounds used in the susceptibility experiments were prepared as follows: stock 
solutions of vanillin (320 mM), mycophenolic acid (MPA, 50 mM) and atorvastatin (10 
mM) were prepared by dissolving the compounds in 99% ethanol. Mevastatin, 
lovastatin, and simvastatin stock solutions (50 mM) were prepared as described 
previously (Morimoto et al., 2013). Briefly, the solid compounds were dissolved in 1 
mL of 99% ethanol, preheated to 50°C, alkalinized with 0.5 mL of 0.6 M NaOH and 
incubated at 50°C for 2 hours. The pH of the solutions was then adjusted to 7.2 by 
adding 0.4 M HCl. The final volume of the solutions was adjusted to 2 mL with 
water, resulting in stock solutions of 50 mM. All stock solutions were filter-sterilized 
and stored at -20°C. Mevastatin and atorvastatin were purchased from Toronto 
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Research Chemicals, lovastatin from Tokyo Chemical Industry, MPA and vanillin 
from Sigma-Aldrich, and simvastatin from Ark Pharm.  
 
6.2.4 Fluorescent Microscopy 
 
 For fluorescent microscopy the mlcE-RFP- and RFP-expressing strains 
(ARX1 and ARX2, respectively) were cultured in liquid SC medium at 30°C with 150 
rpm agitation overnight and analyzed by fluorescence and visible light microscopy 
using a Nikon Eclipse E1000 microscope equipped with an oil-immersed objective 
at 100 x magnification. The images were captured with QImaging Retiga Exi digital 
camera using Image Pro Plus 5.1 software. The brightness of images to be 
compared was adjusted pairwise using Adobe Photoshop CS6. 
 
6.2.5 Susceptibility experiments  
 
 For susceptibility assays on solid media tenfold dilution series of S. 
cerevisiae WT and ARX3 strains (Table 1), starting with an OD600 of 0.02 were 
prepared from overnight cultures in SC medium (30°C/150 rpm). 4.5 µL of each 
dilution were plated on a set of YPD agar plates containing different cytotoxic 
compounds. The plates were incubated at 30°C for 3 days, after which the growth 
of the yeast strains was recorded by photography. 
 For susceptibility assay in liquid medium, strains were grown aerobically in 
SM, containing different concentrations of lovastatin. Yeast optical density 
measurements were performed in 48 wells plates in a plate reader (BioTek’s 
Synergy™ Mx Microplate Reader) at 30°C with fast shaking intensity setting (19 Hz 
speed, linear shake, which translates into 1140 rpm according to the BioTek`s 
instructions) in 400 µL of SM. Cells were harvested from overnight shake flask 
cultures (30°C/150 rpm) in late exponential phase and diluted to an OD600 of 0.1 in 
SM medium with 0.7, 1.2 or 2.0 mM of activated lovastatin or an equal volume of 
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control solution (99% ethanol treated as described above – preparation of the 
compounds for the susceptibility experiments). Triplicate OD600 measurements were 
taken every 5 minutes for 24 hours.  
 
6.3 Results and Discussion 
 
6.3.1 Topology prediction and phylogenetic clustering of MlcE 
 
 MlcE, a putative efflux pump from the P. citrinum mevastatin biosynthetic 
gene cluster shows significant sequence similarity to drug resistance proteins of the 
major facilitator superfamily (MFS) (Marger and Saier, 1993). MFS transporters are 
characterized by using the proton gradient across the plasma membrane as an 
energy source for the translocation they mediate (Pao et al., 1998). The drug 
resistance protein subfamily of MFS transporters is further divided into two families, 
depending on the number of transmembrane spanning regions (TMS) the proteins 
consist of; 12-TMS family and 14-TMS family (Paulsen and Skurray, 1993; Paulsen 
et al., 1996), also termed as Drug:H+ antiporter 12 TMS (DHA12) family, and 14 TMS 
(DHA14) family, respectively (Pao et al., 1998). The performed phylogenetic analysis 
showed that MlcE, as well as LovI and MokI (Fig. 2), clustered with known members 
of 14-TMS family of drug resistance proteins, such as the cercosporin facilitator 
protein (CFP) from Cercospora kikuchii (Callahan et al., 1999) and HC-toxin efflux 
pump (ToxA) from Cochliobolus carbonum (Pitkin et al., 1996) (further proteins are 
listed in Supplementary Table S1). This classification is supported by the performed 
topology prediction, which showed that MlcE comprises of 14 TMS (data not 
shown), indicating that it is indeed a member of 14-TMS family. We next performed 
an in silico prediction of MlcE’s subcellular localization, using CELLO v.2.5 to see 
where in eukaryotic cells the protein would be localized. The prediction suggests 
that it is most likely localized at the plasma membrane (score = 4.942 and a 
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combined reliability score of 0.997 for the five used prediction methods). 
Collectively, this proposes that MlcE is likely localized in the plasma membrane and 
functions as a statin efflux pump driven by the proton gradient found across the 
plasma membrane. 
 
 
Fig. 2. Phylogenetic clustering of putative statin efflux pumps (MlcE, MokI and LovI) with major facilitator 
superfamily (MFS) transporters involved in the efflux of toxic compounds, belonging to the subfamily of proteins 
with 14 transmembrane domains (14-TMS family). Proteins used to construct the phylogenetic tree are listed in 
Supplementary Table S1, where information about the source organism and the substrate of each protein is 
provided. 
 
6.3.2 Subcellular localization of MlcE 
 
 To experimentally determine the subcellular localization of MlcE in S. 
cerevisiae we tagged MlcE with the red fluorescent protein (RFP) at its carboxylic 
terminus and expressed it as a single copy gene from the yeast genome (Fig. 3A). 
Fluorescent microscopy of the resulting strain, ARX1, revealed a ring-like 
 129 
distribution of the fluorescent protein at the periphery of the cells and inside the 
vacuole (Fig. 3B), indicating that the RFP-tagged MlcE was localized to the plasma 
and vacuolar membranes. In contrast, when RFP was expressed alone it was found 
to have a uniform cytoplasmic distribution in the control cells ARX2. This subcellular 
localization of MlcE in S. cerevisiae supports the hypothesis that MlcE is a 
transmembrane protein, which is localized to the plasma membrane. 
 
 
 
Fig. 3. Subcellular localization of MlcE in S. cerevisiae. (A) Strain construction summary. (B) Fluorescent microscopy 
of the constructed strains (see Materials and methods for experimental details). 
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6.3.3 Investigation of the potential of MlcE to confer the resistance to statins in 
S. cerevisiae 
 
 We next tested if the localization of MlcE to the yeast plasma membrane 
would enable it to export statins from yeast, and thereby increase the yeast`s 
resistance to statins. For that, mlcE was expressed from a defined genomic locus in 
S. cerevisiae as a single copy gene under the control of the strong constitutive 
promoter TEF1 (Fig. 4A). The resulting strain ARX3 was tested for its susceptibility to 
mevastatin, MlcE’s predicted natural substrate, by serial dilution plating on YPD 
agar plates supplemented with the active form of mevastatin. The mlcE-expressing 
strain showed an increased resistance to mevastatin compared to the reference 
strain (Fig. 4B). 
 To determine if MlcE would be able to excrete other structurally related 
compounds, we tested the effects of lovastatin and simvastatin. Again, the mlcE-
expressing strain displays an increased resistance compared to the reference strain, 
and the putative pump was able to protect the cells against both the natural statin 
lovastatin and its semi-synthetic derivative simvastatin (Fig. 4B). This shows that 
MlcE is able to accept not only its native substrate but also structurally related 
natural compounds, and even compounds it has not encountered during evolution, 
when expressed in yeast. To determine whether MlcE should be considered as a 
general pleiotropic efflux pump, or a dedicated statin pump, we tested the 
susceptibility of the ARX3 strain to other toxic compounds. This analysis showed 
that MlcE was not able to protect yeast against the lethal effects of the synthetic 
statin, atorvastatin or the effects of the natural compounds vanillin and 
mycophenolic acid (MPA) (Fig. 4B). These results suggests that MlcE is not a multi-
drug resistance efflux pump. The specificity of MlcE and its presence in the 
mevastatin biosynthetic gene cluster suggest that it has likely evolved as a statin 
efflux pump; however, testing in the endogenous species is still required to confirm 
this. 
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Fig. 4. Investigation of the potential of MlcE to confer the resistance to statins in S. cerevisiae. (A) Strain 
construction summary. (B) Susceptibility assay. Ten-fold dilution series of WT (CEN.PK 113-11C) and ARX3 strains 
(harboring MlcE efflux pump), starting with and OD600 of 0.02 were prepared from overnight cultures and plated on a 
set of YPD agar plates containing different cytotoxic compounds. The plates were incubated at 30°C for 3 days, 
after which the growth of the strains was recorded by photography. The plate in the black square represents the 
reference plate (no compounds added to YPD) (for experimental details see Materials and methods). 
 
 
6.3.4 MlcE and a future S. cerevisiae based statin cell factory 
 
 Statins are currently commercially produced by fermentation of natural 
statin-producing species of filamentous fungi. The highest titers reported for these 
systems have been achieved by submerged cultivation, reaching levels up to 950 
mg/L (2.35 mM) of lovastatin (Jia et al., 2010) and 1200 mg/L (3.07 mM) of 
mevastatin (Choi et al., 2004), respectively. For future heterologous production of 
statins to be competitive, these titers will likely have to be matched and preferably 
exceeded. For the last decade several groups have been working on establishing S. 
cerevisiae based statin cell factories, and in 2013 Xu et al. succeed in producing 
dihydromonacolin L acid (0.11 mM), the first stable intermediate in the lovastatin 
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pathway (Xu et al., 2013). However, no one has yet reported whether S. cerevisiae 
will be able to cope with the required product levels. To test this, we cultured the 
reference wild type strain (WT) in liquid synthetic medium supplemented with 
increasing concentrations of activated lovastatin in a micro-fermentation setup. The 
analysis revealed that the IC50 value for extracellularly added lovastatin is approx. 1 
mM (less than half of the required concentration) in the wild type and that even low 
concentrations of lovastatin greatly reduced the aerobic maximum specific growth 
rate and final optical density (Table 2). 
 These results show the necessity of establishing a non-destructive self-
resistance mechanism in a future yeast statin cell factory to allow for titers similar to 
those reported for statin-producing filamentous fungi. For this, MlcE constitutes a 
potential tool for tackling the described self-intoxication problem. To investigate if it 
would also provide protection from statins in liquid cultures, the MlcE expressing 
strain (ARX3) was tested as described above for the reference wild type strain (Table 
2). The analysis showed that while the growth of S. cerevisiae wild type strain was 
almost completely inhibited at lovastatin concentrations similar to those achieved by 
fermentation of A. terreus, growth of the ARX3 strain was only slightly affected by 
the same high concentration of lovastatin. The liquid culture experiment also 
allowed for determination of the strains growth efficiencies (Table 2), which revealed 
that expression of mlcE did have a cost (9% reduction), but that this cost did not 
change as function of the statin concentration, within the tested concentration 
range. 
 Direct proof of the effects of implementing the MlcE based resistance in a S. 
cerevisiae statin cell factory is currently not possible as only part of the biosynthetic 
pathway at this time has been established in yeast (Xu et al., 2013). However, 
implementation could likely have additional benefits such as increasing titers by 
reducing feedback inhibition of the pathway enzymes caused by high intracellular 
concentrations of statins and furthermore reduce product purification costs. 
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Table 2 
Aerobic maximum specific growth rates and growth efficiencies calculated as Δ(OD600,max-OD600,t=0) of S. cerevisiae 
strains WT (CEN.PK 113-11C) and ARX3 (harboring MlcE efflux pump) on glucose and different concentrations of 
activated lovastatin. In the samples with 0 mM lovastatin, an equal volume of solvent was added. Averages and 
standard deviations were obtained from triplicate experiments. 
Lovastatin 
concentration (mM) 
Growth rate (h-1) Growth efficiency 
WT ARX3 WT ARX3 
0 0.28 ± 0.004 0.31 ± 0.01 0.90 ± 0.008 0.82 ± 0.04 
0.7 0.18 ± 0.01 0.34 ± 0.008 0.37 ± 0.04 0.87 ± 0.02 
1.2 0.10 ± 0.008 0.27 ± 0.003 0.28 ± 0.01 0.84 ± 0.02 
2.0 0.04 ± 0.005 0.27 ± 0.005 0.10 ± 0.01 0.86 ± 0.02 
 
 
 
6.4 Conclusions 
 
 We provide evidence that mlcE from the P. citrinum mevastatin biosynthetic 
gene cluster encodes a transmembrane protein that localizes to the plasma and 
vacuolar membranes in S. cerevisiae. Moreover, MlcE significantly increases yeast 
resistance to both, natural and semi-synthetic statins, likely by exporting the 
compounds from the cells. This resistance mechanism has a potential to improve 
future yeast based production of natural and semi-synthetic statins. 
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Table S1 
Drug resistance proteins used for the construction of the phylogenetic tree. Proteins are divided into two families of 
the major facilitator superfamily (MFS) transporters: Drug:H+ antiporter family 1 (DHA12) with 12 transmembrane-
spanning regions (12TMS) and Drug:H+ antiporter family 2 (DHA14) with 14 transmembrane-spanning regions 
(14TMS). 
Protein name Microorganism 
Representative 
Substrate 
Accession Number 
(UniProtKB) 
MFS ­ DHA14 (14 TMS) 
ToxA Cochliobolus carbonum HC-toxin Q00357 
Tri12 Fusarium sporotrichioides Trichotechene O93842 
CFP Cercospora kikuchii Cercosporin O93886 
Atr1 Saccharomyces cerevisiae Aminotriazole P13090 
Sge1 Saccharomyces cerevisiae Crystal violet P33335 
EmrB Escherichia coli 
Carbonyl cyanide m-
chlorophenyl hydrazone 
P0AEJ0 
LfrA Mycobacterium smegmatis Acriflavin Q50392 
QacA Staphylococcus aureus Benzalkonium chloride Q1XG09 
SmvA Salmonella typhimurium Ethidium bromide P37594 
ActVa 1 Streptomyces coelicolor Actinochodrin Q53903 
CmcT Nocardia lactamdurans Cephamycin Q04733 
Mmr Streptomyces coelicolor Methylenomycin A P11545 
Pur8 Streptomyces lipmanii Puromycin P42670 
MFS - DHA12 (12 TMS) 
Ctb4 Cercospora nicotinae Cercosporin A0ST42 
CefT Acremonium chrysogenum Cephalosporin Q8NKG7 
Mdr1 Canidida albicans Fluconazole P28873 
Flu1 Candida albicans Fluconazole G1UB37 
Bcr Escherichia coli Bicyclomycin C6EA15 
Blt Bacillus subtilis Acriflavin M1U4Q0  
EmrD Escherichia coli 
Carbonyl cyanide m-
chlorophenyl hydrazone 
P31442 
CaMDR1 Candida albicans Benomyl Q9URI2 
NorA Staphylococcus aureus Acriflavin P0A0J7 
CyhR Candida maltosa Cycloheximine P32071 
CmlA Pseudomonas aeruginosa Chloramphenicol Q83V15 
Flr1 Saccharomyces cerevisiae Fluconazole P38124 
Tpo1 Saccharomyces cerevisiae Spermine Q07824 
Dtr1 Saccharomyces cerevisiae Dityrosine P38125  
Aqr1 Saccharomyces cerevisiae Quinidine P53943 
Putative Statin Efflux Pumps - unknown family 
MlcE Penicillium citrinum Mevastatin Q8J0F3 
LovI Aspergillus terreus Lovastatin Q9Y7D4 
MokI Monascus pilosus Monacolin Q3S2U5 
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Overall Conclusions and 
Perspectives 
 
 One of the future perspectives in biotechnological production of natural and 
semi-synthetic statins is in the use of a fast-growing heterologous host, such as 
Saccharomyces cerevisiae. The focus of my research was on the development of S. 
cerevisiae cell factory for the production of compactin, a natural statin that is 
synthesized as a secondary metabolite by the filamentous fungus Penicillium 
citrinum. I covered two different aspects of the cell factory development; 
heterologous expression of the compactin biosynthetic pathway in S. cerevisiae and 
establishing a statin resistance mechanism in S. cerevisiae. 
 In Chapter 4 I describe my work aimed at the production of compactin in S. 
cerevisiae. I used a chromosomal gene integration approach to express the 
compactin biosynthetic genes (mlcA, mlcC, mlcF and mlcG), which are required for 
the synthesis of the compactin nonaketide intermediate ML-236A, as well as two 
putative self-resistance genes (mlcE and mlcD). Two different PPTases (i.e. npgA 
and sfp), required for the posttranslational modification of the PKS MlcA were co-
expressed individually in the strain harboring the four compactin biosynthetic genes. 
However, the constructed strains did not synthesize the expected intermediates. 
Fluorescence microscopy of strains expressing RFP-tagged MlcA suggested that 
MlcA accumulated as protein aggregates. The latter can arise from improper folding 
of the protein, a situation that could explain the inability of MlcA to catalyze the 
polyketide formation. Lowering the cultivation temperature, an action that can 
positively affect protein folding, did not result in the production of compactin 
intermediates. Additional studies of the expression of the required proteins, their 
localization, and post-translational modification need to be carried out to 
understand the problem and find a suitable solution. My ambition to develop a yeast 
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cell factory for compactin production was not accomplished, however Xu et al. 
succeeded in production of dihydromonacolin L acid, first stable lovastatin 
intermediate, in S. cerevisiae, suggesting that the future production of statins in 
yeast is possible. With the broad availability of molecular genetic manipulation tools, 
as well as synthetic biology and metabolic engineering tools, production of statins in 
yeast will open an avenue of opportunities for optimization of statin production. 
Moreover, advances in the understanding the polyketide biosynthetic mechanisms 
has in other systems enabled manipulation of both, the synthesis of the polyketide 
backbones by PKSs and the post-PKS synthesis modifications by tailoring 
enzymes, which resulted in production of entirely new compounds. Together with 
the combinatorial biochemistry approach, such manipulations could be also applied 
for the biosynthesis of new statins with alter pharmacokinetic and 
pharmacodynamics properties. On this matter, the synthesis of statins in S. 
cerevisiae would provide a much better platform than natural producers, filamentous 
fungi, due to the ease of genetic manipulation and absence of native secondary 
metabolism, which can complicate polyketide biosynthesis due to cross-reactivity. 
 Construction of a S. cerevisiae cell factory for the production of high 
concentrations of statins will require the establishment of a non-destructive self-
resistance mechanism to overcome the undesirable growth inhibition effects of 
statins. The second aspect of my research activities focused on finding solutions for 
tackling the problem with S. cerevisiae statin-sensitivity. In Chapter 5 I investigated 
the potential of the putative HMGCR MlcD, from the P. citrinum biosynthetic gene 
cluster, to confer the statin resistance in S. cerevisiae and I aimed at elucidating the 
molecular biological basis behind mlcD-derived statin resistance. I showed that 
mlcD can mediate statin resistance when expressed heterologously in S. cerevisiae. 
Successful complementation of Sc-HMG1 and Sc-HMG2 in yeast, in addition, 
provides evidence that MlcD functions as HMGCR. Next I investigated the 
mechanism of the self-resistance provided by MlcD; do natural statin producers 
avoid self-intoxication by increasing the concentration of HMGCR in the cell at the 
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time of statin synthesis, and thus reducing the relative concentration ratio between 
the bioactive compound and the target protein? Or do the statin producers possess 
a unique version of HMGCR, possibly statin-insensitive? I addressed this question 
with the use of bioinformatics. The phylogenetic clustering of fungal HMGCRs and 
analysis of their domain organization suggested that the three HMGCRs from the 
known statin gene clusters (mlcD and lvrA/mokG) are likely derived from HMGCRs 
involved in primary metabolism. However, the occurrence of these genes in the 
different statin gene clusters probably did not arise from a recent duplication of the 
primary HMGCR. Instead, I propose that the HMGCR-encoding genes must at some 
time during evolution have duplicated and then recruited to the statin gene clusters, 
a situation that has increased the chance for becoming co-regulated with the cluster 
and hence statin production. Results obtained with the bioinformatics approach 
suggest that the statin self-resistance mechanism is based on the association with 
the cluster, e.g. increased concentration of HMGCR at the right time, and not on the 
expression of the statin-insensitive version of HMGCR. However, this question 
remains unresolved and further biochemical characterization of the HMGCRs from 
the statin-clusters is required to determine their statin sensitivity. Comparison of the 
statin binding affinities (Ki values) for the HMGCRSs from the statin clusters and for 
the ones encoded elsewhere in the genome will provide insight into the statin 
resistance mechanism.  
 Work described in Chapter 6 also concerns the resistance mechanism, but it 
includes expression of another putative resistance gene from the compactin cluster, 
namely mlcE, in S. cerevisiae. I provide evidence mlcE encodes a transmembrane 
protein that localizes to the plasma and vacuolar membranes in S. cerevisiae, and 
most importantly, MlcE significantly increases yeast resistance to both, natural and 
semi-synthetic statins, likely by exporting the compounds out of the cells.  
 The work presented in Chapter 5 and 6 shows that understanding the 
molecular biological basis underlying the self-resistance mechanisms in secondary 
metabolite producers can provide tools for improvement of biotechnological 
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processes. Solutions for tackling the problem with S. cerevisiae statin sensitivity 
could have an enormous impact on the future production of statins in yeast. I show 
that both MlcD and MlcE can improve the yeast statin resistance, and thus provide 
means for improvement of this cell factory for future statin production. Besides the 
improved statin resistance, expression of mlcE in S. cerevisiae has a potential for 
reducing purification cost, and also removing the negative feedback inhibition that 
sometimes limits the biosynthesis of the end product. 
 Fungal secondary metabolite gene clusters are not just an important source 
of enzymes for the synthesis of valuable compounds, but can also contain genes for 
the self-resistance mechanisms, which are largely unexplored. Like in the case of 
statin gene clusters, other fungal gene clusters could also represent a good source 
for identifying the resistance genes and discovering the underlying resistance 
mechanisms that can protect heterologous cell factories from the toxic compounds, 
and thus ensure an efficient production of desired secondary metabolites. 
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APPENDIX: Patent 
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STATIN RESISTANCE AND EXPORT
Technical field of the invention
The present invention relates e.g. to methods of producing statins in transgenic,5
non-filamentous microorganisms such as Saccharomyces cerevisiae. Further, the
present invention relates to the transgenic, non-filamentous microorganisms as
such as well as various uses of transmembrane statin efflux pump(s) originating
from various filamentous fungi.
10
Background of the invention
Statins are important inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A
reductase (HMGR), the regulatory and rate-limiting enzyme in the mevalonate
pathway, which leads to the production of sterols, such as cholesterol in human,15
and ergosterol in fungi.
The blood cholesterol level in mammals is a result of de novo synthesis and
dietary intake. Elevated levels of blood cholesterol often lead to atherosclerosis,
i.e. deposits of LDL particles on the inside of the arterial walls, leading to various20
cardiovascular diseases. Treatment of elevated cholesterol levels is typically a
combination of dietary changes and medical treatment with statins to control de
novo synthesis.
With their effective cholesterol-lowering ability, statins have been widely used as25
hypercholesterolemia drugs to prevent and treat cardiovascular diseases and has
become one of the best-selling pharmaceuticals in the past decade.
Typically, statins are divided into three classes based on their mode of synthesis:
natural, semi-natural and synthetic. Natural statins, such as lovastatin/monacolin30
K and compactin, are synthesised via the polyketide biosynthetic pathway by
filamentous fungi including Aspergillus terreus, Monascus purpureus and
Penicillium citrinum. The natural statin compounds are utilized by the fungi to
inhibit the growth of eukaryotic competitors that inhabits the same
ecosystems/niche. Semi-natural statins are natural statins, which post-purification35
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has been modified through synthetic chemistry or via a biotransformation. The
synthetic statins differ significantly in structure from that of the natural and semi-
natural statins and are produced by chemical synthesis.
More specifically, the two known natural statins, compactin and lovastatin, are5
produced as secondary metabolites by filamentous fungi; compactin is produced
by Penicillium species, e.g. P. solitum and P. brevicompactum, whereas lovastatin
is produced by Aspergillus and Monascus species, e.g. A. terreus, M. purpureus
and M. pilosus.
10
In general, bioactive secondary metabolites often provide a selective advantage to
the producing microorganism in their natural environment. However, said
metabolites can also be toxic to the producing microorganisms if they themselves
contain the target site of the compound. Therefore, the secondary metabolite
biosynthesis gene clusters, in addition to the biosynthetic enzymes, often also15
contain genes encoding a secretion system(s), which in addition can provide a
resistance mechanism to prevent self-intoxication.
This is also the case in relation to both the compactin and the lovastatin
biosynthesis gene clusters, where putative efflux pump genes have been20
identified, namely the mlcE gene from the compactin biosynthetic gene cluster,
lovI gene (also referred to in the art as: ORF10 or lovH - thus, for the purpose of
simplicity the gene is hereinafter referred to as lovI/H) from the lovastatin gene
cluster and mokI from the monacolin K cluster.
25
Well-known methods of producing natural statins, as well as their semi-synthetic
derivatives, are mainly based on fermentation processes with strains of naturally
statin-producing filamentous fungi.
Commercial production of natural and semi-natural statins is based on liquid30
fermentation of the relevant fungal species followed by purification and
subsequent modification for the semi-natural statins. However, it is also well
known that filamentous fungi are difficult to culture efficiently in fermenters, inter
alia due to their unique physiology and morphology.
35
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Hence, in order to overcome these problems and to increase the yields, several
statin-manufacturing companies have switched to solid state fermentation, a
challenging approach that is prone to contamination and involves a relatively high
risk for the formation of undesirable side products. This is also well known in the
art.5
Also, it is well-known in the art that there is a common problem while fermenting
statins in fungi as the final products are - besides being cholesterol lowering
agents - also active antifungals and thereby limit the productivity in fungal hosts.
A possible solution to this problem could be to transfer the metabolic pathway to10
easily fermentable unicellular microorganisms, such as yeast. However, this
solution is not easily achievable inter alia since yeast does not naturally produce
any polyketides, which is one of the reasons why the relevant genes encoding the
biosynthetic machinery for the formation of statins have to be functionally
expressed simultaneously at a balanced level. Additional challenges for producing15
statins in yeast include a limited availably of the necessary substrates (acetyl-CoA
and malonyl-CoA) and co-factors (NADPH). Further challenges includes problem
with self-intoxication as yeast only has a basal level of statin-resistance (Riccardo
& Kielland-Brandt, 2011).
20
Thus, in an effort to provide an alternative mode of biosynthesis, researcher has
for the last decade been working on transferring the statin biosynthetic pathway
from the traditionally used filamentous fungi into easily fermentable
microorganisms such as Saccharomyces cerevisiae.
25
Xu W. et al. (2013), discloses inter alia the expression in yeast of the genes
responsible for the biosynthesis of the lovastatin intermediate, monacolin J acid.
However, the Xu W. et al. -article did not contain any disclosure of the expression
of the statin efflux pump genes mlcE, mokI and/or lovI/H in e.g. Saccharomyces
cerevisiae, but merely discloses the expression of genes responsible for the30
biosynthesis of monacolin J acid which is an intermediate capable of being
converted into the commercially attractive agent, simvastatin acid, in a single
enzymatic step.
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Abe et al. (2002) discloses inter alia that mlcE is a putative efflux pump which
may be involved in conferring resistance to compactin as well as in metabolite
secretion in the naturally producing microorganism (Penicillium citrinum).
However, the Abe et al. -article contains no disclosure or suggestions of
transferring and/or expressing the mlcE, mokI or lovI/H genes in yeast, let alone5
in Saccharomyces cerevisiae.
An article by Hirata D., & Yano K. (1994), discloses inter alia that the pdr5 gene
encodes an efflux pump in Saccharomyces cerevisiae.
10
Likewise, in an article by Riccardo L., & Kielland-Brandt MC. (2011) is disclosed
that pdr5 gene encodes a pump that has shown to confer basic-level of statin-
resistance in Saccharomyces cerevisiae. Also disclosed in said article is the
susceptibility to lovastatin of Saccharomyces cerevisiae strains deleted for PDR
genes, i.e. genes encoding for drug resistance pumps responsible for exporting15
hydrophobic and amphiphilic drugs, such as lovastatin.
WO09133089 A1 disclosed inter alia a process for increasing the compactin,
pravastatin, lovastatin and/or simvastatin productivity by a fermentation process
carried out with host organisms that are genetically engineered to have increased20
resistance to said statins. More specifically, a process is provided which makes use
of microorganisms (preferably Penicillium chrysogenum) in which genes encoding
proteins which mediate statin resistance are overexpressed. Also disclosed in
WO09133089 A1 is the compactin biosynthetic gene cluster of Penicillium citrinum
(i.e. mlcA, mlcB, mlcC, mlcD, mIcE, mlcF, mlcH, mlcG, mlcR) as well as the25
lovastatin biosynthetic gene cluster of Aspergillus terreus (i.e. ORF1, ORF2, lovA,
ORF5, lovC, lovD, ORF8, lovE, ORF10, lovF, ORF12, ORF13, ORF14, ORF15,
ORF16, ORF18). However, WO09133089 A1 contains no disclosure of neither the
functions of said genes nor the transferring and expression of the statin efflux
pump encoding lovI/H, mokI or mlcE genes in Saccharomyces cerevisiae.30
WO0129073A1 disclosed to the use of so-called MFS-transporters (named PUMPI
and PUMP2) and their ability to confer resistance to otherwise toxic levels of
lovastatin when expressed in Saccharomyces cerevisiae. However, as there is no
disclosure or suggestion in WO0129073A1 of transferring and expressing the35
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statin efflux pump encoding lovI/H, mokI or mlcE genes in Saccharomyces
cerevisiae.
WO0037629 disclosed inter alia a method of increasing the production of
lovastatin in a lovastatin-producing or a non-lovastatin-producing microorganism.5
ORF10 (lovI/H) is disclosed in WO0037629 as a gene relevant for the
transportation of metabolites. There is no disclosure in WO0037629 of lovI/H,
mokI or mlcE, let alone of the transfer and expression of said genes in a
Saccharomyces cerevisiae host e.g. for improving the statin resistance in said
host.10
WO2009/077523 disclosed inter alia a method for the fermentative production of
e.g. compactin (mevastatin) and lovastatin where said method comprises
culturing a mutant host capable of producing e.g. lovastatin wherein the esterase
activity in said mutant host is more than 25% below the activity of said esterase15
in the parent host. However, there is no disclosure in WO2009/077523 of e.g. the
mlcE, mokI and/or lovI/H genes encoding statin specific efflux pumps let alone of
transferring and expression of said genes in Saccharomyces cerevisiae.
WO2007147827 discloses inter alia Saccharomyces cerevisiae containing a20
compactin biosynthesis gene and a gene for conversion of compactin into
pravastatin. The mlcE gene is disclosed as being one of these compactin
biosynthesis genes. There is no disclosure or suggestion in WO2007147827 that
e.g. mlcE, mokI and/or lovI/H is capable of encoding statin specific efflux pumps
in Saccharomyces cerevisiae, let alone of the transferring and expression of said25
genes in Saccharomyces cerevisiae.
WO2010034686 discloses inter alia a method for the fermentative production of
e.g. compactin (mevastatin) and lovastatin where the method involves culturing a
host, e.g. Saccharomyces cerevisiae, e.g. by use of the lovE transcription30
regulator gene. There is, however, no disclosure or suggestion in WO2010034686
of e.g. the mlcE, mokI and/or lovI/H genes is/are capable of encoding statin
specific efflux pumps in e.g. Saccharomyces cerevisiae, let alone of a transfer and
expression of said genes in Saccharomyces cerevisiae.
35
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WO10069914 discloses a method for the fermentative production of e.g.
compactin (mevastatin) and lovastatin where the method involves culturing a
host, e.g. Saccharomyces cerevisiae, e.g. by use of specifically defined
transcription regulator genes.
WO10069914 also discloses that mlcE encoding an efflux pump in Penicillinum5
citrinum. However, WO10069914 contains no disclosure or suggestions that said
efflux pump gene can be expressed in e.g. Saccharomyces cerevisiae.
As is apparent from the above-outlined prior art documents, the three genes
mlcE, mokI and lovI/H have not previously been characterized in depth, let alone10
when transferred into other host organisms. The article by Hutchinson et al.
(2000), discloses the function of the lovI gene and states inter alia that
heterologous expression of the putative lovastatin efflux pump gene lovI in
Aspergillus nidulans did not result in increased resistance to lovastatin in said host
organism (no experimental data is provided in the article). Moreover, said article15
contains no disclosure of e.g. expressing the mlcE, mokI and/or lovI/H genes in
yeast.
It is well known that statins are toxic for the statin-producing host cells, e.g. due
to the inhibition of ergosterol biosynthesis (fungal equivalent of cholesterol). It is20
therefore crucial to establish a nondestructive resistance mechanism in a given
host cell (said host cell is also commonly referred to as a “cell factory”) in order to
establish a commercially profitable production of statins.
In order to avoid the undesirable effects of self-intoxication in the host cell several25
approaches has previously been utilized the most common being: 1)
overexpression of the HMGR encoding gene and/or 2) development of a statin-
insensitive HMGR.
The present invention relates to a novel approach for avoiding the undesirable30
effects of self-intoxication in easily fermentable host microorganisms by
introduction of a transmembrane statin efflux pump in said microorganism for
removing the toxic statins from said host.
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This novel approach has the additional advantage that it also ensures the export
out of microorganism of any produced statins, which inter alia eases the
subsequent purification steps.
Hitherto, however, it has not been clear whether the putative efflux pumps from5
the statin biosynthetic gene clusters have the potential to export statins out of the
statin-producing microorganisms. Thus, the inventors of the present application
surprisingly found that introduction of genes encoding transmembrane statin
efflux pumps, such as the mlcE, mokI and/or lovI/H gene(s) into statin sensitive
yeast hosts was indeed feasible and additionally found that said introduction10
turned out to increase the yeast`s resistance to statins present in the relevant
growth media.
Hence, to summarize, there is a need for improvement in the art of the
productivity of fungal fermentations due the anti-fungal properties of statins.15
Drawbacks of the state of the art processes of producing statins – which are
overcome by the present invention - involve inter alia:
(i) the fact that filamentous fungi, traditionally used for statin-production, are
difficult to culture efficiently in fermenters, inter alia due to their unique20
physiology and morphology.
(ii) the potential negative effects of the traditionally used method of
overexpression of HMGR (in order to reduce statin self-intoxication) might have on
the central metabolism of the host microorganism
(iii) the potentially deleterious effects of the statin self-intoxication of the statin-25
producing host microorganisms
(iv) the contamination problems and the risk of the formation of undesirable side
products associated with the traditionally used “solid state fermentation” methods
of producing statins. Moreover, it is well known in the art that collecting and/or
purifying the produced statin in the traditionally used “solid state fermentation” is30
both laborious and cost-ineffective.
53429EP01
8
Summary of the invention
The object of the present invention is inter alia to provide a method to solve some
of the problems encountered in prior art processes of producing statins.
Preferably, a process is provided which makes use of easily fermentable
microorganisms, such as Saccharomyces cerevisiae, in which genes encoding5
statin efflux pumps are overexpressed.
Based on the hypothesis that the proteins MlcE, LovI/H and MokI - from the
compactin, lovastatin and monacolin K gene clusters respectively - are in fact
transmembrane statin specific efflux pumps the inventors of the present10
application have successfully expressed and overexpressed e.g. the mlcE gene in
different Saccharomyces cerevisiae strains and tested the responses of said
strains to increasing statin levels.
Thus, the present invention relates to the transferring of the compactin, lovastatin15
or monacolin K gene cluster into easily fermentable microorganisms, such as
Saccharomyces cerevisiae, followed by overexpression of the efflux pump
encoding mlcE, mokI and/or lovI/H genes in said microorganisms.
This expression or overexpression turned out to increase resistance to statins in20
easily fermentable microorganisms such as, Saccharomyces cerevisiae, Pichia
pastoris and Schizosaccharomyces pomp.
Moreover, the present invention relates to the use of the transmembrane statin
efflux pumps, such as MlcE, for increasing the resistance in transgenic25
microorganisms to the potentially deleterious effects of exogenous added statins
on said microorganisms in connection with production of said statins in the
organism.
This reduction of statin self-intoxication in the producing host microorganism allow30
for the production of elevated concentrations of natural statins compared to
statin-producing methods known in the art. Moreover, overexpression in said
hosts of the genes encoding the transmembrane statin efflux pumps, i.e. the
mlcE, lovI/H and mokI genes, eliminates the potentially adverse effects of
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overexpression the genes encoding the HMGR enzyme, i.e. one of the methods
traditionally used in the art to produce statins in microorganisms.
Moreover, expression of the mlcE, lovI/H and mokI genes increased export of
statins from the cytoplasma to the growth medium, easing purification of said
statins.5
Definitions
Prior to discussing the present invention in further details, the following terms will
first be defined. In the context of the present application, the following terms10
have the following meanings. The below-outlined terms are listed in alphabetical
order:
Activated lovastatin: Lovastatin, as well as other statins comprise of a lactone ring
unit, which can be present in an open or closed form, depending on the pH.15
Statins are biologically active (i.e. are able to inhibit HMGR) only when their
lactone ring is in an open confirmation (dihydroxy open-acid form). Activated
lovastatin is lovastatin with an open lactone ring.
ARX3 strain: Saccharomyces cerevisiae strain originating from CEN.PK 113-11C20
strain with the efflux pump encoding gene mlcE from the compactin biosynthetic
gene cluster integrated into the genome using method described by Mikkelsen et
al., 2012.
Codon optimization: A codon is a DNA entity composed of three nucleotides that is25
being translated into a specific amino acid residue in a polypeptide chain. The
Genetic code is degenerated, meaning that many amino acids can be encoded by
more than one codon. Different organisms show preferences for particular codons
that encode specific amino acids. Codon optimization is a method for optimizing
gene sequences in a way that the amino acid residues of the polypeptide chain are30
encoded by the codons preferred by the organism, in which we would like to
express the gene.
53429EP01
10
Constitutive promoter (e.g. TEF1): Promoter that is active under all conditions in
the cell. Gene expressed under a constitutive promoter is being continuously
transcribed in the cell.
Crystal violet efflux pump (Sge1): Sge1 protein from Saccharomyces cerevisiae is5
a member of the drug-resistance protein family, and is capable of conferring
resistance in yeast to crystal violet and other toxic substances.
C-terminal mRFP fusion: In order to determine subcellular localization of proteins,
the proteins can be tagged with a reporter protein, e.g. red fluorescent protein10
(RFP) at their C terminus or N terminus. Because of the ability of RFP to emit light
when illuminated with light of a specific wavelength, the fused proteins can be
tracked in cells using fluorescence microscopy.
”Drug:H+ antiporter 2 family”: Drug:H+ antiporter 2 family is a family of15
multidrug resistance transport proteins from the major facilitator superfamily
(MFS). Proteins in this family are membrane-bound enzymes containing 14
transmembrane spanning domains. They catalyze a reaction in which hydrogen
protons and drugs are pumped in opposite direction across a membrane.
20
HC-toxin efflux pump (ToxA): ToxA protein form Cochliobolus carbonum is an HC-
toxin efflux pump which contributes to self-protection against HC-toxin and/or
secretion of HC-toxin into the extracellular environment.
HMGR: 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) is the rate-25
limiting enzyme in the mevalonate pathway, which leads to the production of
sterols, such as cholesterol in human, and ergosterol in fungi. The enzyme is
inhibited by products from the mevalonate pathways via a negative feedback loop.
Major facilitator superfamily (MFS): MFS is a family of membrane transport30
proteins that facilitate movement of small molecules across cell membranes in
response to chemiosmotic ion gradients.
Mevastatin: also referred to in the art as compactin (and ML-236B) is a
hypolipidemic agent that belongs to the statins class.35
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MlcE topology: Topology describes the orientation of regular secondary structures,
such as alpha-helices and beta strands in a protein structure and in relation to cell
membranes. MlcE topology refers to the topology of the efflux pump MlcE.
mRFP: monomeric red fluorescent protein is a reporter protein used in5
fluorescence microscopy for subcellular localization of proteins to which mRFP is
fused.
OD600: Optical density (also called absorbance) is a measure of concentration of
cells in a suspension. It is determined in a spectrophotometer at a wavelength of10
600 nm.
Overexpression: describes the various methods by which a gene or a protein can
be modified in order to increase the concentration of active enzyme, including
inter alia (i) introduction of additional gene copies encoding host or heterologous15
proteins; (ii) overexpression of host proteins from a strong promoter; (iii)
modifying the transcriptional regulation of the genes encoding enzymes mediating
statin resistance; (iv) modifying the mRNA to increase the rate of translation
initiation; (v) mutation of critical amino acids leading to proteins with improved
kinetic properties; (vi) mutations causing an increased half-life of the enzyme;20
(vii) modifying the mRNA molecule in such a way that the mRNA half-life is
increased; Other methods which are well-known in the art may be envisaged.
pdr5 deletion strain (Pleotropic Drug Resistance gene): the pdr5 gene encodes a
pump that has shown to confer a basic level of statin-resistance in Saccharomyces25
cerevisiae. The pdr5 deletion strain (herein denoted as: pdr5Δ) does not contain 
said pump.
Plate dilution assay (spot assay): This assay allows testing of the toxic effects of
the compounds added to a solid growth medium. It is based on culturing a dilution30
series of a microorganism on said plates, following the growth of a microorganism
and observing at which dilution the microorganism is unable to grow. The growth
of individual microorganisms as a function of time is recorded by photography of
the plates.
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Penicillium citrinum: the compactin-producing filamentous fungi (also referred to
in the art as Penicillium solitum)
Recombinant host strains: refers to host strains in which genetic material from
one or multiple sources have been brought together, creating sequences that5
would not otherwise be found in biological organisms.
RFP-tagged MlcE: To investigate subcellular localization of efflux pump MlcE, the
relevant protein has been fused with RFP at its C terminus.
10
Standard Protein BLAST: Basic Local Alignment Search Tool is an algorithm for
comparing biological sequence information. Standard Protein BLAST, available at
e.g. http://www.ncbi.nlm.nih.gov is commonly used for identifying a query amino
acid sequences in protein databases. The search tool is designed to identify local
regions of similarity.15
Substantially homologous polynucleotide: A polynucleotide with nucleotide
sequences that are substantially homologous to a reference sequence is defined
as a polynucleotide with a nucleotide sequence with a degree of identity to the
specified nucleotide sequence of at least 80%, preferably at least 85%, more20
preferably at least 90%, still more preferably at least 95%, still more preferably at
least 97%, still more preferably at least 98%, most preferably at least 99%
Substantially homologous polypeptide: A polypeptide with amino acid sequences
that are substantially homologous to a reference sequence is defined as a25
polypeptide with an amino acid sequence with a degree of identity to the specified
amino acid sequence of at least 80%, preferably at least 85%, more preferably at
least 90%, still more preferably at least 95%, still more preferably at least 97%,
still more preferably at least 98%, most preferably at least 99%. Substantially
homologous polypeptides may for example contain only conservative30
substitutions of one or more amino acids of the specified amino acid sequences or
substitutions, insertions or deletions of non-essential amino acids.
TEF promoter: constitutive promoter that regulates transcription of the
‘Transcription Elongation Factor b’ encoding gene35
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TOPCONS server: TOPCONS server is a tool for consensus prediction of membrane
protein topology. It is available online at http://topcons.net/
Wild type strain: Reference Saccharomyces cerevisiae strain, in this study CEN.PK
113­11C (MATa MAL2­8C SUC2 his3Δ ura3­52). 5
YPD agar plates: YPD is a complete medium for yeast growth composed of yeast
extract, peptone and glucose. If YPD is used as a solid medium, agar is added to
YPD, and the medium is solidified in plates for cultivation of microorganisms.
10
Advantages of the present invention
The inventors of the present application surprisingly showed that it is possible to
use the transmembrane statin efflux pumps MlcE, LovI/H and MokI as a resistance
mechanism, i.e. for reducing the potentially deleterious effects of self-intoxication15
caused by the produced statins in a statin-producing microorganism, e.g. in
yeasts such as Saccharomyces cerevisiae. This is a surprising finding in light of
the prior art which e.g. suggested that this could not be the case as expression of
the mlcE gene in e.g. the filamentous fungus Aspergillus nidulans, which is
normally sensitive to statins, did not increase its resistance against the tested20
compounds (see e.g. the article by Hutchinson et al., 2000).
An additional advantage of the present invention, in addition to providing
resistance against both natural and semi-statins, is that the statin efflux pumps
also provides an elegant solution for exporting the produced statins into the25
extracellular medium in statin-producing hosts other than filamentous fungi, e.g.
in yeasts such as Saccharomyces cerevisiae.
Furthermore, by expressing e.g. the mlcE gene in easily fermenting hosts such as
Saccharomyces cerevisiae there is no longer a need for the traditionally used30
overexpression of HMGR which in turn eliminates the potential negative effects
that HMGR might have on the central metabolism of the host microorganism.
The above-mentioned statin pumps, e.g. MlcE, with their ability of exporting
natural and semi-natural statins across the plasma membrane has a great35
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potential for improving a statin-producing yeast cell factory. Not only do said
pumps, e.g. MlcE, provide the resistance to a range of statins in yeast; it also
ensures the export of the produced statins into the extracellular environment,
which can significantly ease the subsequent purification of the produced
compounds compared to the traditionally used “solid state fermentation” methods5
based on naturally producing species of Penicillium, Aspergillus and Monascus.
Hence, the inventors of the present application provided evidence indicating that
the polypeptides encoded by the mlcE, LovI/H and MokI genes are
transmembrane efflux pumps capable of transporting both natural and semi-10
natural statins out of the statin-producing host cell.
Moreover, the inventors of the present application showed that MlcE, LovI/H and
MokI are statin-specific transporters, with the ability to transport compactin as
well as the compactin-related compounds lovastatin, simvastatin and pravastatin,15
across the plasma membrane. Therefore, in light of the above, overexpression of
e.g. mlcE in statin-producing microorganisms, such as Saccharomyces cerevisiae
could greatly improve the commercial production of natural and semi-natural
statins compared to well-known statin-producing methods.
20
In general this means that the statin efflux pumps MlcE, LovI/H and MokI provide
resistance to both, natural and semi-natural statins, making them great tools for
optimizing e.g. yeast cell factories for statin production.
25
Detailed description of the invention
Thus, it is an object of the present invention to provide a statin producing method
and statin producing transgenic, non-filamentous microorganisms that solves the
above mentioned problems of the prior art.
30
Thus, one aspect of the invention relates to a method for the production of statin
in a transgenic microorganism, wherein the method comprises expression in said
microorganism of one or more polynucleotide(s) encoding one or more
transmembrane statin efflux pump(s).
35
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In a preferred embodiment, the polynucleotide(s) of said method are chosen from
the group consisting of SEQ ID NOs: 1, 2, 3, 4 and/or 5.
In a further preferred embodiment, the polynucleotide(s) of said method is/are
chosen from the group consisting nucleotide variants comprising sequences with a5
degree of identity to any of SEQ ID NOs: 1, 2, 3, 4 and/or 5 of at least: 80%,
preferably at least 85%, more preferably at least 90%, still more preferably at
least 95%, still more preferably at least 97%, still more preferably at least 98%,
most preferably at least 99%.
10
In an even further preferred embodiment, the polynucleotide(s) SEQ ID NOs: 1,
2, 3, 4 and/or 5 of said method is/are overexpressed.
In an even further preferred embodiment, the above-mentioned polynucleotide
variant(s) of SEQ ID NOs: 1, 2, 3, 4 and/or 5 is/are overexpressed.15
Another aspect of the invention relates to a method for the production of statin in
a transgenic microorganism, wherein the method comprises expression in said
microorganism of polypeptide(s) chosen from the group consisting of SEQ ID NOs:
17, 18, 19 and/or 20.20
In a further preferred embodiment, the polypeptide(s) of said method is/are
chosen from the group consisting of variants comprising sequences with a degree
of identity to any of SEQ ID NOs: 17, 18, 19 and/or 20 of at least: 80%,
preferably at least 85%, more preferably at least 90%, still more preferably at25
least 95%, still more preferably at least 97%, still more preferably at least 98%,
most preferably at least 99%.
In an even further preferred embodiment, the polypeptide(s) of SEQ ID NOs: 17,
18, 19 and/or 20 of said method is/are overexpressed.30
In an even further preferred embodiment, the above-mentioned polypeptide
variants of SEQ ID NOs: 17, 18, 19 and/or 20 is/are overexpressed.
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In an even further preferred embodiment, the transgenic microorganism for use in
the production of statins is a non-filamentous fungus selected from the group
consisting of Saccharomyces cerevisiae, Pichia pastoris and Schizosaccharomyces
pomp.
5
In an even further preferred embodiment, the present invention relates to statins
produced by any of the above methods.
Another aspect of the present invention relates to transgenic microorganism for
use in the production of statin, wherein the microorganism comprises one or more10
polynucleotide(s) encoding one or more transmembrane statin efflux pump(s).
In a preferred embodiment, said transgenic microorganism comprises one or more
polynucleotide(s) chosen from the group consisting of SEQ ID NOs: 1, 2, 3, 4
and/or 5.15
In a further preferred embodiment, the transgenic microorganism comprises one
or more nucleotide variant(s) comprising sequences with a degree of identity to
any of SEQ ID NOs: 1, 2, 3, 4 and/or 5 of at least: 80%, preferably at least 85%,
more preferably at least 90%, still more preferably at least 95%, still more20
preferably at least 97%, still more preferably at least 98%, most preferably at
least 99%.
In an even further preferred embodiment, the transgenic microorganism
comprises one or more polynucleotide(s) according to SEQ ID NOs: 1, 2, 3, 425
and/or 5 which is/are overexpressed.
In an even further preferred embodiment, the transgenic microorganism
comprises one or more of the above polynucleotide variants of SEQ ID NOs: 1, 2,
3, 4 and/or 5 which are overexpressed.30
In a preferred embodiment, said transgenic microorganism comprises one or more
polypeptides chosen from the group consisting of SEQ ID NOs: 17, 18, 19 and/or
20.
35
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In a further preferred embodiment, the transgenic microorganism comprises one
or more polypeptide variant(s) comprising sequences with a degree of identity to
any of SEQ ID NOs: 17, 18, 19 and/or 20 of at least: 80%, preferably at least
85%, more preferably at least 90%, still more preferably at least 95%, still more
preferably at least 97%, still more preferably at least 98%, most preferably at5
least 99%.
In an even further preferred embodiment, the transgenic microorganism
comprises one or more polypeptide(s) according to SEQ ID NOs: 17, 18, 19
and/or 20, which is/are overexpressed.10
In an even further preferred embodiment, the transgenic microorganism
comprises one or more of the above polypeptide variants of SEQ ID NOs: 17, 18,
19 and/or 20, which is/are overexpressed.
15
In an even further preferred embodiment, the above transgenic microorganism is
a non-filamentous fungus selected from the group consisting of Saccharomyces
cerevisiae, Pichia pastoris and Schizosaccharomyces pomp.
Yet another aspect of the present invention relates to use of a transmembrane20
statin efflux pump in a transgenic non-filamentous statin-producing
microorganism, for the production of statins in the microorganism and/or
increasing the statin resistance in the microorganism and/or decreasing the statin
self-intoxication in the microorganism and/or increasing the export of the
produced statins into the extracellular medium.25
Also envisaged is the use of the statins obtained in any of the above-outlined
methods in the production of a medicament.
A further aspect of the invention concerns a use of a transmembrane statin efflux30
pump in a microorganism, for the:
(i) bioconversion of statins in the microorganism and/or
(ii) increasing the statin resistance of the microorganism and/or
(iii) increasing the export of statins into the extracellular medium
35
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An even further aspect of the invention concerns a polypeptide selected from the
group consisting of SEQ ID NOs: 17, 18, 19 and/or 20 which, when incorporated
into a transgenic non-filamentous microorganism, is capable of
(ii) providing statin resistance in the microorganism and/or
(ii) exporting of the produced statins out of the microorganism5
Also envisaged is one or more polypeptide variant(s) comprising a sequence with
a degree of identity to any of SEQ ID NOs: 17, 18, 19 and/or 20 of at least: 80%,
preferably at least 85%, more preferably at least 90%, still more preferably at
least 95%, still more preferably at least 97%, still more preferably at least 98%,10
most preferably at least 99% which, when incorporated into a transgenic non-
filamentous microorganism, is capable of
(ii) providing statin resistance in the microorganism and/or
(ii) exporting of the produced statins out of the microorganism
15
A further aspect of the invention concerns a nucleic acid construct comprising any
of the polynucleotide sequence according to SEQ ID NOs: 1, 2, 3, 4 and/or 5
operably linked to one or more control sequences that facilitate production of the
polypeptide in an expression host.
20
An even further aspect of the invention concerns a recombinant expression
cassette comprising said construct either maintained in the expression host as a
self-replicating plasmid or integrated into the genome.
All patent and non-patent references cited in the present application, are hereby25
incorporated by reference in their entirety.
Brief description of the figures and the SEQ ID NOs
30
Figure 1:
Phylogenetic tree of representative members of the two families of MFS drug
resistance proteins; family DHA1 with Drug:H+ antiporters consisting of 12 TMS
and family DHA2 with Drug:H+ antiporters consisting of 14 TMS are shown.The
three putative statin efflux pumps (MlcE, LovI and MkI from compactin, lovastatin35
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and monacolin biosynthetic gene clusters, respectively) are predicted to belong
the DHA2 family. Protein sequences were obtained from UniProt Knowledgebase
(UniProtKB, http://www.uniprot.org/help/uniprotkb), aligned with multiple
sequence alignment tool MAFFT version 7 (Multiple sequence Alignment using Fast
Fourier Transform) available at the European Bioinformatics Institute5
(http://mafft.cbrc.jp/alignment/server/). The tree was generated with ClustalW2
alignment program at EMBL-EBI using Neighbor-Joining clustering method
(Setting: distance correction on, exclude gaps on), and viewed with FigTree
software, version 1.4 (http://tree.bio.ed.ac.uk/software/figtree).
10
Figure 2:
Strain construction and subcellular localization of MlcE-RFP. A) Schematic
representation of strain construction. Expression cassettes containing mlcE and its
RFP-tagged version were integrated into the genome, under the control of the
constitutive promoter TEF1 (strains ARX3 and ARX1, respectively). RFP alone has15
been expressed from the same locus and promoter, and the resulting strain
(strain ARX2) was used as a control for fluorescence microscopy. B) Fluorescence
microscopy results. For subcellular localization of the putative efflux pump MlcE
strain ARX1, and a control strain ARX2 were incubated overnight in 10 mL of SC
medium, shaking (150 rpm) at 30°C. Images obtained by differential interference20
contrast microscopy (DIC) (left panel) and corresponding fluorescence images
(right panel) are shown.
Figure 3:25
Investigation of the potential of MlcE to confer the resistance to statins in yeast.
Tenfold dilution series of Saccharomyces cerevisiae WT and ARX3 strain
harbouring the putative efflux pump MlcE, starting with an OD600 of 0.02 were
prepared from overnight cultures. 4.5 microliters of each dilution were plated on a
set of YPD agar plates containing different cytotoxic compounds. The plates were30
incubated at 30°C for 2 days, after which the growth of the strains was recorded
by photography.
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Figure 4:
Investigation of the potential of MlcE to complement the PDR5 efflux pump in
yeast. Fivefold dilution series of Saccharomyces cerevisiae WT, ARX3, AR29 pdr5Δ 
and pdr5Δ strains, starting with an OD600 of 0.2 were prepared from overnight
cultures. Four microliters of each dilution were plated on a set of YPD agar plates5
with increasing concentration (0.74 mM and 1.98 mM) of lovastatin. The plates
were incubated at 30°C for 3 days, after which the growth of the strains was
recorded by photography.
SEQ ID NO: 1 represents the nucleotides of mlcE (coding sequence, from the10
compactin biosynthetic gene cluster (GenBank accession number: AB072893.1))
SEQ IN NO: 2 represents the nucleotides of mlcE (coding sequence, synthetic
codon optimized version)
15
SEQ ID NO: 3 represents the nucleotides of mlcE-mRFP (coding sequence,
synthetic codon optimized version of mlcE with mRFP fusion)
SEQ ID NO: 4 represents the nucleotides of lovI/H (coding sequence (GenBank
accession number: AF141925.1))20
SEQ ID NO: 5 represents the nucleotides of mokI (coding sequence (GenBank
accession number: DQ176595.1))
SEQ ID NO: 6 represents the nucleotides of the primer mlcE-F25
SEQ ID NO: 7 represents the nucleotides of the primer mlcE-R
SEQ ID NO: 8 represents the nucleotides of the primer TEF1-d
30
SEQ ID NO: 9 represents the nucleotides of the primer PGK1-s
SEQ ID NO: 10 represents the nucleotides of the primer RFP_F+
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SEQ ID NO: 11 represents the nucleotides of the primer RFP_R+
SEQ ID NO: 12 represents the nucleotides of the primer mlcE-RFP-R
SEQ ID NO: 13 represents the nucleotides of the primer RFP-F5
SEQ ID NO: 14 represents the nucleotides of the primer C1_TADH1_F
SEQ ID NO: 15 represents the nucleotides of the primer PDR5-DEL-F
10
SEQ ID NO: 16 represents the nucleotides of the primer PDR5-DEL-R
SEQ ID NO: 17 represents the amino acids of MlcE (GenBank accession number:
BAC20568.1)
15
SEQ ID NO: 18 represents the amino acids of LovI/H (GenBank accession
number: AAD34558.1)
SEQ ID NO: 19 represents the amino acids of MokI (GenBank accession number:
ABA02247.1)20
SEQ ID NO: 20 represents the amino acids of MlcE-mRFP
The invention will now be described in further details in the following non-limiting
examples.25
Example 1 (integration of the mlcE gene into Saccharomyces cerevisiae)
General setup
The mlcE gene was codon optimized and expressed from a genomic locus in
Saccharomyces cerevisiae as a single copy gene under the control of a strong30
constitutive promoter (TEF1). The gene was introduced into a ‘wild type’ strain
and a pdr5 deletion strain (pdr = Pleotropic Drug Resistance gene). The pdr5 gene
encodes a pump that has shown to confer a basic level of statin-resistance in
Saccharomyces cerevisiae (Hirata & Yano, 1994; Riccardo & Kielland-Brandt,
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2011). Furthermore, it has previously been shown that elimination of the pdr5
gene sensitize the strain in question which, in turn, allows for a larger dynamic
test range with respect to statin effects.
The efflux pump encoding gene mlcE was integrated into a defined locus of5
Saccharomyces cerevisiae, CEN.PK 113­11C (MATa MAL2­8C SUC2 his3Δ ura3­
52), genome using a yeast expression platform established by Mikkelsen et al.
2012
The yeast strain CEN.PK 113-11C (MATa MAL2-8C SUC2 his3Δ ura3-52) was10
donated by Dr. Petter Kötter, Institut für Mikrobiologie, der Johan Wolfgang
Goethe-Universität, Frankfurt am Main, Germany. Escherichia coli, DH5 , was
used to propagate the plasmids.
The media15
Yeast strains were cultivated in standard liquid yeast peptone dextrose (YPD) or
synthetic complete (SC) medium. Yeast transformants were selected on SC
medium lacking uracil. Removal of the URA3 marker, via direct repeat
recombination, was achieved by growing the strain on SC medium containing 740
mg/L 5-fluororotic acid (5-FOA) and 30 mg/L uracil. The E. coli transformants20
were selected on LB medium containing 100 µg/mL ampicillin.
The inventors of the present application then tested yeast susceptibility to statins
and statin-unrelated compounds by growing yeast strains on solid YPD medium
supplemented with compactin, lovastatin, simvastatin, pravastatin sodium,25
atorvastatin, mycophenolic acid (MPA) or vanillin respectively. Vanillin, MPA and
atorvastatin stock solutions were prepared by dissolving the compounds in 99.9%
ethanol followed by filter-sterilization. Compactin, lovastatin, and simvastatin
were converted to their active forms.
30
More specifically, the solid compounds were dissolved in 1 mL 99% ethanol,
preheated to 50°C, alkalinized with 0.5 mL of 0.6 M NaOH and incubated at 50°C
for 2 hours. The pH of the solutions was then adjusted to 7.2 by adding 0.4 M HCl.
Final volume of all the solutions was adjusted to 2 mL with water, resulting in
stock solutions of 50 mM. The statin stock solutions were filter-sterilized and35
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stored at -20°C. Compactin and atorvastatin were purchased from Toronto
Research Chemicals, lovastatin from Tokyo Chemical Industry, MPA and vanillin
from Sigma-Aldrich, and simvastatin was purchased from Ark Pharm.
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Compound Concentration of the
stock solution [mM]
Source
Compactin 50 Toronto Research
Chemicals (Canada,
Ontario, Toronto)
Lovastatin 50 Tokyo Chemical Industry
(Japan, Tokyo)
Simvastatin 50 Ark Pharm (USA, Illinois,
Libertyville)
Atorvastatin 10 Toronto Research
Chemicals (Canada,
Ontario, Toronto)
Vanillin 30 Sigma-Aldrich (USA,
Missouri, St. Louis)
MPA 320 Sigma-Aldrich (USA,
Missouri, St. Louis)
Plasmid construction
The mlcE gene was codon-optimized for expression in Saccharomyces cerevisiae5
(by the company Evolva). The codon-optimized version of the mlcE gene was
amplified from plasmid pEN669 (source: Evolva) with primers mlcE-F and mlcE-R.
Together with the TEF1 promoter, the amplified gene was cloned into the X-3
vector via USER cloning technique, resulting in plasmid pX3-TEF1-mlcE. To
determine the intracellular localization of MlcE, a red fluorescent protein (RFP)10
was fused to its C-terminus.
For that plasmid pX3-TEF1-mlcE-RFP and a control plasmid pX3-TEF1-RFP were
constructed: mlcE without the stop codon was amplified from plasmid pEN669
using primers mlcE-F and mlcE-RFP-R, and RFP was amplified from plasmid15
pWJ1350 using either RFP-F (for tagging mlcE) or RFP_F+ (for the control
plasmid) and RFP_R+ primers. All fragments were amplified by PCR using a USER
cloning compatible PfuX7 polymerase.
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Table: List of plasmids used
Name Description Reference
pEN669 mlcE template Purchased from Evolva
pWJ1350 RFP template Lisby et al. 2003
pSP-G2 PGK1,TEF1 template Partow et al. 2010
pX3 TEF1 mlcE Plasmid carrying a gene-
targeting cassette for
expressing mlcE in yeast.
This study
pX3 TEF1- RFP Plasmid carrying a gene-
targeting cassette for
expressing RFP-tagged
mlcE in yeast.
This study
pX3 TEF1 mlcE RFP Plasmid carrying a gene-
targeting cassette for
expressing RFP in yeast.
This study
5
Strain construction
The constructed plasmids were digested with the NotI restriction enzyme
(purchased form New England Biolabs), and the linear fragments were used for
yeast transformation using the lithium acetate/polyethylene glycol/single carrier
DNA transformation method. The URA3 marker in all the constructed strains was10
excised by direct repeat recombination, and the correct integrations of the gene
were verified by colony PCR with one primer annealing in the yeast genome next
to the integration site, and one primer annealing inside the introduced DNA.
Targeted deletion of the pleiotropic drug resistance pump (pdr5) encoding gene in15
the reference and X3::TEF1-mlcE expressing strains was performed, as described
by Güldener et al 1996, using the primers PDR5-DEL-F and PDR5-DEL-R.
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Table: list of strains used
Name Genotype Reference
CEN.PK113-
11C
MATα MAL2­8C SUC2 his3Δ 
ura3-52
Kindly donated by Dr. Petter
Kötter, Institut für
Mikrobiologie, der Johan
Wolfgang Goethe-Universität,
Frankfurt am Main, Germany
ARX3 MATα MAL2­8C SUC2 his3Δ 
ura3-52 X3(pTEF1-mlcE)
This study
pdr5Δ MATα MAL2­8C SUC2 his3Δ 
ura3­­52 pdr5Δ
This study
AR29pdr5Δ MATα MAL2­8C SUC2 his3Δ 
ura3-52 X3(pTEF1-mlcE)
This study
ARX1 MATα MAL2­8C SUC2 his3Δ 
ura3-52 (pTEF1-mlcE-RFP)
This study
ARX2 MATα MAL2­8C SUC2 his3Δ 
ura3-52 (pTEF1-RFP)
This study
Example 2 (phylogenetic tree)5
An initial sequence comparison investigation of the putative efflux pump MlcE
from the compactin biosynthetic gene cluster using Standard Protein BLAST
showed that this protein strongly resembles some of the known export proteins
from the major facilitator superfamily (MFS), such as crystal violet efflux pump
Sge1 from Saccharomyces cerevisiae and HC-toxin efflux pump ToxA from10
Cochliobolus carbonum. Moreover, prediction of MlcE topology using the TOPCONS
server suggested that MlcE comprises 14 transmembrane-spanning regions
(TMS), possibly classifying MlcE to the Drug:H+ antiporter 2 family (DHA2; 14
TMS) of the MFS drug transporters, a family which ToxA and Sge1 belong to as
well. The inventors of the present application constructed a phylogenetic tree,15
which suggests that MlcE, together with its orthologs from the lovastatin and
monacolin biosynthetic gene clusters, LovI and MkI, respectively, does indeed
belong to the DHA2 family of drug resistance proteins with 14 TMS (Figure 1).
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Table: Proteins used for the phylogenetic tree construction
Protein Microorganism Representative
Substrate
Accession
Number
(UniProtKB)
MFS-DHA2 (14 TMS)
ToxA Cochliobolus
carbonum
HC-toxin Q00357
Tri12
Fusarium
sporotrichioides
Trichotechene O93842
CFP Cercospora kikuchii Cercosporin O93886
Atr1
Saccharomyces
cerevisiae
Aminotriazole P13090
Sge1
Saccharomyces
cerevisiae
Crystal violet P33335
EmrB Escherichia coli CCCP b P0AEJ0
LfrA
Mycobacterium
smegmatis
Acriflavin Q50392
QacA
Staphylococcus
aureus
Benzalkonium
chloride
Q1XG09
SmvA
Salmonella
typhimurium
Ethidium bromide P37594
ActVa 1
Streptomyces
coelicolor
Actinochodrin Q53903
CmcT
Nocardia
lactamdurans
Cephamycin Q04733
Mmr
Streptomyces
coelicolor
Methylenomycin A P11545
Pur8 Streptomyces lipmanii Puromycin P42670
MFS - DHA 1 (12 TMS)
Ctb4 Cercospora nicotinae Cercosporin A0ST42
CefT
Acremonium
chrysogenum
Cephalosporin Q8NKG7
Mdr1 Canidida albicans Fluconazole P28873
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Flu1 Candida albicans Fluconazole G1UB37
Bcr Escherichia coli Bicyclomycin C6EA15
Blt Bacillus subtilis Acriflavin M1U4Q0
EmrD Escherichia coli CCCP b P31442
CaMDR1 Candida albicans Benomyl Q9URI2
NorA
Staphylococcus
aureus
Acriflavin P0A0J7
CyhR Candida maltosa Cycloheximine P32071
CmlA
Pseudomonas
aeruginosa
Chloramphenicol Q83V15
Flr1
Saccharomyces
cerevisiae Fluconazole P38124
Tpo1
Saccharomyces
cerevisiae
Spermine Q07824
Dtr1
Saccharomyces
cerevisiae
Dityrosine P38125
Aqr1
Saccharomyces
cerevisiae
Quinidine P53943
Statin Efflux pumps - unknown family
MlcE Penicillium citrinum Compactin Q8J0F3
LovI Aspergillus terreus Lovastatin Q9Y7D4
MkI Monascus pilosus Monacolin Q3S2U5
Example 3 (toxicity analysis on dilution tests)
The constructed strains response to different lovastatin levels present in the5
growth medium were tested using a agar-plate dilution assay (also known as a
spot assay). Overnight cultures of the four Saccharomyces cerevisiae strains (wt,
ARX3, AR29 pdr5Δ, pdr5Δ,) were diluted to OD600 of 0.2 and a fivefold dilution
series for each strain was made. Four microliters of each dilution were deposited
on a series of agar plates with different concentrations of activated lovastatin (010
mM, 0.74 mM, 1.98 mM). The idea behind this assay is that it allows for
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reproducible testing of toxic effects by observing at which dilution steps the
different strains are able to form visible colonies, under a given concentration of
the toxic compound. The growth of the individual strain as a function of time was
recorded by photography.
5
The plate assay (figure 4) confirmed that the pdr5Δ strain is more sensitive to 
lovastatin than the wild type (wt), as evidenced by the lack of growth even at the
lowest tested concentration (0.74 mM). Expression of the mlcE gene allows both
the wild type and pdr5Δ strain to grow at elevated statin concentrations and at 
the higher dilutions evidencing that the MlcE efflux pump indeed can provide10
statin resistance in yeast cells, such as Saccharomyces cerevisiae.
Example 4 (subcellular localization of the MlcE efflux pump)
To determine the subcellular localization of the MlcE efflux pump in15
Saccharomyces cerevisiae and in order to test the hypothesis that the MlcE
protein is in fact a transmembrane efflux pump, the inventors of the present
application constructed a C-terminal mRFP fusion and expressed it from the same
locus in Saccharomyces cerevisiae. The resulting strain was analyzed by
fluorescent microscopy and compared to a Saccharomyces cerevisiae strain that20
expressed mRFP (cytoplasmic localization) from the same promoter and the same
locus as the strain with the RFP-tagged MlcE.
More specifically, the MlcE was tagged with RFP at the C- terminus, and integrated
into the previously described site in the yeast genome under the control of TEF125
promoter, resulting in the yeast strain ARX1 (Figure 2A). Fluorescent microscopy
of ARX1 revealed a ring-like distribution of fluorescence around the cell (Figure 2B
top panel), indicating that the tagged putative efflux pump was localized in the
plasma membrane. In contrast, the mRFP alone was found to have a uniform
cytoplasmic distribution in the control cells ARX2 (Figure 2B bottom panel),30
expressing RFP alone from the same locus and controlled by the promoter as in
strain ARX1. These results support the prediction that MlcE is a trans-membrane
protein and shows that the protein is targeted to the plasma membrane in S.
cerevisiae.
35
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Moreover, to determine if the putative efflux pump MlcE has the ability to export
statins across the plasma membrane the inventors of the present application also
tested whether MlcE confers resistance to statins in yeast. To achieve that, mlcE
was expressed from a defined genomic locus in Saccharomyces cerevisiae as a
single copy gene under the control of a strong constitutive promoter pTEF15
(Figure 2A). The resulting yeast strain ARX3 was tested for susceptibility to
compactin by serial dilution plating of both wild type (WT) and ARX3 strains on
YPD agar plates supplemented with the active form of compactin (Figure 3). The
efflux pump harbouring strain ARX3 showed an increased resistance to compactin
present in the medium compared to the wild type strain, suggesting that MlcE is10
indeed a compactin efflux pump capable of exporting this natural statin out of the
cells and not into storage compartments such as the vacuole.
Example 5 (the MlcE pump in Saccharomyces cerevisiae confers15
resistance against other types of statins)
The inventors of the present application additionally showed that Saccharomyces
cerevisiae strains with the inserted transmembrane efflux pump MlcE had an
increased resistance not only to compactin but also to the other natural statin,
lovastatin, when compared to the wild type yeast strain.20
In addition to this, the inventors of the present application surprisingly found that
introduction of the transmembrane efflux pump MlcE into Saccharomyces
cerevisiae strains also resulted in increased resistance to the semi-natural statin
simvastatin, when compared to the wild type yeast strain.25
In contrast, MlcE does not seem to have the ability to export compounds, which
are structurally unrelated to its natural substrate compactin, namely atorvastatin,
vanillin and mycophenolic acid (MPA) because ARX3 strain does not show an
increased resistance to these compounds (Figure 3).30
On this basis the inventors of the present application concluded that MlcE is not a
multi-drug resistance efflux pump such as for example Pdr5 and Sge1 from
Saccharomyces cerevisiae but rather a transmembrane statin specific efflux
pump.35
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In general this means that the efflux pump MlcE provides resistance to both,
natural and semi-natural statins, making it a great tool for optimizing yeast cell
factories for statin production.
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Claims
1. Method for the production of statin in a transgenic microorganism, wherein the
method comprises expression in said microorganism of one or more
polynucleotide(s) encoding one or more transmembrane statin efflux pump(s).5
2. Method according to claim 1, wherein the polynucleotide(s) are chosen from
the group consisting of SEQ ID NOs: 1, 2, 3, 4 and/or 5.
3. Method according to claim 2, wherein the polynucleotide(s) comprise(s) one or10
more nucleotide variant(s) comprising sequences with a degree of identity to any
of SEQ ID NOs: 1, 2, 3, 4 and/or 5 of at least: 80%, preferably at least 85%,
more preferably at least 90%, still more preferably at least 95%, still more
preferably at least 97%, still more preferably at least 98%, most preferably at
least 99%.15
4. Method according to any of claims 2 or 3, wherein one or more of the
polynucleotide(s) according to SEQ ID NOs: 1, 2, 3, 4 and/or 5 is/are
overexpressed and/or wherein one or more of the polynucleotide variant(s)
according to claim 3 are overexpressed.20
5. Method according to any of claims 1-4, wherein the transgenic microorganism
is a non-filamentous fungus.
6. Method according to claim 5, wherein the non-filamentous fungus is selected25
from the group consisting of Saccharomyces cerevisiae, Pichia pastoris and
Schizosaccharomyces pomp.
7. Statins produced by a method according to any of claims 1-6.
30
8. Transgenic microorganism for use in the production of statin, wherein the
microorganism comprises one or more polynucleotide(s) encoding one or more
transmembrane statin efflux pump(s).
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9. Transgenic microorganism according to claim 8, wherein the polynucleotide(s)
is/are chosen from the group consisting of SEQ ID NOs: 1, 2, 3, 4 and/or 5.
10. Transgenic microorganism according to claim 9, wherein the polynucleotide(s)
comprises one or more nucleotide variant(s) comprising sequences with a degree5
of identity to any of SEQ ID NOs: 1, 2, 3, 4 and/or 5 of at least: 80%, preferably
at least 85%, more preferably at least 90%, still more preferably at least 95%,
still more preferably at least 97%, still more preferably at least 98%, most
preferably at least 99%.
10
11. Transgenic microorganism according to any of claims 9 or 10, wherein one or
more of the polynucleotide(s) according to SEQ ID NOs: 1, 2, 3, 4 and/or 5 is/are
overexpressed and/or wherein one or more of the polynucleotide variants
according to claim 10 is/are overexpressed.
15
12. Transgenic microorganism according to any of claims 8 or 11, wherein the
transgenic microorganism is a non-filamentous fungus.
13. Transgenic microorganism according to claim 12, wherein the non-filamentous
fungus is selected from the group consisting of Saccharomyces cerevisiae, Pichia20
pastoris and Schizosaccharomyces pomp.
14. Use of a transmembrane statin efflux pump in a transgenic non-filamentous
statin-producing microorganism, for the:
(i) production of statins in the microorganism and/or25
(ii) increasing the statin resistance in the microorganism and/or
(iii) decreasing the statin self-intoxication in the microorganism and/or
(iii) increasing the export of the produced statins into the extracellular medium
15. Use of the statins obtained in any one of claims 1 to 7 in the production of a30
medicament.
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Abstract
The present invention relates e.g. to methods of producing statins in transgenic,
non-filamentous microorganisms such as Saccharomyces cerevisiae. In addition,
the present invention relates to the transgenic, non-filamentous microorganisms
as such as well as various uses of transmembrane statin efflux pump(s)5
originating from various filamentous fungi. Moreover, the present invention
relates to the transferring the compactin, lovastatin or monacolin K gene cluster
originating from non-filamentous fungi into easily fermentable microorganisms,
followed by expression or overexpression of the efflux pump encoding genes in
said microorganisms in order to increase the microorganisms resistance to statins10
which in turn allows for production of elevated concentrations of natural statins
compared to statin-producing methods known in the art.
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Figure 1:
Phylogenetic tree
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Figure 2:
Strain construction and subcellular localization
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Figure 3:
Investigation of the potential of MlcE to confer the resistance to statins in yeast
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Figure 4:
Investigation of the potential of MlcE to complement the PDR5 efflux pump in yeast
